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Overview and organisation of thesis 
 
The overarching aims of this thesis are to review the existing evidence for the 
use of lumbar facet joint injections (FJIs) for the management of chronic low 
back pain (LBP), and to assess the feasibility of carrying out a definitive study to 
evaluate the effectiveness of FJIs in chronic LBP management.  This thesis is 
organised as follows: 
 
Chapter 1 presents the scientific background and rationale behind the 
management of chronic LBP and the need for a feasibility study, with an 
overview of the prevalence and burden of LBP, current management strategies, 
and the clinical practice guidelines based on the existing evidence.  Chapter 2 
details the literature search to identify systematic reviews of randomised 
controlled trials of intra-articular lumbar FJIs for chronic LBP management; the 
methodological quality of the included systematic reviews is assessed.  
Chapters 3 and 4 present the methods and results of the FACET feasibility 
study respectively.  Funded by the National Institute for Health Research Health 
Technology Assessment programme and led by the author, this study aimed to 
assess the feasibility of conducting a definitive study to evaluate the clinical- 
and cost-effectiveness of FJIs compared with a sham procedure in patients with 
non-specific LBP of more than three months’ duration.  Chapter 5 discusses the 
results of the literature review and feasibility study, reflecting on the findings 
with regards to interpretation, generalisability and overall evidence.  
Recommendations for further systematic reviews and future clinical research 
are presented.  Chapter 6 draws together the conclusions on the thesis with 
implications for clinical practice and healthcare policy. 
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Abstract 
 
Background 
 
Low back pain is a leading cause of disability worldwide and has a significant 
economic burden.  Targeted lumbar facet joint injections may be used to relieve 
this pain and aid rehabilitation, but high quality clinical evidence to support their 
use is lacking.  The National Institute for Health and Care Excellence (NICE) 
does not recommend spinal injections for the management of chronic low back 
pain. 
 
Critical appraisal of systematic reviews 
 
A critical appraisal of systematic reviews of randomised controlled trials 
concluded that the existing evidence to support the use of facet joint injections 
in low back pain management is equivocal, with methodological variability 
detected across the studies and reviews. 
 
FACET feasibility study 
 
The FACET feasibility study was a blinded parallel two-arm pilot randomised 
controlled trial to assess the feasibility of carrying out a definitive study 
evaluating the effectiveness of lumbar facet joint injections compared with a 
sham procedure, in patients with non-specific low back pain of more than three 
months’ duration.  The study recruited from the pain and spinal orthopaedic 
clinics at Barts Health NHS Trust only, although a multicentre study was 
planned. 
 
Adult patients referred to the specialist clinics with non-specific low back pain 
despite NICE-recommended best non-invasive care were randomised and 
blinded to receive either intra-articular lumbar facet joint injections with steroid 
or a sham procedure, following a positive response to diagnostic medial branch 
nerve blocks.  Both groups were invited to attend a combined physical and 
psychological programme. 
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Measures of feasibility included the recruitment and retention rate, and 
adherence to the study protocol.  Questionnaires were used to assess a range 
of pain- and disability-related issues.  Of 628 participants screened for eligibility, 
nine were randomised to receive the study intervention and eight participants 
completed the study. 
 
Failure to recruit sufficient participants led to early closure of the study by the 
funder, and no conclusions were drawn on the clinical effectiveness of lumbar 
facet joint injections for the management of non-specific low back pain in this 
sub-group of patients.  Although the target recruitment rate was not achieved, a 
robust study protocol was developed and the intended interventions delivered 
safely, thus addressing many of the feasibility objectives. 
 
Conclusions 
 
Further high quality randomised controlled trials and systematic reviews are 
required to inform decision makers, with implications for both clinical practice 
and policy.  Stronger collaborations with primary care may improve the 
recruitment of patients earlier in their pain trajectory, suitable for inclusion in a 
future trial. 
 
Study registration 
 
EudraCT 2014-003187-20 and Current Controlled Trials ISRCTN12191542. 
 
Funding details 
 
The FACET feasibility study was funded by the National Institute for Health 
Research Health Technology Assessment programme (reference number HTA 
11/31/02). 
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Chapter 1: Introduction 
 
The prevalence and burden of low back pain 
   
Low back pain (LBP) is a significant problem worldwide; an updated systematic 
review of its global prevalence has shown that the mean lifetime prevalence of 
activity-limiting LBP is 38.9%, with an annual prevalence of 38%.1  This group 
defined severe chronic LBP as ‘constant low back pain, which causes difficulty 
dressing, sitting, standing, walking and lifting things.  The person sleeps poorly 
and feels worried’.2  The Declaration of Montréal, agreed at the International 
Pain Summit in 2010, has stated that access to pain management is a 
fundamental human right.3 
 
The Global Burden of Disease (GBD) project aims to integrate all existing 
healthcare knowledge into a universal framework to quantify levels and trends 
in health.  The most recent GBD study published in 2016, examining worldwide 
observational epidemiological trends in disease, injuries and risk factors since 
1990 estimated that the prevalence of LBP has increased by over 17% between 
2005 and 2015, a possible reflection on improving health and longer life 
expectancy, but decreasing overall functional health.  Occupational ergonomic 
factors were also suggested to play a significant role in the development of 
LBP.  The global burden of chronic pain is expected to continue to increase, in 
parallel with the burden of disabling non-communicable disease conditions.4 
 
LBP was the leading cause of years lived with disability (YLDs) in 2015, causing 
more disability globally than any other condition in most countries, and all high-
income countries.5  LBP remained the leading case of YLDs in 2016.6  In 1990 
low back and neck pain was the 12th leading cause of global disability-adjusted 
life years (DALYs), an expression of burden and quantified as a year of life lost 
for each DALY; this increased in 2005 and 2015 to 8th and 4th positions 
respectively.7  In the United Kingdom, the same systematic analysis concluded 
that low back and neck pain represented the second leading cause of DALYs in 
2015, behind ischaemic heart disease. 
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LBP has an economic burden not only on health service providers, but also on 
the individual.  Estimates of healthcare costs can vary even within the same 
country, with cost discrepancies being described at a local level in one review 
paper.8  The direct costs (such as for hospital services and medications) 
associated with back pain in the United Kingdom in 1998 was estimated to be 
£1632 million, which was approximately 20% of total health expenditure that 
year.  Approximately 35% was incurred within the private sector, in contrast to 
employment and informal care costs, which ranged from a conservative 
estimate of £5018 million to an upper estimate of £10 668 million.9   As the most 
recent direct financial cost estimates for the United Kingdom were published 
twenty years ago, it is likely that the current costs may be significantly greater 
due to inflation and other changes to the economic and political landscape.  The 
indirect costs may be substantially greater still.  The inconsistencies of pain 
service provision across the United Kingdom is detailed in the final report of the 
National Pain Audit published in 2012.10 
 
One systematic review identified a number of studies that have attempted to 
estimate the direct, indirect and total costs of LBP in the United States and 
internationally.11  The review concluded that LBP represented an important 
economic burden worldwide, but methodological differences meant that it was 
difficult to compare the costs across studies and between countries.  It again 
noted however that outside the United States, the direct costs were relatively 
low compared with indirect costs, which relate to productivity and employment.  
Although estimation of societal costs was outside the scope of this review, it 
inferred that interventions that have the potential to reduce LBP and associated 
disability claims may present an opportunity to reduce the economic burden in 
the long term. 
 
General overview of chronic low back pain management 
 
LBP can be defined as pain, muscle tension, or stiffness localised below the 
costal margin and above the inferior gluteal folds, with or without leg pain.12  
 19 
Non-specific LBP, where symptoms are experienced without any recognisable 
pathology,13 is thought to affect around 90% of all LBP sufferers; between 1 to 
5% of patients presenting with LBP will have a serious spinal pathology, such 
as vertebral fractures, malignancy, infection, and inflammatory disease.14 
 
A number of individual risk factors have been identified from twenty prospective 
studies which may predict the development of persistent disabling LBP; these 
include maladaptive pain coping behaviours such as fear avoidance behaviour, 
nonorganic signs (including an exaggerated painful response, or non-
reproducible pain), functional impairment, general health status, and psychiatric 
co-morbidities.15  Although it is believed that the majority of those affected with 
LBP will recover within a few months, others will develop chronic symptoms and 
experience recurrent episodes.16  Other early prognostic indicators contributing 
to the transition from acute to chronic LBP with disability at 12 months after 
onset include being unemployed, having widespread pain, a high level of pain 
disability as assessed using the Chronic Pain Grade, catastrophising, and fear 
of pain.17  Screening tools may be used in the primary care setting to identify 
risk factors for a poor disability outcome and prolonged absenteeism from work, 
which have the potential to affect future care decisions.18 
 
In 2015, the International Association for the Study of Pain (IASP) established a 
task force to propose a new category for chronic pain in the 11th revision of the 
International Classification of Diseases (ICD) of the World Health Organisation, 
stating that chronic pain is not represented adequately in the current 10th 
revision ICD-10.  In the proposal, chronic pain is defined as ‘persistent or 
recurrent pain lasting longer than three months’ and chronic primary pain is 
‘pain in one or more anatomic regions that persists and recurs for longer than 
three months and is associated with significant emotional distress or significant 
functional disability (interference with activities of daily living and participation in 
social roles) and that cannot be explained by another chronic pain condition’.19  
Non-specific chronic LBP will be categorised as ‘localised chronic primary pain’. 
 
There remains a lack of gold standard for the diagnosis of chronic LBP.  One 
systematic review of diagnostic tests to identify the tissue source of LBP from 
potentially pain-generating sites such as the intervertebral disc, facet joint or 
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sacroiliac joint concluded that diagnostic tests were of questionable value in 
clinical practice especially in formulating treatment options.20  Diagnostic 
imaging for LBP, such as the routine use of computed tomography (CT) or 
magnetic resonance imaging (MRI), has not been shown to improve clinical 
outcomes in a meta-analysis of six randomised controlled trials funded by the 
American Pain Society,21 and are not recommended in many clinical practice 
guidelines unless features of serious spinal pathology (‘red flags’) are 
suspected. 
 
A number of treatment options are available for the management of chronic 
LBP.  These range from conservative treatments (including acupuncture, 
medications, pain management programmes and physical therapies) to spinal 
injections and surgery.  Some of these management strategies will be 
discussed in further detail in this chapter. 
 
Non-specific LBP research is considered challenging due to the lack of gold 
standards in inclusion criteria, definitions, assessments and outcome measures; 
this heterogeneity has meant that it was not always possible to compare 
studies.22  In 2014, a Research Task Force of the National Institutes of Health 
Pain Consortium developed research standards for chronic low back studies,23 
potentially allowing for pain phenotyping, and facilitating comparisons between 
studies. 
 
Clinical practice guidelines 
 
Clinical practice guidelines for the management of LBP exist in more than 13 
countries, including the United Kingdom, France, Germany, Canada, and the 
United States.24  National healthcare decisions are often informed and 
influenced by specific programmes or independent agencies including The 
National Institute for Health and Care Excellence (NICE) in the United Kingdom, 
the Haute Autorité de Santé (HAS) in France, the Institute for Quality and 
Efficiency in Health Care (IQWiG) in Germany, the Canadian Agency for Drugs 
and Technologies in Health (CADTH), and the Effective Health Care Program 
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(EPC) of the Agency for Healthcare Research and Quality (AHRQ) in the United 
States.  These groups aim to increase the value of healthcare services and 
improve national decision making despite increasing healthcare expenditures 
and limited resources, utilising systematic reviews of technologies or healthcare 
interventions in guideline development.  The use of graded recommendations 
based on the best available quality evidence may therefore reduce variations in 
the quality of care both nationally and worldwide. 
 
These international guidelines generally have consensus on many 
recommendations for chronic LBP management.  Table 1 summarises some of 
these recommendations. 
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Table 1.  International clinical guidelines and recommendations on the treatment of low back pain.  Adapted from 
Table 49-3, Melzack and Wall’s Textbook of Pain 6th edition (2013).12  The United Kingdom guidelines were written after the 
textbook was published and are adapted from NICE guideline NG59 ‘Low back pain and sciatica in over 16s: assessment and 
management’ (2016)25 
 
Country Education Medication Exercises Manipulation Bed rest Referral to specialist 
United 
Kingdom 
(2016)25 
 
Provide people 
with advice and 
information, 
tailored to their 
needs and 
capabilities, to 
help them self-
manage their 
LBP with or 
without 
sciatica, at all 
steps of the 
treatment 
pathway 
 
 
 
Oral NSAIDs at 
the lowest 
effective dose for 
the shortest 
possible period of 
time 
 
Consider weak 
opioids (with or 
without 
paracetamol) for 
managing acute 
LBP only if an 
NSAID is 
contraindicated, 
not tolerated or 
 
Consider a 
group exercise 
programme 
(biomechanical, 
aerobic, mind–
body or a 
combination of 
approaches) 
within the NHS 
for people with a 
specific episode 
or flare-up of 
LBP with or 
without sciatica 
 
Take people's 
specific needs, 
 
Do not offer 
traction for 
managing LBP 
with or without 
sciatica 
 
Consider 
manual therapy 
(spinal 
manipulation, 
mobilisation or 
soft tissue 
techniques such 
as massage) for 
managing LBP 
with or without 
sciatica, but only 
 
No 
recommendation 
 
Consider referral for 
assessment for 
radiofrequency 
denervation for people 
with chronic LBP when 
non-surgical treatment 
has not worked for them 
and the main source of 
pain is thought to come 
from structures supplied 
by the medial branch 
nerve and they have 
moderate or severe levels 
of localised back pain 
(rated as 5 or more on a 
visual analogue scale, or 
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Country Education Medication Exercises Manipulation Bed rest Referral to specialist 
Include 
information on 
the nature of 
LBP and 
sciatica and 
encouragement 
to continue with 
normal 
activities 
 
has been 
ineffective 
Do not offer 
paracetamol, 
opioids, selective 
serotonin 
reuptake 
inhibitors, 
serotonin-
norepinephrine 
reuptake 
inhibitors, tricyclic 
antidepressants 
or 
anticonvulsants 
 
preferences and 
capabilities into 
account when 
choosing the 
type of exercise 
as part of a 
treatment 
package 
including 
exercise, with or 
without 
psychological 
therapy  
 
equivalent) at the time of 
referral 
Only perform 
radiofrequency 
denervation in people with 
chronic LBP after a 
positive response to a 
diagnostic medial branch 
block 
 
Consider spinal 
decompression for people 
with sciatica when non-
surgical treatment has not 
improved pain or function 
and their radiological 
findings are consistent 
with sciatic symptoms 
France 
(2000) 
 
Short-term 
education 
about the back, 
in groups, is 
not beneficial 
 
Acute and 
chronic: regular 
simple 
analgesics, 
NSAIDs, and 
 
Acute: flexion 
exercises have 
not been shown 
to be of benefit. 
No 
 
Acute and 
chronic: 
provides short-
term benefit. No 
recommendation 
 
Acute and 
chronic: not 
recommended 
 
Acute: no 
recommendation 
 
Chronic: recommended 
physiotherapy/behavioural 
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Country Education Medication Exercises Manipulation Bed rest Referral to specialist 
muscle relaxants. 
No evidence for 
systemic 
corticosteroids 
 
Chronic: 
additional 
recommendations 
for acetylsalicylic 
acid, level II 
following failure to 
respond to level I 
and level III 
(strong opioids) 
on case-by-case 
basis. 
Tetrazepam, 
tricyclic 
antidepressants 
recommendation 
on extension 
exercises 
 
Chronic: 
physical 
exercise is 
recommended; 
no particular 
type advocated 
for one form of 
manual therapy 
over another 
therapy/multidisciplinary 
program if non-response 
to first-line care 
Germany 
(2007) 
 
Acute: 
stimulate daily 
activities, 
explain that 
 
Acute and 
chronic: (1) 
paracetamol, (2) 
NSAIDs (oral or 
 
Acute: exercise 
therapy not 
effective 
 
 
Acute: optional 
within the first 4–
6 weeks 
 
 
Maximum of 2 
days’ bed rest 
 
Immediate surgery 
indicated for cauda equina 
syndrome 
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Country Education Medication Exercises Manipulation Bed rest Referral to specialist 
moving is not 
dangerous 
 
Chronic: more 
intense 
psychotherapy 
indicated in 
case of 
psychological 
co-morbidity 
topical), (3) 
muscle relaxants 
(in patients with 
muscle spasms, 
(4) opioids 
Subacute and 
chronic: exercise 
therapy well 
supported by 
evidence 
Chronic: option if 
short lasting 
Optional referral for 
surgery: therapy-resistant 
(>6 weeks) plus signs of 
nerve root compression 
 
Surgery may be an option 
if after 2 years’ 
conservative treatment, 
including a 
biopsychosocial treatment 
program, was 
unsuccessful 
Canada 
(2007) 
 
Reassurance 
and advice to 
return to work 
and usual 
activities 
 
NSAIDs, muscle 
relaxants, and 
analgesics for 
acute pain 
 
Low evidence for 
NSAIDs and 
analgesics for 
subacute pain 
 
Strengthening 
exercises, 
extension 
exercises, and 
specific 
exercises not 
recommended 
for acute but 
recommended 
for subacute and 
chronic pain with 
 
Acute: 
recommended 
for short-term 
pain reduction 
 
Subacute and 
chronic: 
recommended 
with low 
evidence 
 
 
Not 
recommended 
 
Refer patients with 
neurological signs or 
symptoms if functional 
deficits persistent or 
deteriorating after 4 
weeks 
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Country Education Medication Exercises Manipulation Bed rest Referral to specialist 
no superior form 
of exercise 
United 
States 
(2007) 
 
Provide 
information on 
prognosis, 
staying active, 
self-
management 
 
Self-care 
education 
books 
recommended 
 
Paracetamol, 
NSAIDs 
recommended as 
first-line drugs 
 
Acute: muscle 
relaxants, 
benzodiazepines, 
tramadol, opioids 
 
Subacute or 
chronic: 
antidepressants, 
benzodiazepines, 
tramadol, opioids 
 
Acute: not 
effective 
 
Subacute and 
chronic: 
recommended 
 
For acute LBP if 
not improving 
 
Even if required 
for severe 
symptoms, 
patients should 
be encouraged 
to return to 
normal activities 
as soon as 
possible 
 
For interdisciplinary 
intervention if chronic 
 
If suspicion of significant 
nerve root impingement or 
spinal stenosis 
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Controversies arising from the clinical practice guidelines 
 
Guidelines in the United Kingdom 
 
In May 2009, NICE published clinical guideline 88 (CG88), ‘Low back pain: early 
management of persistent non-specific low back pain’.  Its aim, based on the 
‘best available evidence’, was to advise healthcare professionals such as 
general practitioners (GPs) on the management of tension, soreness and 
stiffness in the low back (between the rib cage and buttock creases) without a 
specific cause, which lasted for more than six weeks but less than twelve 
months.26 
 
NICE CG88’s Guideline Development Group (GDG) aimed to answer the 
research question, ‘What is the effectiveness of injections or nerve blocks 
compared with usual care or sham on pain, functional disability or psychological 
distress?’.26  One systematic review of lumbar facet joint injections in chronic 
LBP management was identified,27 and one randomised controlled trial met the 
inclusion criteria; this was double-blind, placebo-controlled randomised 
controlled trial published by Carette et al. which compared intra-articular lumbar 
facet joint injections with steroid against intra-articular saline injections, in 
participants who had a positive response to a single diagnostic block.28  
 
NICE CG88’s GDG did not recommend injections of therapeutic substances into 
the back for non-specific LBP due to insufficient evidence, advising instead a 
more conservative approach including exercise, spinal manipulation and 
acupuncture (see figure 1).  The Faculty of Pain Medicine of the Royal College 
of Anaesthetists had expressed concerns over these guidelines, as their 
nominated pain medicine specialist and expert in non-surgical inventions was 
not selected for membership of the GDG.29  They issued stakeholder comments 
to the draft guideline in November 2008, which concluded: 
 
‘National guidelines for this common clinical problem would be very helpful but 
these current recommendations are seriously flawed and not suitable for a 
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NICE publication.  We believe that there are insurmountable problems with the 
methodology used by the Guideline Development Group, the strength of 
available evidence, the interpretation of the data and therefore conclusions and 
recommendations.  Significantly more work needs to be undertaken on this 
topic with input from others who will be able to assist in the appropriate 
interpretation of the available (but scant) evidence.’30 
 
The publication of these guidelines led to the resignation of the President of the 
British Pain Society,31 and concerns were expressed that funding for pain clinics 
and services may be reduced as a direct consequence.32  The Council of the 
British Pain Society recommended withdrawal of the guidelines in a consensus 
statement published in their Autumn 2009 newsletter.33 
 
In November 2016, NICE CG88 was replaced by NICE guideline 59 (NG59), 
‘Low back pain and sciatica in over 16s: assessment and management’.25  The 
updated guideline had an expanded remit and advised consideration of 
radiofrequency denervation in the management of LBP after a positive 
response to a diagnostic medial branch block, in cases where non-surgical 
treatment had failed. 
 
NICE NG59’s GDG explored the research question, ‘What is the clinical and 
cost effectiveness of spinal injections in the management of non-specific low 
back pain?’.25  The interventions and comparators in the review protocol 
included steroid, local anaesthetic, sclerosants, Botox and hyaluronans, and 
were to be compared versus each other and also with a sham, placebo or 
saline, usual care, or other treatments.  Six image-guided intra-articular lumbar 
facet joint injection studies were identified and split into pre-defined sub-groups.  
Studies of monotherapy28, 34, 35 and combination therapy36-38 were reviewed by 
the GDG. 
 
The two GDGs differed in terms of the composition of the group members (for 
example, an interventional pain specialist was represented in NICE NG59’s 
group), and in how the included studies were identified; NICE CG88’s GDG 
identified a randomised controlled trial from a systematic review paper, whereas 
NG59’s GDG published a new clinical review protocol.39 
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Different interpretations can be applied to the same study; one example is the 
study published by Carette et al. in 1991, which NICE CG88’s GDG concluded, 
in concordance with the study’s authors themselves, showed little value in intra-
articular steroid injections for chronic LBP management.28  NG59’s GDG noted 
that although there was a change in the Mean Sickness Impact Profile in favour 
of the steroid group at six months, it was not clear what a meaningful magnitude 
of change was.  Staal and colleagues however concluded that this study had 
‘positive results’ in their Cochrane review.40  This indicates that study outcomes 
can be difficult to interpret clinically; statistically significant results may not have 
clinical relevance for example, and are therefore open to interpretation. 
 
Some of the differences between the included studies can be attributed to the 
dates of the literature searches; December 2006 and December 2015 for NICE 
CG88 and NICE NG59 respectively.  The single study used for guideline 
development by NICE CG88’s GDG compared facet joint injections with a sham 
procedure, whereas NICE NG59’s GDG included comparator trials in addition to 
a placebo study, and studies with a usual care arm.  Although NICE NG59’s 
GDG noted that there was heterogeneity between the trials, spinal injections 
were again not recommended for managing LBP based on their summary of the 
evidence (see figure 2).  Despite their differences in some aspects of their 
deliberation, both GDGs drew the same final conclusions with regards to lumbar 
facet joint injections. 
 
LBP and sciatica were selected by the Trauma Programme of Care Board as 
their Pathfinder Project; these projects were established by NHS England in 
2013 in order to set up clear ‘end-to-end’ generic pathways from primary care 
into specialised services as required, enabling collaborative commissioning and 
incorporation of the latest evidence into the pathways.41  The National Low 
Back and Radicular Pain Pathway 2017 was updated following the publication 
of the NICE guidelines NG59, and included all of NICE’s recommendations (see 
figure 3).  
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Figure 1.  Flowchart for the management of persistent non-specific low back pain (NICE CG88, 2009).  Adapted from 
‘Low back pain: early management of persistent non-specific low back pain’ (NICE clinical guideline 88).  Quick reference 
guide42 
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Figure 2.  NICE Pathways.  Managing low back pain and sciatica (NICE NG59, 2016).  Adapted from the interactive NICE 
Pathways http://pathways.nice.org.uk/pathways/low-back-pain-and-sciatica43 
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Figure 3.  Back pain pathway flowchart from the National Back Pain and 
Radicular Pain Pathway.  Adapted from NHS England’s Trauma Programme 
of Care, National Radicular Pain Pathway 201741
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Guidelines in the United States 
 
In concordance with the NICE guidelines in the United Kingdom, the American 
Pain Society similarly do not recommend facet joint injections with steroid for 
persistent non-radicular LBP, based on ‘moderate-quality evidence’;44 the 
authors however stated that future research could change these 
recommendations.  These guidelines were criticised by Manchikanti and 
colleagues in 2010, who described a number of alleged methodological failures 
and inappropriate analyses, potentially resulting in misleading conclusions.45 
 
The views expressed by the American Pain Society have also been challenged 
by the American Society of Interventional Pain Physicians in their 2013 
publication ‘An update of comprehensive evidence-based guidelines for 
interventional techniques in chronic spinal pain.  Part II: guidance and 
recommendations’.46  This group reviewed a number of spinal interventional 
procedures and found limited evidence to support the use of intra-articular 
lumbar facet joint injections based on the results of one moderate quality 
randomised controlled trial and five observational studies. 
 
Potential implications of the clinical practice guidelines  
 
Despite the widespread availability of clinical guidelines for the management of 
non-specific LBP in various countries, adherence to these guidelines have been 
demonstrated to be suboptimal; one systematic review and meta-synthesis of 
qualitative studies has identified a number of implementation barriers in 
guideline adherence by primary care providers including GPs and 
physiotherapists.47  The authors concluded that clinicians had an inherent lack 
of trust in the guideline development process and in their dissemination, and 
that the guidelines were perceived to be lacking in credibility.  One finding from 
this review was that clinicians tended to adopt a biomedical approach to LBP 
management (seeing pain as a symptom of a physical disorder), rather than 
utilising a biopsychosocial model, where the physical, psychological and social 
components of pain are considered together.  Popular clinical practice included 
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the use of imaging techniques and interventions against current guideline 
recommendations. 
 
A review of utilisation of interventional pain techniques in the fee-for-service 
Medicare population, the largest insurer in the United States, showed that there 
was an annual increase of 10.7% (overall increase of 313%) in facet joint 
interventions and sacroiliac joint blocks between 2000 and 2014.48  Beckworth 
and colleagues noted that between 2007 and 2012 approximately 1.5 million 
lumbosacral facet joint injections were being carried in the Medicare population 
each year, with an average increase of 11% per year from 2000 until 2012.49  
These figures have however been challenged by Manchikanti and colleagues, 
citing methodological issues and the inclusion of denied services.50  Both 
groups however acknowledge a decline in growth per year from 2010, when 
billing became limited to image-guided injections only (fluoroscopic or CT-
guided), of no more than three spinal levels. 
 
In the United Kingdom, Hospital Episode Statistics record the number of 
procedures carried out using the procedural classification Office of Population 
Censuses and Surveys Classification of Interventions and Procedures version 4 
(OPCS-4).51  A search for the code V54.4 ‘Injection of spinal facet of spine’, 
carried out on 1st December 2017, gave an estimate of the number of facet joint 
injections carried out per year in England (see figure 4).  These figures 
demonstrate a generally increasing trend in the numbers of procedures carried 
out each year, although the accuracy of these figures is unclear.  The plateau in 
growth in recent years may reflect policy changes as a result of the NICE 
guidelines published in 2009 and 2016.25, 26 
 
Comparison of the percent changes of recorded facet joint injections and 
interventional pain procedures each year between the United States and 
England show comparable trends in the rate of growth and decline of these 
procedures being carried out (see table 2).  This may again reflect policy 
changes at a government level such as the introduction of the Affordable Care 
Act in the United States, and changes in how the fee-for-service codes were 
being applied (see figure 5). 
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Table 2.  Percent change in facet joint injections and interventional pain 
procedures recorded in England and the United States compared to the 
previous year 
 
Year 
Percent change in facet joint injections and 
interventional pain procedures recorded compared to 
the previous year (%) 
England (data 
from Hospital 
Episode 
Statistics)51 
United States 
(Manchikanti et 
al.)48 
United States 
(Beckworth et 
al.)49 
2001 +14.3 +18.6 +25 
2002 +10.7 +22.6 +26 
2003 +5.1 +15.5 +25 
2004 +9.2 +28.4 +23 
2005 +20.9 +7.8 +23 
2006 +13.2 +11.1 +25 
2007 +25.4 -2.9 -5 
2008 +19.2 +5.1 +1 
2009 +9.7 +3.9 0 
2010 +6.2 -3.8 -14 
2011 -7.8 +2.2 +3 
2012 +12.2 -1.3 0 
2013 +7.4 -3.4 n/a 
2014 +9.1 -1.2 n/a 
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Figure 4.  Number of OPCS-4 V54.4 ‘Injection of spinal facet of spine’ procedures recorded per year in England.  
Search carried out on 1st December 2017. 
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Figure 5.  Percent change in facet joint injections and interventional pain procedures recorded in England and the 
United States compared to the previous year, between 2001 and 2015 
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Diagnosis of low back pain of facet joint origin 
 
A number of anatomical structures within the low back are associated with the 
development and persistence of LBP, including the facet joints, sacroiliac joints, 
intervertebral discs, ligaments, soft tissue and fascia, muscle, and nerve roots.  
Lumbar facet joints, also known as zygapophyseal joints, are paired synovial 
joints between the superior and inferior articular processes of consecutive 
lumbar vertebrae, and between the fifth lumbar vertebra and the sacrum (see 
figure 6).  Their role is to provide structure and integrity to the lumbar spine, and 
to guide movement, including flexion-extension and some rotation.  These facet 
joints are innervated by free and encapsulated nerve endings supplied by the 
medial branches of the dorsal rami (‘medial branch nerves’), which 
neuroanatomic studies have shown to contain substance P and calcitonin gene-
related peptide.52  Pain perceived from the facet joint can be considered to arise 
from any structure that is part of the joint, including the fibrous capsule, synovial 
membrane, hyaline cartilage, and bone.  One evidence-based review has 
estimated the prevalence of lumbar facet joint pain to be between 5 and 15% of 
the axial LBP population, although the prevalence increases with age.53 
 
The diagnosis of facet joint pain at present is largely a clinical one, based on 
history and physical examination.  Typically, sufferers complain of bilateral axial 
LBP which may be referred to the groin or thigh, rarely distal to the knee.  
Lumbar paraspinal tenderness has been shown to be associated with a 
successful outcome following lumbar facet joint interventions, and is considered 
a reliable indicator of pain of facet joint origin.54  Revel and colleagues 
described a number of clinical characteristics for lumbar facet joint pain in their 
1998 publication ‘Capacity of the clinical picture to characterize low back pain 
relieved by facet join anesthesia’;55 these include: 
 
§ Pain not worsened when rising from forward flexion 
§ Pain well relieved by recumbency 
§ Pain not exacerbated by coughing 
§ Pain not worsened by extension-rotation 
§ Pain not worsened by hyperextension 
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These tests have however not been shown to be a useful clinical screening tool 
for lumbar facet joint interventions, with one study demonstrating the test’s low 
sensitivity and high specificity.56  One modified Delphi survey of pain experts 
reached a consensus on indicators of LBP of facet joint origin, which included 
pain on palpation of the facet joint or transverse process, worsening pain on 
trunk extension but not flexion, paravertebral muscle spasm over the affected 
joint, no pain referral below the knee, and no radicular symptoms.57 
 
As discussed in the previous section, the existing clinical guidelines do not 
recommend routine imaging in the management of LBP unless there are 
features of serious spinal pathology.  Computed tomography (CT) imaging is 
considered to be a preferred method for demonstrating evidence of facet joint 
arthritis although Kalichman and colleagues have concluded that the 
association between facet joint osteoarthritis as seen on CT imaging and LBP 
remains unclear.58  This group carried out a cross-sectional study of a 
community-based population with 188 participants and found a prevalence of 
facet joint arthritis (as diagnosed on CT imaging) of 59.6% in men and 66.7% in 
women which increased with age, with the highest prevalence at the L4/5 spinal 
level.  No significant association between facet joint arthritis and LBP was 
found. 
 
Diagnostic injections may be utilised to help diagnose LBP of facet joint origin, 
usually prior to further spinal interventions.  These involve an injection of local 
anaesthetic either into the joint itself, or more commonly to its nerve supply, the 
medial branch nerves.  A positive response to a diagnostic block is a reduction 
in pain for the duration of the local anaesthetic’s action, although single blocks 
may be associated with a false positive response.59  Dual or double 
comparative blocks can be used, where the procedure is repeated with a 
different local anaesthetic, which has a different duration of action.  Lidocaine (a 
short-acting local anaesthetic) and bupivacaine (a longer-acting local 
anaesthetic) are commonly used.  Placebo-controlled blocks and triple 
comparative blocks have also been used and are described in the literature. 
 
 40 
A multicentre, randomised controlled trial of 151 participants in the United 
States has concluded that it is more cost-effective to proceed immediately to 
radiofrequency denervation of the lumbar facet joint medial branch nerves, 
without first carrying out diagnostic blocks.  The group receiving no diagnostic 
blocks had the highest number of total successful procedures after three 
months, compared with the groups who received single or dual blocks.60 
 
In recent years, a number of systematic reviews have been published on the 
diagnostic accuracy and utility of lumbar facet medial branch nerve blocks, often 
reviewing randomised controlled trials from the same groups of authors.61-63  
Falco and colleagues published an updated review in 2012, concluding that 
there is good evidence for the use of dual blocks with 75% to 100% pain relief 
as the criterion standard.61  Boswell and colleagues demonstrated level 1 
evidence for the use of dual blocks in diagnosing chronic lumbar facet joint 
pain, based on evidence obtained from multiple relevant high quality 
randomised controlled trials and diagnostic accuracy studies.62  Manchikanti 
and colleagues reviewed 7 controlled diagnostic studies with 80% or more pain 
relief, and 6 studies with at least 75% pain relief, and again concluded that 
there was level 1 evidence to support their use.63
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Figure 6.  Lumbar facet joint anatomy 
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Therapeutic lumbar facet joint interventions 
 
LBP of facet joint origin can be treated with spinal injections including lumbar 
facet joint injections, medial branch nerve blocks, and radiofrequency 
denervation of the medial branch nerves.  At present, there is no consensus or 
gold standard on their indications or the technique of these procedures.  These 
injections can be used to serve both a therapeutic and a diagnostic purpose; 
this appears to be common practice in the United Kingdom, to presumably 
avoid the need to return for further interventions.64 
 
Lumbar facet joint injections involve the injection of an active substance, such 
as steroids with or without a local anaesthetic, into the joint itself (intra-articular 
injections), or next to the joint (peri-articular injections).  They are commonly 
carried out under x-ray or fluoroscopic guidance, although can be performed 
under ultrasound or CT guidance.65  The NICE Guideline Development Group 
for the guideline NG59 ‘Low back pain and sciatica in over 16s: assessment 
and management’ has acknowledged the widespread use of image-guided 
facet joint injections with steroid despite the current body of evidence.25  The 
evidence for their use will be discussed further in Chapter 2.   
 
The use of steroids in intra-articular injections stems from the rationale that they 
can reduce inflammation;66 particulate corticosteroids such as 
methylprednisolone and triamcinolone are commonly used for lumbar facet joint 
injections.  One randomised controlled trial of sixty subjects demonstrated that 
steroids were ‘effective’ in the treatment of LBP, whether administered 
systemically or via intra-articular injection; this study however was not placebo-
controlled (and therefore any improvement due to the natural progression of 
LBP could not be ruled out), and no invasive diagnostic test for pain of facet 
joint origin was used.67  Local anaesthetics have also been shown to have anti-
inflammatory effects, and have long-term effectiveness following nerve blocks.68  
It is considered usual practice in the United Kingdom to inject the steroid and 
local anaesthetic into the joint at the same time.64 
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There is at present no agreed technique for lumbar facet joint injections.  One 
research group in the United Kingdom used a consensus conference process to 
develop a protocol for therapeutic facet joint injections for a randomised 
controlled trial.64  The injections were to be carried out in the prone position with 
no intravenous sedation, under x-ray imaging without radio-opaque contrast to 
visualise the joint and confirm needle entry into the joint cleft.  A total of 7.5mg 
bupivacaine and 20mg methylprednisolone would be injected via pre-filled 
syringes (2ml total volume per joint), and a maximum of six facet joints injected 
at the L3/4, L4/5 and L5/S1 spinal levels bilaterally.  An ‘oblique needle 
technique’ has also been described in the literature, with the patient placed in 
an oblique prone position, typically around 60° for optimal visualisation of the 
lower lumbar facet joints, with no more than 2ml injected into the joint capsule to 
avoid capsule rupture and extravasation.69 
 
Lumbar facet medial branch nerves can be injected with local anaesthetic as 
part of the diagnostic procedure to confirm facet joint pain, or as a therapeutic 
procedure often with local anaesthetic and steroid.  The Spine Intervention 
Society, formerly known as the International Spine Intervention Society, has 
developed practice guidelines including a step-by-step needle placement 
technique for this procedure.70  An oblique approach is used and the target 
points identified using C-arm fluoroscopy, at the junction of the superior articular 
process and the transverse process, halfway between the superior border of the 
transverse process and the mamillo-accessory notch.  Confirmation of correct 
needle placement on the target nerve in the postero-anterior view is required 
prior to injection of radio-opaque medium to exclude intravascular spread, 
followed by injection of 0.5ml of local anaesthetic. 
 
Therapeutic lumbar facet joint nerve blocks have however in the past been 
overlooked in clinical guidelines despite their potential to relieve LBP of facet 
joint origin.71  Manchikanti and colleagues reviewed two high quality 
randomised controlled trials and one moderate to high quality randomised 
controlled trial of therapeutic nerve blocks and concluded that there was level II 
evidence for their use in the lumbar spine.68  Both Falco et al. and Datta et al. 
found moderate evidence for their use in the treatment of chronic LBP in their 
systematic reviews.72, 73 
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Radiofrequency denervation creates a well-circumscribed lesion at the target 
site, via the placement of a thermocouple probe inserted through an insulated 
radiofrequency cannula with an exposed tip.  One method described by Gauci 
recommends placing the cannula in close proximity to the target (the lumbar 
facet medial branch nerve), and using sensory stimulation at a frequency of 
50Hz and the lowest possible voltage to locate the nerve.74  A low frequency of 
2Hz is then applied to rule out motor nerve involvement.  A radiofrequency 
current of approximately 300Hz can then be passed through the probe, 
generating heat within the surrounding tissues and denaturing the target nerve.  
The lesion size has been shown to increase with time initially in a linear fashion, 
before reaching a steady state (see figure 7). 
 
The updated Cochrane review ‘Radiofrequency denervation for chronic low 
back pain’ published in 2015 concluded that there was very low to moderate 
quality evidence for the use of radiofrequency denervation in providing pain 
relief or improving function, and that there was a lack of high-quality trials, 
based on a review of 23 randomised controlled trials.75  The current NICE 
guidelines in the United Kingdom for managing pain of lumbar facet joint origin 
however reviewed eight randomised controlled trials and recommend 
radiofrequency denervation of the medial branch nerves as a cost-effective way 
of managing moderate to severe chronic LBP when non-surgical treatment has 
not helped, after a positive response to a diagnostic medial branch block.25 
 
At the time of writing, there however remains conflicting advice on the use of 
radiofrequency denervation in the management of chronic LBP.  Lee and 
colleagues carried out a meta-analysis of seven randomised controlled trials 
(454 patients) of patients undergoing radiofrequency denervation compared 
with control procedures; they concluded that the radiofrequency group had less 
LBP after one year, with the best response seen in those who had a positive 
result following a diagnostic block.76  In contrast, the Mint study concluded that 
there was no evidence to support the use of radiofrequency denervation in 
addition to a 3-month standardised exercise programme with psychological 
support for participants with pain of facet joint origin, sacroiliac joint origin, or 
originating from the intervertebral discs.77 
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The Mint study was a Dutch multicentre non-blinded randomised controlled trial 
which included 251 participants in the facet joint arm who had chronic LBP and 
a positive response to a diagnostic block; no clinically important differences 
were observed between the intervention group and those who received the 
exercise programme only.  A statement representing twelve medical specialty 
societies including interventional pain specialists, surgeons and physicians has 
however rejected the findings, criticising its study design (including the lack of 
baseline pain and function scores), patient selection (controlled diagnostic 
blocks were not used), injection techniques and data analysis.78  Provenzano 
and colleagues also described methodological flaws, which they suggested 
were due to educational gaps within the interventional pain community.79  
Another critical review by Kuijk and colleagues has concluded that patient 
selection and recruitment were suboptimal, the interventional pain techniques 
were not standardised, and the conclusions were erroneous due to inaccurate 
presentation and misinterpretation of the results.80
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Figure 7.  Plot of lesion size versus exposure time to radiofrequency current.  Adapted from Gauci’s manual of RF 
techniques (2008)74 
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Conservative management 
 
Conservative management of LBP is non-invasive and includes 
pharmacological and non-pharmacological interventions.  The latter group can 
be further categorised into combined physical exercise and psychological 
treatments (cognitive behavioural therapy and interdisciplinary rehabilitation), 
physical exercise therapy (such as stretching and yoga), manual therapy 
(including spinal manipulation and acupuncture), and information and 
education.  One systematic review has shown that these treatments are cost-
effective options in the management of LBP.81 
 
The 2009 NICE clinical guideline 88 ‘Early management of persistent non-
specific low back pain’, which has since been superseded, recommended 
consideration for referral for a combined physical and psychological programme 
of around 100 hours over a maximum of eight weeks to those who had no 
satisfactory improvement after an exercise programme, a course of manual 
therapy, or acupuncture, and with high disability or significant psychological 
distress.26  The National Spinal Taskforce’s report ‘Commissioning spinal 
services – getting the service back on track’ published in 2013 had identified 
that a combined physical and psychological programme was the most serious 
gap in current services in the United Kingdom.82  The updated NICE guideline 
NG59 ‘Low back pain and sciatica in over 16s: assessment and management’ 
again recommended a combined physical and psychological programme with a 
cognitive behavioural approach, when previous treatments had not been 
effective and where ‘significant psychosocial obstacles’ were identified.25 
 
Lamb and colleagues carried out a definitive large-scale randomised controlled 
trial of a cognitive behavioural approach that could be delivered in fewer hours 
than recommended in the NICE clinical guideline 88.83  Registered health 
professionals would receive 2 days’ training to deliver the group-based Back 
Skills Training (BeST) programme, which the research group had demonstrated 
to show long-term effectiveness and cost-effectiveness in managing subacute 
and chronic LBP.  The training would be provided on-line to allow trainers to 
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deliver an individual session of 60 minutes, followed by six group sessions 
lasting 90 minutes each.84 
 
The latest evidence from a systematic review for the American College of 
Physicians clinical practice guideline for LBP has concluded that nonsteroidal 
anti-inflammatory drugs (NSAIDs) had smaller benefits than placebo for LBP 
than previously observed, and that duloxetine (a serotonin and noradrenaline 
reuptake inhibitor) had some benefit in chronic LBP management.85  The recent 
American College of Physicians clinical practice guidelines published in 2017 
emphasise the use of non-pharmacological treatments such as superficial heat 
and massage, and recommend NSAIDs as first-line therapy where non-
pharmacological therapy has failed, followed by tramadol or duloxetine as 
second-line therapy.  Opioids were only to be considered after an informed 
discussion where the potential benefits were perceived to outweigh the risks.86 
 
Outcomes for chronic pain trials 
 
Effective comparison of outcome assessments between clinical trials require 
comparable outcome measures.  Kaiser and colleagues reviewed core outcome 
measures recommended for use in trials of chronic pain in general, and for 
studies of non-specific LBP.87  This review group noted that there were overlaps 
in the recommended core domains but also commented on potential gaps 
between the recommendations, most significantly in psychometric tests of 
emotional functioning and emotional wellbeing. 
 
Deyo and colleagues proposed certain outcome measures for trials of chronic 
LBP, later approved by the National Institutes of Health (NIH) Pain Consortium 
in the United States, with the aim of standardising these measurements across 
clinical trials.88  They have advised that clinical researchers use measurement 
tools with a greater degree of precision than those used in routine clinical 
practice (see table 3).  Bombardier has also proposed core outcome domains 
for trials of chronic LBP, based on a non-formal consensus process.  These 
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include back-specific function, generic health status, pain, work disability, and 
patient satisfaction.89 
 
The Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials 
(IMMPACT) have recommended core outcome measures that should be 
considered for clinical trials of chronic pain treatment efficacy and effectiveness, 
based on consensus from experts in the field of chronic pain treatment 
outcomes.90, 91  The six core outcome domains are pain, physical functioning, 
emotional functioning, participant ratings of global improvement and satisfaction 
with treatment, symptoms and adverse events, and participant disposition.  
Specific measures were also recommended for each core outcome domain, for 
example an 11-point numerical rating scale of pain intensity, and the use of 
rescue analgesics during the course of the trial. 
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Table 3.  Proposed outcome measures for clinical trials of chronic low 
back pain.  Adapted from Deyo et al.’s ‘Outcome measures for low back pain 
research: a proposal for standardized use’ (1998)88 
 
Domain Specific instrument 
 
Pain 
symptoms 
 
Bothersomeness or severity and frequency of LBP and leg 
pain 
 
Back-related 
function 
 
Roland Morris Disability Questionnaire92 (or adaptations), or 
Oswestry Low Back Pain Disability Questionnaire93 (or 
adaptations) 
 
Generic well-
being 
 
SF-1294 (12-Item Short Form Health Survey) or EuroQol 
instrument for utility-weighted health status;95 also, “If you 
had to spend the rest of your life with the symptoms you have 
right now, how would you feel about it?” 
 
Disability 
(social role) 
 
Days of work absenteeism, cut down activities, bed rest 
 
Satisfaction 
with care 
 
Single question on overall satisfaction (optional) 
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Is new evidence needed to support the use of lumbar facet joint 
injections?  The FACET feasibility study 
 
NICE guideline 88, which covered the early treatment and management of 
persistent LBP, had acknowledged that there is some evidence from case 
studies that intra-articular lumbar facet joint injections in the management of 
persistent LBP may be effective, but insufficient evidence from randomised 
controlled trials to support their use.26  In order to provide further high quality 
evidence, the National Institute for Health Research (NIHR) Health Technology 
Assessment (HTA) programme issued a commissioning brief in 2011 to answer 
the research question, ‘Is a definitive study to assess the effectiveness and 
cost-effectiveness of facet joint injections compared to best non-invasive care 
for people with persistent non-specific low back pain feasible?’.  The 
commissioning brief stated that the control or comparator should be: 
 
‘(i) usual care, as defined by NICE guidelines, 
(ii) sham facet joint injection (method of delivering the sham procedure to be 
investigated in the feasibility phase).’96 
 
Two teams were funded by NIHR in response to this commissioned call with 
different trial designs as requested by the funder; one team explored the 
addition of intra-articular facet joint injections to best usual non-invasive care 
(Facet Feasibility, HTA 11/31/01),97, 98 and the other was a multicentre double-
blind randomised controlled trial comparing intra-articular lumbar facet joint 
injections to a sham procedure, followed by a combined physical and 
psychological programme (FACET feasibility study, HTA 11/31/02).96, 99  The 
FACET feasibility study is explored in detail in this thesis, and the different 
approaches to trial design by the study teams is discussed further in chapter 5. 
 
There are currently no published, standardised, validated sham procedures for 
lumbar facet joint injections, or consensus on what would constitute a suitable 
sham procedure.  Vekaria and colleagues defined a sham procedure as one 
where the participants believed that steroid had been injected into the facet 
joints, for example when a needle is inserted into the joint but no substance 
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injected, although the steroid may be injected elsewhere.  This group defined a 
placebo as an inactive or insert substance such as normal saline being injected 
into or around the joint.100  One prospective triple crossover study in patients 
with chronic LBP utilised a sham technique where the needle was positioned 
outside the facet joint without any substance injected, to avoid irritation of the 
joint capsule; the other two groups received volume injections with a local 
anaesthetic and normal saline respectively.69  Previous controlled trials had 
used volume injections only, such as one carried out by Lilius et al. which 
compared intra-articular steroid injections with peri-capsular steroid injections 
and intra-articular saline injections.36 
 
The current international and national guidelines do not recommend intra-
articular lumbar facet joint injections with therapeutic substances for LBP 
management, despite their widespread use and potential to relieve LBP and aid 
rehabilitation.  Some practitioners routinely carry out intra-articular facet joint 
injections of steroid with or without local anaesthetic, whilst others regard these 
injections as only of diagnostic or short-term value, preferring instead 
denervation of the facet joint by an ablative treatment modality (radiofrequency 
denervation) with the aim of achieving longer-term improvement.  Further 
confusion and uncertainty arise from the different approaches to the diagnosis 
and management of suspected facet joint disease.  
 
The next chapter will identify and critically appraise the existing literature on 
lumbar facet joint injections for chronic LBP management, and will assess the 
need to carry out a new or updated systematic review and meta-analysis. 
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Chapter 2: An overview of systematic reviews and 
meta-analyses of therapeutic lumbar facet joint 
injections 
 
Introduction 
 
Systematic reviews in interventional pain management are considered to be 
essential not only for improving clinical care, but also in policy making and the 
development of clinical practice guidelines.101  Systematic reviews have in the 
past been criticised for their failure to address real-world healthcare decisions; 
the AHRQ’s publication ‘Method guide for effectiveness and comparative 
effectiveness reviews’ recommend that study characteristics should be relevant 
and applicable to the population of interest.102  The Cochrane handbook defines 
a systematic review as a way of answering a specific research question by 
collating all empirical evidence that fulfils pre-specified eligibility criteria.  When 
systematic methods are applied correctly in the identification, selection, 
synthesis and summary of studies, the risks of bias are minimised, in order to 
draw clear conclusions and decisions.103 
 
A systematic review consists of key components which must be addressed; 
these include clearly stating the objectives and eligibility criteria, reproducible 
methodology, systematic search strategies, an assessment for validity (such as 
risk of bias), and a systematic presentation of the findings. 
 
The Institute of Medicine in their 2011 publication ‘Finding what works in health 
care: standards for systematic reviews’ have recommended steps to minimise 
bias of study quality, defined as ‘the tendency for a study to produce results that 
depart systematically from the truth’.104  This involves establishing a review 
team, user and stakeholder involvement, managing bias in reporting and 
publication, disclosing conflicts of interest, defining the research topic, and 
writing a peer-reviewed protocol that is publicly available. 
 
 54 
Chapter 1 has identified the need for high quality research evidence in the 
development of clinical practice guidelines of intra-articular lumbar facet joint 
injections for the management of chronic LBP.  In this chapter, the steps taken 
to identify the existing systematic reviews and meta-analyses of therapeutic 
injections for LBP will be outlined, and each review meeting the inclusion criteria 
will be described in terms of their scope using a systematic approach.  The 
methodological quality of each review will be assessed using a validated 
checklist.105  Finally, the possibility of carrying out statistical techniques to 
combine and summarise data from the current body of evidence will be 
discussed. 
 
Methods 
 
A protocol with the inclusion criteria was developed prior to the initial literature 
search, with reference to the Preferred Reporting Items for Systematic Review 
and Meta-analysis Protocols (PRISMA-P) guidelines.106  This structured 
approach was used to screen for eligible systematic reviews and meta-analyses 
of randomised controlled trials of adult participants with chronic LBP, 
undergoing therapeutic intra-articular lumbar facet joint injections.  The protocol 
was not prospectively registered on a database of systematic reviews. 
 
Objective 
 
To identify existing systematic reviews and meta-analyses of randomised 
controlled trials of intra-articular lumbar facet joint injections for chronic LBP 
management, to assess their methodological quality. 
 
Eligibility criteria 
 
To be eligible for inclusion, the systematic review must have included an adult 
population with chronic LBP, undergoing intra-articular lumbar facet joint 
injections with a therapeutic substance as the main intervention.  Articles 
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reviewing other therapeutic interventional pain procedures such as medial 
branch nerve blocks, radiofrequency denervation and epidural injections, and of 
diagnostic accuracy, were included if therapeutic lumbar facet joint injections 
were reviewed also.  All comparators were included for review.  The outcomes 
were not to be limited in the search strategy but were expected to include a 
reduction in pain intensity and an improvement in functioning.  Only systematic 
review papers of randomised controlled trials and meta-analyses were to be 
included.  Outdated systematic reviews with a published update were excluded.  
Clinical practice guidelines, which drew solely on the evidence from published 
systematic reviews, were excluded. 
 
Search strategy 
 
Librarian assistance was sought to develop appropriate search terms to identify 
relevant studies (see appendix 1 for the detailed search strategies).  The 
databases searched were Medline, Embase and the Cochrane Central Register 
of Controlled Trials (CENTRAL).  Additional studies were to be identified from 
citation tracking and reviewing the references of identified studies. 
 
The search period included articles published between 1966 and February 
2017, without language restrictions.  The search was repeated in May 2017, 
prior to submission of the monograph to the NIHR Journals Library, to ensure 
that no new systematic reviews had been published in the intervening period. 
 
Two reviewers (Saowarat Snidvongs and Fausto Morell-Ducós) independently 
screened and assessed the full-text articles for eligibility. 
 
Results 
 
The results of the database searches are shown in table 4, and the PRISMA 
flow diagram of the different phases of the search is illustrated in figure 8. 
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The Medline search identified 123 results, with 6 duplicates.  These 117 records 
were screened, and 11 full-text articles were assessed for eligibility.  Searching 
the Embase database identified 144 results, with 10 duplicates.  The remaining 
134 records were screened, with 10 full-text articles assessed for eligibility.  The 
CENTRAL search identified 163 results of which 33 were systematic reviews.  
One was screened and assessed for eligibility.  The systematic review papers 
identified using these search methods revealed significant overlap in the lists of 
retrieved articles, with 122 duplicates when the results from the three databases 
were combined. 
 
Citation tracking and reference checking of the identified systematic reviews 
and bibliographies were carried out, identifying a further three papers that met 
the search criteria.107-109  No meta-analyses of therapeutic lumbar facet joint 
injections were identified. 
 
One systematic review paper had a published update and was excluded.27, 110  
It was noted that the Cochrane review had updated a previous review, which 
had since been withdrawn and was not identified in the databases using the 
search strategies.40, 111  The Cochrane review was also published in duplicate in 
another journal;112 the duplicate was excluded.  Although the systematic review 
paper published by Falco and colleagues was an update of an earlier 
systematic review, the reviewers felt that they were sufficiently different in scope 
and conclusion for both to be included.72, 73 
 
One systematic review paper was excluded as it only assessed lumbar facet 
joint nerve blocks, and not intra-articular injections.62 
 
 
 57 
Table 4.  Systematic review papers of therapeutic lumbar facet joint injections identified from the database searches 
 
 
Slipman 
et al. 
2003107 
Boswell 
et al. 
2005110 
Boswell 
et al. 
200727 
Staal 
et al. 
200840 
Staal et 
al. 2009112 
Datta 
et al. 
2009 
73 
Chou 
et al. 
2009 
108 
Henschke 
et al. 
2010109 
Falco 
et al. 
2012 
72 
Manchikanti 
et al. Surg 
Neurol Int 
2015113 
Boswell et 
al. Pain 
Phys 
201562 
Manchikanti 
et al. Pain 
Phys 201562 
Vekaria 
et al. 
2016100 
Manchikanti 
et al. World 
J Orthop 
201663 
Medline 
              
Embase 
 
  
 
 
            
CENTRAL 
 
              
Other 
sources 
              
Reasons 
for 
exclusion, 
if 
applicable 
 
Published 
update 
  
Duplicate 
publication 
     
Intervention 
not of 
interest 
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Figure 8.  PRISMA flow diagram depicting the phases of the literature 
search for systematic reviews and meta-analyses of lumbar facet joint 
injections for chronic low back pain management114 
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Discussion 
 
Eleven systematic review papers meeting the inclusion criteria were identified 
from the search.  Of these, five included the term ‘systematic review’ in the 
title,27, 68, 100, 109, 113 one paper had the title ‘critical review’,107 and another was a 
‘systematic assessment’.73  It is however recognised that it is Cochrane policy 
to not include the terms ‘systematic review’ or ‘meta-analysis’ in the title.103 
 
The systematic review written by Boswell and colleagues had a potentially 
misleading title of ‘..systematic appraisal of the diagnostic accuracy and utility of 
facet (zygapophysial) joint injections in chronic spinal pain’ but only reviewed 
studies of facet joint nerve blocks and not intra-articular injections.62 
 
In 2004, a review of the reporting characteristics of systematic reviews carried 
out by Moher et al. found that 50% of systematic reviews did not include the 
term ‘systematic review’ or ‘meta-analysis’ in the title or abstract,115 although an 
update ten years later noted that this proportion had increased to 85% overall, 
or 94% when Cochrane reviews were omitted.116  It is recommended in the 
Preferred Reporting Items for Systematic Reviews and Meta-analyses 
(PRISMA) statement that these terms are included in the title, as an informative 
title improves identification and indexing in databases.117 
 
It was not always clear to the reviewers whether some of the reviews were 
systematic or not, and these papers required further analysis and a consensus 
discussion.  The reviewers referred to the definition of a systematic review as 
described by Moher and colleagues, where a report was considered to be a 
systematic review if explicit methods were used, and the objective was clearly 
stated to summarise evidence from multiple studies.115 
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The scope of the systematic reviews 
 
A structured approach was employed to frame the five components used to 
develop the research question of each systematic review, as detailed by 
Liberati et al.117  The components consist of: study population or condition being 
addressed, the interventions, the comparator, the outcome or study endpoint, 
and the types of study design included for review.  Identification of these 
components will allow each systematic review to be described in terms of their 
scope. 
 
Slipman et al. Spine, 2003 
 
Slipman and colleagues published ‘A critical review of the evidence for the use 
of zygapophysial injections and radiofrequency denervation in the treatment of 
low back pain’ in 2003, to ‘analyse the best studies evaluating various options 
for lumbar zygapophysial joint syndrome and provide that information to the 
spine physician community’.107  The authors did not include the literature search 
dates.  Although systematic methods to identify suitable prospective studies 
were described, the separate components of the research question were not 
clearly defined a priori; however, the keywords used in the database search 
indicated that the study population included those with chronic low back, 
involving the lumbar facet joints.  The interventions under review included 
lumbar facet joint injections and lumbar facet joint radiofrequency denervation.  
No comparator nor outcomes were specified.  The types of study design 
included in the review were all prospective studies, including randomised 
controlled trials, a controlled but non-randomised trial, and a case series (of 
radiofrequency denervation). 
 
Boswell et al. Pain Physician, 2007 
 
In ‘A systematic review of therapeutic facet joint interventions in chronic spinal 
pain’ Boswell and colleagues carried out an updated systematic review in 2007 
to review the effectiveness of therapeutic facet joint interventions for the 
management of chronic spinal pain of facet joint origin.27  The initial literature 
search included papers published between January 1966 and November 2004, 
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and the updated search reviewed papers published between November 2004 
and December 2006.  The population was defined in an earlier systematic 
review from the same group in 2005,110 to include patients with ‘chronic spinal 
pain’ for at least 3 months (but 6 months for studies of radiofrequency 
denervation), who had received lumbar facet joint injections.  Included studies 
should have had the existence of spinal pain confirmed with, ideally, controlled 
diagnostic facet joint or nerve blocks, although single block studies would also 
be considered.  This systematic review article also addressed studies of medial 
branch blocks and radiofrequency denervation.  A comparator was not 
specified.  The primary outcome measure was pain relief, and the secondary 
outcome measures were functional or psychological improvement, return to 
work, and complications.  The reviewers selected randomised controlled trials 
and also included observational studies, as well as reports of complications. 
 
Staal et al. Cochrane Database of Systematic Reviews, 2008 
 
In 2008, Staal and colleagues published an updated Cochrane review, ‘Injection 
therapy for subacute and chronic low-back pain’,40 superseding an earlier 2000 
publication which was withdrawn in 2007.111  The literature search included 
papers published up until March 2007.  The objective was to assess the 
effectiveness of injection therapy in patients with subacute (lasting 4 weeks or 
longer) or chronic (lasting over 12 weeks) LBP.  Studies of participants aged 
from 18 to 70 years with LBP of at least one month’s duration were considered 
for inclusion.  The intervention was injection therapy for pain relief, including 
lumbar facet joint injections in addition to epidurals and local site injections.  
The authors excluded studies of epidural steroids for radicular pain, injections 
into the intervertebral discs, prolotherapy (injections of irritant substances into a 
joint), ozone therapy, injections into the sacroiliac joints, and studies where 
drugs were administered indirectly via a catheter.  In contrast to the earlier 
Cochrane review where homogeneity was not demonstrated between the 
included studies,111 the comparators were to be classified according to the 
therapeutic agent used (steroids or local anaesthetics), and studies were further 
subdivided into placebo-controlled trials (steroids versus placebo) and trials 
comparing injections against other treatments.  Pain needed to be included as 
an outcome measure; other outcome measures of importance included a global 
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measure of improvement, back-specific disability, generic health status or well-
being, disability for work, and patient satisfaction.  Only randomised controlled 
trials were included in this review. 
 
Datta et al. Pain Physician, 2009 
 
Datta and colleagues presented a systematic review in 2009, ‘Systematic 
assessment of diagnostic accuracy and therapeutic utility of lumbar facet joint 
interventions’ to evaluate the effectiveness of therapeutic lumbar facet joint 
interventions for the management of chronic LBP of lumbar facet joint origin, 
and to assess its diagnostic accuracy.73  The literature search included papers 
published from 1966 until December 2008.  This review group selected from a 
population of patients with chronic LBP of greater than 3 months’ duration, who 
had achieved at least 80% pain relief following controlled fluoroscopic guided 
diagnostic blocks (placebo or dual blocks) for the duration of the local 
anaesthetic used, and improved functional ability.  The interventions included in 
the review were intra-articular lumbar facet joint injections, as well as medial 
branch nerve blocks and radiofrequency denervation.  There was no specified 
comparator.  Studies to be included required a primary outcome measure of 
pain relief, with secondary outcome measures of functional status improvement, 
psychological status improvement, return to work, and opioid intake.  Certain 
study designs were excluded, including non-clinical studies, case reports, book 
chapters, non-evidence-based guidelines, letters and expert opinions. 
 
Chou et al. Spine, 2009 
 
In 2009, Chou and colleagues published ‘Nonsurgical interventional therapies 
for low back pain: a review of the evidence for an American Pain Society clinical 
practice guideline’108 as part of a larger evidence review to evaluate and guide 
management of LBP, commissioned by the American Pain Society.71  The 
included databases were searched until July 2008.  The population was 
selected from non-pregnant adults aged over 18, with LBP of any duration, 
alone or with leg pain.  Fourteen interventions were chosen for review by an 
expert panel of the American Pain Society, which were further grouped into four 
categories.  Facet joint injections (defined as ‘injection of corticosteroid into the 
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facet joints’) were grouped into the ‘intraspinal steroid injections’ category; the 
other categories to be assessed were ‘injections outside the spine’, 
‘radiofrequency denervation and related procedures’, and ‘spinal cord 
stimulation’.  No comparator was specified.  The outcome measures included 
back-specific function, generic health status, pain, work disability, and patient 
satisfaction.  Only randomised controlled trials and systematic reviews were 
included.  Studies of intra-articular facet joint injections and therapeutic medial 
branch blocks were grouped together in the discussion. 
 
Henschke et al. European Spine Journal, 2010 
 
Henschke and colleagues carried out a systematic review in 2010, ‘Injection 
therapy and denervation procedures for chronic low-back pain: a systematic 
review’ to evaluate the current evidence for injections into and outside the spine 
for non-specific chronic LBP management.109  The literature search was carried 
out until November 2009.  Studies were selected to include adult participants 
with chronic LBP, defined as pain persisting for over 12 weeks’ duration, 
including radiculopathy.  Randomised controlled trials of non-specific 
degenerative pathology such as osteoarthritis were included, but studies of 
pathological conditions (for example ankylosing spondylosis or spinal stenosis) 
were excluded.  The interventions to be assessed were injections of 
medications or proteolytic enzymes, and radiofrequency or thermal denervation 
procedures, into predefined anatomical sites for LBP, specifically facet joints, 
intervertebral discs, and spinal nerves.  There was no comparator.  The primary 
outcome measures were pain and functional status; outcome measures should 
include at least one of: pain intensity, back-specific functional status, perceived 
recovery, and return to work.  Only randomised controlled trials were 
considered for review. 
 
Falco et al. Pain Physician, 2012 
 
Falco and colleagues noted that previously published systematic reviews of 
spinal injections for chronic LBP management such as the American Pain 
Society’s evidenced-based clinical practice guidelines and the Cochrane review 
reported conflicting conclusions.40, 108  The literature search dates were from 
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database inception until June 2012.  In 2012, this group published ‘An update of 
the effectiveness of therapeutic lumbar facet joint interventions’, updating a 
previous systematic review73 to determine the effectiveness of lumbar facet joint 
interventions.72  Studies to be included for review were of adult participants with 
‘chronic lumbar facet joint pain’ of at least 3 months’ duration, and participants 
should have failed previous treatments such as pharmacotherapy or exercise 
therapy prior to receiving an interventional pain procedure.  The interventions 
reviewed were lumbar facet joint interventions (further subdivided into 
radiofrequency neurotomy, facet joint nerve blocks, and intra-articular 
injections) carried out under fluoroscopic, CT or MRI guidance.  Studies were 
excluded if they had been performed blind or under ultrasound imaging.  A 
comparator was not described.  The primary outcome measure was pain relief, 
and the secondary outcome measures included functional improvement, 
change in psychological status, return to work, opioid reduction, other drugs, 
other interventions, and complications.  Randomised controlled trials were 
included, alongside non-randomised observational studies and case reports 
and reviews for adverse events. 
 
Manchikanti et al. Surgical Neurological International, 2015 
 
In 2015, Manchikanti and colleagues carried out a systematic review 
‘Comparison of the efficacy of saline, local anesthetics, and steroids in epidural 
and facet joint injections for the management of spinal pain: A systematic 
review of randomized controlled trials’ published in Surgical Neurological 
International  to describe the role of saline and local anaesthetics in epidural 
and facet joint injections, and to compare their long-term effects with steroid.113  
The literature search included papers published from 1966 until March 2014.  
The population was not clearly defined a priori but included studies of patients 
with LBP of at least 3 months’ duration.  The interventions to be assessed were 
epidurals (via caudal, interlaminar and transforaminal routes), facet joint 
injections, and nerve blocks, in the cervical, thoracic and lumbar regions.  As a 
comparator, studies to be included for review required a true active control 
design, where substances were injected into the same area to compare two 
difference procedures or drugs.  True placebo study designs, with injections of 
inactive solutions into inactive structures, were excluded.  The primary outcome 
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measure was pain relief, and the secondary outcome measure was functional 
improvement.  This systematic review only included randomised active or 
placebo controlled trials. 
 
Manchikanti et al. Pain Physician, 2015 
 
In the same year, Manchikanti and colleagues also published a systematic 
review in Pain Physician, ‘A systematic review and best evidence synthesis of 
the effectiveness of therapeutic facet joint interventions in managing chronic 
spinal pain’, with an aim of assessing the effectiveness of therapeutic facet joint 
injections with ‘appropriate methodology’.68  The literature search period was 
between 1966 and March 2015.  The population to be reviewed had pain in the 
neck, mid-back, upper back and low back for at least 3 months; studies were 
excluded if the pain was due to acute trauma, fractures, malignancy or 
inflammatory diseases.  The review included studies of cervical, thoracic and 
lumbar facet joint interventions with ‘proper technique’ under fluoroscopic, CT or 
MRI guidance.  No comparator was specified a priori.  The primary outcome 
measure was pain relief, and the secondary outcome measure was functional 
status improvement.  Randomised controlled trials and observational studies 
were included for review. 
 
Vekaria et al. European Spine Journal, 2016 
 
Vekaria and colleagues published a systematic review in 2016 of randomised 
controlled trials of therapeutic lumbar facet joint injections, ‘Intra-articular facet 
joint injections for low back pain: a systematic review’.100  The literature search 
included papers published from database inception through April 2015.  The 
authors reviewed studies of adult participants reporting LBP, which were further 
subdivided into acute (less than six weeks), sub-acute (six to twelve weeks) and 
chronic (over twelve weeks) categories.  The interventions were injections into 
or around the facet joints.  The comparators included a sham procedure (a 
needle or device is inserted into the facet joint but no substance injected, to 
make the participant believe that the active drug had been injected), placebo 
injection (an inactive substance such as saline is injected into or around the 
facet joint) or conservative therapy.  The conservative therapies used as 
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comparators included medications, steroid injections into areas other than the 
facet joints, physical therapies, and psychological interventions.  The primary 
outcome measures were symptom relief based on pain and back-specific 
functional status, and the secondary outcome measure was adverse events.  
Only randomised controlled trials were included for review. 
 
Manchikanti et al. World Journal of Orthopedics, 2016 
 
In 2016, Manchikanti and colleagues published a further systematic review to 
assess the therapeutic effectiveness of lumbar facet joint interventions, and 
also to assess the diagnostic accuracy of lumbar facet joint nerve blocks, 
‘Management of lumbar zygapophysial (facet) joint pain’.63  The literature 
search dates were between 1966 and March 2015.  Studies of patients over 18 
years of age with ‘chronic lumbar facet joint pain’ of at least 3 months’ duration 
were considered for review; to be included, patients must have additionally 
failed previous pharmacotherapy, physical therapy and exercise therapy.  The 
interventions to be assessed included ‘multiple interventional techniques’ and 
were not clearly defined a priori; amongst the therapeutic interventions, studies 
of radiofrequency denervation, lumbar facet joint nerve blocks and lumbar intra-
articular injections were included.  A comparator was not specified.  The 
primary outcome measure for efficacy studies was pain relief, and the 
secondary outcome measure was functional improvement.  Randomised 
controlled trials of efficacy in managing lumbar facet joint pain were included. 
 
Is there heterogeneity between the scopes of the systematic reviews? 
 
Population 
 
All the systematic reviews identified included studies of adult patients with 
chronic LBP of at least three months’ or twelve weeks’ duration, although Staal 
et al. also reviewed patients with pain for at least one month, with subacute pain 
defined as pain lasting for four weeks or longer.40  Similarly, Vekaria et al. 
included studies of acute (under six weeks’ duration) and sub-acute (six to 
twelve weeks) LBP.100 
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Falco et al. and Manchikanti et al. (in World Journal of Orthopedics) only 
included studies where patients had failed previous non-interventional 
treatments such as pharmacotherapy or physical therapy.63, 72 
 
The majority of the systematic reviews did not specify how the diagnosis of pain 
originating from the lumbar facet joints was reached; however, Datta et al. only 
included studies in which patients had already received controlled (placebo or 
dual, with comparative local anaesthetics) diagnostic medial branch nerve 
blocks and obtained at least 80% pain relief and functional improvement.73  
Boswell et al. accepted single diagnostic blocks too, as the authors 
acknowledged that studies with dual blocks were scarce.27  Falco et al. and 
Manchikanti et al. (in Pain Physician) excluded reports ‘without appropriate 
diagnosis’ although it was not clear what this involved.68, 72 
 
Interventions 
 
All the systematic reviews included interventional studies of intra-articular 
lumbar facet joint injections; Vekaria et al. accepted studies of injections around 
the facet joints (peri-articular) also.100  The active drugs discussed in the 
reviews included steroids, local anaesthetics, and sodium hyaluronate.34  
Henschke et al. also considered studies of proteolytic enzymes 
(chemonucleolysis).109  Manchikanti et al. (in Surgery Neurological 
International) only included randomised controlled trials with saline, local 
anaesthetic and/or steroid.113 
 
In addition to reviewing studies of intra-articular lumbar facet joint injections, the 
majority of the systematic reviews identified from the searches also assessed 
studies of medial branch nerve blocks,27, 40, 63, 68, 72, 73, 109, 113 as well as studies 
of radiofrequency denervation.27, 40, 63, 68, 72, 73, 109  Staal et al. and Manchikanti et 
al. (in Surgery Neurological International) additionally reviewed studies of 
epidurals and local site injections.40, 113  Chou et al. reviewed 14 ‘nonsurgical 
interventional therapies’ for LBP, as chosen by an expert panel from the 
American Pain Society.108 
 
 68 
Three systematic reviews included studies of interventions at all spinal levels 
(cervical, thoracic and lumbar), 27, 68, 113 whereas the other studies included 
studies involving the lumbar spine only.  Datta et al. and Manchikanti et al. (in 
World Journal of Orthopedics) also included studies of diagnostic accuracy 
within their scope for review.63, 73 
 
Comparator 
 
Many of the systematic reviews did not specify a comparator a priori; Staal et al. 
however grouped studies into those of steroids versus placebo, steroids versus 
other treatments such as Sarapin or a home stretching programme, and local 
anaesthetics versus other treatments such as steroid.40  Manchikanti et al. (in 
Surgery Neurological International) included only those studies where a true 
active control design was utilised, specifically trials comparing saline solution, 
local anaesthetic and steroid.113 
 
Outcomes 
 
All the systematic reviews included pain as an important or primary outcome 
measure.  Other outcome measures included in the reviews were disability and 
functional status improvement, psychological improvement, return to work, 
patient satisfaction, and a reduction in opioid intake.  Some reviews also looked 
at reports of complications and adverse events.27, 72, 100 
 
Study design 
 
All the systematic reviews assessed randomised controlled trials, although 
Slipman et al. included a controlled but non randomised study,107 and Boswell 
et al., Falco et al. and Manchikanti et al. (in Pain Physician) also reviewed 
observational studies.27, 68, 72 
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The different scopes of the systematic reviews 
 
The previous section has demonstrated that no two systematic review papers 
have the same scope; many differ in the population under review, and in the 
types of included studies.  Most authors did not review one intervention only 
(intra-articular lumbar facet joint injections) but also reviewed other 
interventional spinal procedures at other spinal levels. 
 
The different scopes of the systematic reviews allow different yet relevant 
research questions to be answered and reflect the different scopes of the 
studies themselves.  As demonstrated by several authors including the GDGs 
of the NICE LBP guidelines and in the Cochrane review,25, 26, 40 the substantial 
heterogeneity between the studies meant that reviewers often had to split the 
studies depending on the agents injected, and whether the comparator was a 
placebo or sham, or other treatment, in order to carry out any sub-group 
analyses.  This approach could allow for reviews of clinically comparable 
groups instead of a sub-group containing a single study; however, is clear that 
there are still differences within the sub-groups, including the entry criteria and 
use of diagnostic blocks, site of injections, dose of steroid, type of ‘usual care’, 
and outcome measures. 
 
Clinical decision making relies on an evidence-based approach, yet the 
randomised controlled trials of lumbar facet joint injections in chronic LBP 
management have heterogeneous populations with relatively small sample 
sizes and varying entry criteria.  Interpretation of these research outcomes may 
be challenging, and decision-makers should not rely on statistically significant 
differences alone, as the results also need to be clinically meaningful.  Any 
evidence statements from the systematic reviews therefore need to be 
interpreted with caution; is not possible to support or refute the use of spinal 
injections based on the current evidence. 
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Assessing the methodological quality of systematic reviews: AMSTAR 
checklist 
 
A measurement tool for the ‘Assessment of Multiple Systematic Reviews’ 
(AMSTAR) was developed in response to a perceived need for a new 
instrument to assess the methodological quality of systematic reviews of 
randomised controlled trials.105  Shea and colleagues utilised expert opinion to 
review the published literature and update previously available tools to create a 
new 37-item assessment tool, with 11 components in the form of a checklist.  
Since its publication in 2007, it has been shown to have good inter-rater 
agreement, test-retest reliability, face and construct validity, and feasibility.118  
As discussed earlier in this chapter, the assessment process examines the 
likelihood that the review will generate unbiased results; potential types of bias 
include selection bias, performance bias, attrition bias, detection or 
measurement bias, and reporting bias.119 
 
One debate paper critically appraised the AMSTAR checklist from the point of 
view of an assessor.120  The challenges of using this tool were described, and it 
was noted that some items within the checklist appeared to assess the 
reporting quality, rather than the methodological quality, of the systematic 
review.  This paper also commented that difficulties in interpretation of some of 
the questions may lead to heterogeneity of its use, and suggested some 
solutions to improve its reliability as a measurement tool. 
 
The AMSTAR checklist was used by two reviewers (Saowarat Snidvongs and 
Fausto Morell-Ducós) to independently assess each systematic review, with 
reference to the guidance notes on the checklist.121  A consensus process or 
third reviewer was to be used if there were any disagreements.  Each review 
paper was scored out a maximum of eleven points, using the on-line 
calculator.121  One point was given for each item that scored ‘Yes’, and no 
points given for ‘No’, ‘Can’t answer’ or ‘Not applicable’. 
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‘Review of reviews’: results of the AMSTAR checklist 
 
A summary table of the AMSTAR checklist scores for each systematic review is 
shown in table 5. 
 
The reviewers found that item 1 of the checklist, referring to whether an a priori 
or pre-determined research question or inclusion criteria was provided or not, 
was difficult to answer.  Although these were generally well-detailed in most of 
the systematic reviews, it was usually unclear whether these had been 
published in advance.  Only one group stated that their systematic review had 
been prospectively registered with the International Prospective Register of 
Systematic Reviews (PROSPERO), with a published protocol.122, 123  
 
The majority of the systematic review groups clearly stated that there were at 
least 2 independent reviewers selecting the studies for inclusion, and for 
carrying out the data extraction.  Most groups described a consensus process 
in place for disagreements (item 2).  A comprehensive literature search was 
performed by most review groups, including at least two electronic sources 
(usually Medline, Embase and CENTRAL) as well as additional strategies and 
resources, ranging from trial registries and conference abstracts to consulting 
known experts in the field (item 3).  However, most authors did not specifically 
indicate that they also searched for grey or unpublished literature (item 4). 
 
Most of the systematic review papers included a list of included and excluded 
studies (item 5).  However, it was unclear to the reviewers whether the 
excluded studies were from the first phase of the search, where the titles and 
abstracts are evaluated from a larger pool of papers, or from the second phase, 
where the full text articles were assessed.  In the consensus discussion, it was 
decided to accept a list of excluded papers from the second stage only, as it 
would not always be possible to list all the excluded papers from the first stage 
evaluation.  Faggion’s critical appraisal also called for improved clarity on this 
item.120 
 
The characteristics of included studies were sufficiently described by most of 
the authors, either in table format or in the body of the text (item 6).  Similarly, 
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the majority of authors discussed a priori methods of assessing the scientific 
quality of the included studies (item 7) and applied these correctly when 
formulating conclusions (item 8).  None of the authors were able to combine the 
findings of the included studies, and many described heterogeneities within the 
study population which precluded any data synthesis (item 9). 
 
Only two papers (Henscke et al. 2010 and Vekaria et al. 2016) discussed the 
possibility of publication bias, although both groups commented on the small 
numbers of published trials without a positive effect, reducing the likelihood of 
publication bias (item 10).100, 109 
 
The reviewers were unable to score ‘Yes’ on item 11 of the AMSTAR checklist 
for any of the systematic review papers.  This item related to whether conflicts 
of interest were included; the guidance notes state that this should include the 
source of funding or support for the included studies too, and not only for the 
systematic review.  None of the systematic reviews mentioned sources of 
funding for the included studies; this item was included by the AMSTAR authors 
as there is evidence that industry-sponsored studies may favour sponsored 
products.124  As this would not be detected as a design or methodology flaw, 
reporting this would improve confidence in the findings of the review.  
 
Of the eleven systematic review papers scored, it can be seen that no paper 
achieved ‘Yes’ on all eleven items.  Vekaria et al. had the highest score of 
10/11 but like the other papers, did not declare sources of funding or support for 
the included studies.100  Datta et al. had the lowest score of 2/11, in part due to 
its strict inclusion criteria and no included studies, so that many items on the 
checklist were not applicable.73 
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Table 5.  AMSTAR checklist scores for each systematic review.  Yes (Y) = green, No (N) = red, Can’t answer (CA) = 
yellow, Not applicable (NA) = blue 
 
 Item 1 Item 2 Item 3 Item 4 Item 5 Item 6 Item 7 Item 8 Item 9 Item 10 Item 11 
AMSTAR 
score /11 
Slipman et al. 2003107 CA CA N N Y Y Y Y CA N CA 4 
Boswell et al. 200727 CA CA Y CA Y Y Y Y CA N CA 5 
Staal et al. 200840 Y Y Y N Y Y Y Y Y N CA 8 
Datta et al. 200973 CA CA Y CA Y NA NA NA NA N CA 2 
Chou et al. 2009108 CA Y Y Y Y N Y Y N N CA 6 
Henschke et al. 
2010109 
CA CA N N Y Y Y Y Y Y N 6 
Falco et al. 201272 CA Y Y CA Y Y Y Y Y N CA 7 
Manchikanti et al. Surg 
Neurol Int 2015113 
CA Y Y CA Y Y Y Y Y N N 7 
Manchikanti et al. Pain 
Phys 201568 
CA Y Y CA N Y Y Y Y N CA 6 
Vekaria et al. 2016100 Y Y Y Y Y Y Y Y Y Y CA 10 
Manchikanti et al. 
World J Orthop 201663 
CA Y Y CA N Y Y Y N N CA 5 
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Randomised controlled trials included in the best evidence synthesis 
 
The eleven systematic review papers identified a total of fourteen randomised 
controlled trials between them.  The Venn diagram below illustrates that given 
the variation in dates when reviews were undertaken and their precise 
inclusion/exclusion criteria, no one review included all these trials (see figure 9).  
Full-text versions of all but one trial were retrieved.125  These thirteen 
randomised controlled trials are summarised in table 6. 
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Figure 9.  Randomised controlled trials included in each systematic review 
Reproduced from Snidvongs et al.’s ‘Facet-joint injections for non-specific low back pain: a feasibility RCT’ (2017)99 
 
 
 
 
Systematic review paper 
 
 
Slipman et al. 2003107  
Boswell et al. 200727 
Falco et al. 201272 
 
Staal et al. 200840  
Datta et al. 200973  
Chou et al. 2009108  
Henschke et al. 2010109  
Manchikanti et al. 2015 Pain 
Physician68 
Manchikanti et al. 2016 
World J Orthop63 
 
Manchikanti et al. 2015 Surg 
Neurol Int113 
 
Vekaria et al. 2016100  
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Table 6.  Randomised controlled trials of efficacy of therapeutic facet joint injections identified from previous 
systematic reviews.  Reproduced from Snidvongs et al.’s ‘Facet-joint injections for non-specific low back pain: a feasibility 
RCT’ (2017)99 
 
  
 
First author, 
year 
(country, n 
randomised) 
Population Intervention Comparator 
Primary 
outcome 
Follow-up Key findings 
Lilius, 1989  
(Finland, 
n=109)36 
 
Unilateral LBP 
>3 months, 
failed 
analgesics and 
physiotherapy 
No diagnostic 
blocks 
 
1.  X-ray guided intra-
articular lumbar facet 
joint injections with 
bupivacaine and 
methylprednisolone 
2.  X-ray guided 
pericapsular injections 
with bupivacaine and 
methylprednisolone 
 
Sham (x-ray guided 
intra-articular lumbar 
facet joint injections 
with physiological 
saline) 
 
Not stated – 
assessed pain, 
disability and 
return to work 
 
3 months 
 
No difference in 
outcomes at 
follow-up 
between 2 
active groups 
and sham 
Improvement in 
pain, disability 
and work 
attendance in all 
groups 
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First author, 
year 
(country, n 
randomised) 
Population Intervention Comparator 
Primary 
outcome 
Follow-up Key findings 
Carette, 1991 
(Canada, 
n=101)28 
 
LBP >6 months, 
normal 
neurological 
examination 
>50% pain 
reduction after 
single intra-
articular 
diagnostic 
injections with 
lidocaine 
 
Fluoroscopic guided 
intra-articular lumbar 
facet joint injections 
with 
methylprednisolone 
and isotonic saline 
 
Sham (fluoroscopic 
guided intra-articular 
lumbar facet joint 
injections with 
isotonic saline) 
 
Not stated – 
assessed pain 
severity, back 
mobility, and 
limitation of 
function 
 
6 months 
 
No differences 
in outcomes at 
1 and 3 months 
between the 2 
groups 
At 6 months, 
patients in the 
intervention 
group reported 
more self-rated 
improvement, 
less pain 
intensity, and 
less physical 
disability than 
the sham group 
Marks, 1992 
(Scotland, 
UK, n=86)126 
 
LBP >6 months, 
failed non-
narcotic 
 
X-ray guided intra-
articular lumbar facet 
joint injections with 
 
X-ray guided lumbar 
facet joint medial 
branch nerve blocks 
 
Pain intensity 
 
3 months 
 
Marginally 
longer duration 
of response in 
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First author, 
year 
(country, n 
randomised) 
Population Intervention Comparator 
Primary 
outcome 
Follow-up Key findings 
analgesics and 
physiotherapy 
No diagnostic 
blocks 
lidocaine and 
methylprednisolone 
with lidocaine and 
methylprednisolone 
the intervention 
group after 1 
month, 
otherwise no 
difference in 
outcomes at 
other time 
points between 
the 2 groups 
Some short-
term pain relief 
seen in both 
groups 
Revel, 1998 
(France, 
n=80)55 
 
LBP >3 months, 
failed 
analgesics and 
physical 
therapy 
 
Fluoroscopic guided 
intra-articular lumbar 
facet joint injections 
with lidocaine, + peri-
articular corticosteroid 
 
Fluoroscopic guided 
intra-articular lumbar 
facet joint injections 
with saline, + peri-
articular 
corticosteroid steroid 
 
Pain intensity 
using VAS 
 
30 minutes 
after 
injections 
 
Significantly 
reduced pain 
scores in the 
intervention 
group compared 
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First author, 
year 
(country, n 
randomised) 
Population Intervention Comparator 
Primary 
outcome 
Follow-up Key findings 
No diagnostic 
blocks 
steroid injection (not 
evaluated) 
 
injection (not 
evaluated) 
to the 
comparator 
Manchikanti, 
2001 (US, 
N=84)127 
 
LBP >6 months, 
failed 
conservative 
management 
Positive 
response 
following 
controlled 
comparative 
diagnostic 
blocks with 
lidocaine and 
bupivacaine 
 
Lumbar facet medial 
branch nerve blocks 
with lidocaine or 
bupivacaine, Sarapin 
and 
methylprednisolone 
 
Lumbar facet medial 
branch nerve blocks 
with lidocaine or 
bupivacaine, and 
Sarapin 
 
Not stated – 
assessed pain 
characteristics, 
physical health, 
mental health, 
functional status, 
return to work, 
and narcotic 
intake 
 
Up to 2.5 
years 
 
No difference in 
outcomes at 
follow-up 
between the 
groups, 
improvement in 
pain and 
functional 
outcomes in 
both groups  
Mayer, 2004 
(US, n=70)37 
 
‘Chronic 
disabling work 
 
Fluoroscopic guided 
bilateral intra-articular 
   
Not 
specified – 
 
No difference in 
pain and 
 80 
First author, 
year 
(country, n 
randomised) 
Population Intervention Comparator 
Primary 
outcome 
Follow-up Key findings 
related lumbar 
spinal disorder’ 
for >6-12 
months, ‘lumbar 
segmental 
rigidity’ on 
clinical 
examination 
No diagnostic 
blocks 
lumbar facet joint 
injections with 
lidocaine, bupivacaine 
and depot 
corticosteroid, and 
home stretching 
exercise programme 
Home stretching 
exercise programme 
only 
Range of motion, 
pain and 
disability 
after 
completing 
the home 
stretching 
exercise 
programme 
disability report 
at follow-up 
between the 2 
groups, greater 
improvement in 
range of motion 
in the 
intervention 
group 
Fuchs, 2005 
(Germany, 
n=60)34 
 
Low back pain 
>3 months, 
facet joint 
osteoarthritis on 
imaging 
 
CT-guided intra-
articular lumbar facet 
joint injections with 
triamcinolone 
 
CT-guided intra-
articular facet joint 
injections with 
sodium hyaluronate 
 
Pain intensity, 
functioning, and 
quality of life 
 
180 days 
 
No difference in 
outcomes at 
follow-up 
between the 2 
active groups, 
improvement in 
pain and 
functional 
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First author, 
year 
(country, n 
randomised) 
Population Intervention Comparator 
Primary 
outcome 
Follow-up Key findings 
outcomes in 
both groups 
Manchikanti, 
2008 (US, 
n=120)128 
 
LBP >6 months, 
failed 
conservative 
management 
80% pain relief 
following 
controlled 
comparative 
diagnostic 
blocks with 
lidocaine and 
bupivacaine 
 
IA.  Lumbar facet joint 
medial branch nerve 
blocks with 
bupivacaine 
IB.  Lumbar facet joint 
medial branch nerve 
blocks with 
bupivacaine and 
Sarapin  
 
IIA.  Lumbar facet 
joint medial branch 
nerve blocks with 
bupivacaine and 
steroid  
IIB.  Lumbar facet 
joint medial branch 
nerve blocks with 
bupivacaine, steroid 
and Sarapin 
 
Not stated – 
assessed pain 
relief, work 
status, opioid 
intake and 
functional status 
 
1 year 
 
No difference in 
outcomes at 
follow-up 
between the 
groups, 
improvement in 
pain and 
functional 
outcomes in 
both groups 
Kawu, 2011 
(Nigeria, 
n=18)38 
 
LBP >3 months, 
failed 
analgesics, MRI 
 
X-ray-guided lumbar 
facet joint injections 
with bupivacaine and 
methylprednisolone 
 
Physiotherapy 
(McKenzie regimen) 
 
Not stated – 
assessed pain 
relief and 
 
6 months 
 
Greater 
decreases in 
pain in the 
intervention 
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First author, 
year 
(country, n 
randomised) 
Population Intervention Comparator 
Primary 
outcome 
Follow-up Key findings 
features of facet 
joint arthropathy 
No diagnostic 
blocks 
satisfaction with 
treatment 
group compared 
to the 
comparator, and 
higher levels of 
satisfaction 
Celik, 2011 
(Turkey, 
n=80)129 
 
LBP <4 months 
No diagnostic 
blocks 
 
Fluoroscopic guided 
lumbar facet joint 
injections with 
bupivacaine and 
methylprednisolone 
 
Diclofenac, 
thiocolchicoside and 
bed rest for 4 days 
 
Not stated – 
assessed LBP 
disability and 
pain intensity 
 
6 months 
 
Greater 
decreases in 
pain and 
disability in the 
intervention 
group compared 
to the 
comparator, 
improvement in 
pain and 
functional 
outcomes in 
both groups 
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First author, 
year 
(country, n 
randomised) 
Population Intervention Comparator 
Primary 
outcome 
Follow-up Key findings 
Yun, 2012 
(Korea, 
n=57)130 
 
LBP (no 
duration 
specified), 
clinical 
indicators of 
facet syndrome 
No diagnostic 
blocks 
 
Fluoroscopic guided 
lumbar facet joint 
injections with 
lidocaine and 
triamcinolone 
 
Ultrasound-guided 
lumbar facet joint 
injections with 
lidocaine and 
triamcinolone 
 
Pain and 
activities of daily 
living 
 
3 months 
 
No difference in 
outcomes at 
follow-up 
between the 2 
active groups, 
improvement in 
pain and 
functional 
outcomes in 
both groups 
Ribeiro, 2013 
(Brazil, 
n=60)67 
 
LBP >3 months, 
clinical 
diagnosis of 
lumbar facet 
joint syndrome 
No diagnostic 
blocks 
 
Fluoroscopic guided 
intra-articular lumbar 
facet joint injections 
with lidocaine and 
triamcinolone 
 
Intramuscular 
paravertebral 
injections with 
lidocaine and 
triamcinolone 
 
Not stated – 
assessed quality 
of life, functional 
capacity, pain on 
back extension, 
% improvement 
scale, analgesic 
usage 
 
24 weeks 
 
‘Slightly 
superior’ results 
in the 
intervention 
group compared 
to the 
comparator, 
improvement in 
pain and 
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First author, 
year 
(country, n 
randomised) 
Population Intervention Comparator 
Primary 
outcome 
Follow-up Key findings 
functional 
outcomes in 
both groups 
Lakemeier, 
2013 
(Germany, 
n=56)131 
 
LBP >24 
months 
>50% pain 
reduction after 
single intra-
articular 
diagnostic 
injection with 
bupivacaine 
 
Fluoroscopic guided 
intra-articular lumbar 
facet joint injections 
with bupivacaine and 
betamethasone 
 
Radiofrequency 
denervation of the 
lumbar facet joint 
medial branch nerves 
 
LBP-related 
disability using 
Rowland-Morris 
Questionnaire 
 
6 months 
 
No difference in 
outcomes at 
follow-up 
between the 2 
active groups, 
improvement in 
pain and 
functional 
outcomes in 
both groups 
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What is the current evidence for therapeutic lumbar facet joint injections? 
 
Table 7 summarises the best evidence synthesis from each systematic review 
of randomised controlled trials of therapeutic lumbar facet joint injections for 
chronic LBP management. 
 
Of the eleven systematic review papers, three concluded that therapeutic 
lumbar facet joint injections were ineffective,107, 108, 113 although the systematic 
review carried out by Manchikanti and colleagues published in Surgical 
Neurology International also included a randomised controlled trial of cervical 
facet joint injections in the synthesis of evidence.  Four reviews found limited to 
moderate evidence to support their use;27, 63, 68, 109 Henschke and colleagues 
however described this evidence to be of low or very low quality.  The 
remaining three systematic reviews did not find sufficient evidence to support 
the use of lumbar facet joint injections for the treatment of LBP.40, 72, 100 
 
It has already been shown earlier in this chapter however that systematic 
review papers are of variable methodology quality, with AMSTAR scores 
ranging from 2 to 10 out of a maximum of eleven points.  Some systematic 
review authors have been criticised by other review groups; Van Boxem and 
colleagues noted that the paper ‘Injection therapy and denervation procedures 
for chronic low-back pain: a systematic review’ by Henschke and colleagues109 
did not have any input from a clinical expert in pain management, and 
inappropriately grouped different pain syndromes together, despite different 
pathophysiological mechanisms.132  The same group also criticised the 
Cochrane review by Staal et al., ‘Injection therapy for subacute and chronic low-
back pain’,40 as they felt that the patient population was too heterogeneous to 
draw any clinically useful conclusions.133 
 
Despite their methodological drawbacks however, none of the authors 
attempted to pool the results of their findings due to clinical heterogeneity, with 
most of the systematic review papers opting for a narrative discussion instead.  
Staal et al. subdivided the studies according to the target of injection (such as 
lumbar facet joints and according to the therapeutic agent that was used (for 
example steroids or local anaesthetics) with an aim of making the studies more 
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comparable and clinically relevant.40  Similarly, Vekaria et al. also divided the 
outcomes into studies which compared lumbar facet joint injections with a sham 
control, versus a conservative treatment control.100 
 
It can be demonstrated that the evidence varies between the systematic 
reviews, even those analysing the same studies.  None of the review groups 
were able to carry out meta-analyses or data pooling, and any concluding 
evidence was therefore based on relatively small numbers of randomised 
controlled trials, with no more than 8 randomised controlled trials of variable 
quality being reviewed in each systematic review.  Some groups also included 
evidence from observational studies in formulating their conclusions.27, 68, 72  
Designed with an intention to observe and not interfere with routine care, these 
are associated with a higher risk of bias compared to randomised controlled 
trials in terms of selection, performance, detection, attrition, and selective 
outcomes reporting.134
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Table 7.  The evidence for intra-articular lumbar facet joint injections for chronic low back pain management 
 
Systematic review 
paper 
Number of RCTs 
included in evidence 
synthesis 
Summary of evidence 
Slipman et al. 2003107 3 
Level III (moderate) to IV (limited) evidence that therapeutic lumbar facet 
joint injections are not effective 
Boswell et al. 200727 2 
Moderate evidence for intra-articular lumbar facet joint injections with local 
anaesthetic and steroid for short- and long-term improvement in LBP 
Staal et al. 200840 7 No strong evidence to support injection therapy for LBP 
Datta et al. 200973 0 Level III or limited evidence for therapeutic facet joint interventions 
Chou et al. 2009108 7 Fair evidence that intra-articular facet joint steroid injections are not effective 
Henschke et al. 2010109 8 
Low to very low quality evidence to support the use of injection therapy for 
chronic LBP 
Falco et al. 201272 2 Limited evidence for intra-articular injections 
Manchikanti et al. 2015 
Surg Neurol Int113 
2 
Level 1 evidence (obtained from high-quality randomised controlled trials of 
lumbar and cervical facet joint injections) for lack of effectiveness of intra-
articular injections 
Manchikanti et al. 2015 
Pain Physician68 
5 Level 3 (moderate) evidence for lumbar intra-articular injections of steroids 
Vekaria et al. 2016100 6 
Insufficient high-quality evidence to support the use of facet joint injections 
over placebo/sham-controlled procedures or conservative therapy for LBP 
Manchikanti et al. World 
J Orthop 201663 
5 
Level 3 evidence for short-term improvement of 6 months or less for intra-
articular lumbar facet joint injections 
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Is there a need for a new systematic review? 
 
It is generally considered more efficient to update an existing system rather 
than addressing the same research question with a new protocol, as the 
updating process will also take previous comments and criticisms into account, 
to allow for ongoing improvement with time.  Garner and colleagues, as panel 
members for updating guidance for systematic reviews, took part in a workshop 
organised by Cochrane, a global organisation that aims to promote high quality 
health research evidence, in order to develop consensus guidance on this 
process; an updated systematic review was defined by this group as a new 
edition of a published systematic review with changes that can include new 
data, new methods, or new analyses compared to the previous edition.135  A 
number of steps were recommended by the panel to assess currency, to 
identify new relevant methods, studies or other information, and to assess the 
effect of the update i.e. whether any new information will change the findings or 
credibility. 
 
The possibility of updating an existing systematic review of therapeutic lumbar 
facet joint injections for non-specific LBP was explored using the decision 
framework developed by the panel members.  The new review would address a 
current question, as the future for this procedure remains uncertain, due to a 
lack of consistent, good quality evidence from published randomised controlled 
trials.  The existing systematic reviews have had good access and use (for 
example, the systematic review published by Vekaria et al. in 2016 has been 
downloaded over 1500 times in its first year of publication).136  However, the 
methodological quality of previous reviews has been variable, as quantified 
using the AMSTAR checklist, and may have generated biased results and 
conclusions.  One recent survey of 250 journals found that approximately half of 
the systematic reviews were out of date after 5.5 years, and that only one 
journal gave clear guidance on updating the reviews.137 
 
Many existing systematic reviews of lumbar facet joint injections have referred 
to and followed the guidelines for systematic reviews published by the 
Cochrane Back Review Group in 2009.138  No systematic review authors to date 
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have utilised the updated guidelines, which were published in 2015 as a result 
of changing standards and new methodological evidence.119  The Cochrane 
Handbook for Systematic Reviews of Interventions is also regularly updated,103 
reflecting the rapid pace of advancement in methodology and data extraction 
techniques.  The last systematic review on this topic was published by 
Manchikanti and colleagues in 2016, who reviewed the literature until March 
2015.63  Vekaria and colleagues also published a systematic review in 2016 to 
assess lumbar facet joint injections, reviewing the databases from inception 
until April 2015.100  Although it might be assumed that there may be new 
relevant randomised published controlled trials published in the intervening two 
years, one recently published feasibility study in the United Kingdom has 
outlined some of the difficulties experienced in carrying out such a study, in 
particular with patient recruitment.98 
 
Despite a demonstrable need for a new systematic review as the current 
reviews are of variable methodological quality and new methodological 
standards has emerged since the last systematic review was published, there is 
arguably no current value in carrying out a new systematic review at the time of 
writing.  The most recent high quality systematic review, which searched for 
trials from inception through April 2015, concluded that the included randomised 
controlled trials were too heterogeneous in methodology and outcome 
measures to carry out any meta-analyses.100  Figure 10 illustrates the summary 
of designs and entry criteria of included studies, and is adapted from a figure 
published in this systematic review.  Four randomised controlled trials identified 
from the other published systematic reviews have been excluded from the 
illustration as not meeting the Vekaria et al.’s criteria for inclusion; the two 
studies by Manchikanti and colleagues reviewed lumbar facet joint medial 
branch nerve blocks and not intra-articular injections,127, 128 Yun et al.’s study 
compared different radiographic techniques,130 and the full text for Nash’s study 
was not available.125  Inclusion of these studies by the systematic reviewers 
casts doubt on the validity of any evidence syntheses, and further demonstrates 
that it is not possible at present to summarise the evidence. 
 
A future systematic review should therefore include sufficient randomised 
controlled trials from a homogeneous population to carry out data synthesis in 
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the form of a meta-analysis or meaningful data pooling.  This would allow a very 
current research question to be addressed, as intra-articular lumbar facet joint 
injections are not recommended in the latest NICE guidelines for the 
management of LBP due to lack of evidence.  It is possible that the use of new 
methods and the inclusion of new studies or information could change the 
current findings or credibility of existing systematic reviews.  The research 
question remains highly relevant and any new information from a well-
conducted review may ultimately result in a guideline change.
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Figure 10.  Summary of designs and entry criteria of studies published 
between 1966 until May 2017, adapted from Vekaria et al.’s systematic 
review.100  Clinical = clinical assessment only, radiographic = clinical + 
radiological change, block = clinical + positive diagnostic block, acute = pain of 
less than 3 months’ duration, chronic = pain over 3 months’ duration.  Details of 
the changes made to the original figure are in the preceding text. 
This is an open-access article distributed under the terms of the Creative 
Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0./), which permits unrestricted use, 
distribution, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the Creative 
Commons License, and indicate if changes were made. 
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Chapter 3: FACET feasibility study methods 
 
A multicentre double-blind randomised controlled trial to assess the 
clinical- and cost-effectiveness of facet-joint injections in selected 
patients with non-specific low back pain: a feasibility study 
 
Facet-joint injections for non-specific low back pain: a 
feasibility RCT 
 
This randomised controlled feasibility study was accepted for publication in the 
NIHR Journals Library in September 2017, and published in December 2017, 
ahead of submission of this thesis.99  As the lead author of the manuscript and 
main researcher in the study, I have attempted where possible to avoid 
verbatim duplication of previously published work; there however remain 
similarities between the text relating to the FACET feasibility study and the 
monograph.  Any direction reproductions from the publication are 
acknowledged with the following statement: 
 
  
Introduction to the FACET feasibility study 
 
The rationale for carrying out a randomised controlled trial to assess the 
clinical- and cost-effectiveness of facet joint injections in patients with LBP has 
been detailed in Chapter 1.  At present, there is no definitive research to 
support the use of targeted lumbar facet joint injections to manage chronic LBP, 
with current clinical guidelines not supporting their use, and inconsistent 
diagnostic and treatment methods.  Systematic reviews of randomised 
controlled trials of therapeutic lumbar facet joint injections have been 
demonstrated in Chapter 2 to be of variable methodological quality, with 
conflicting conclusions. 
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Before undertaking a full trial to assess the clinical effectiveness and cost-
effectiveness of facet joint injections compared to a sham procedure for non-
specific LBP, there were questions that first need to be assessed by a feasibility 
study (see box 1).  
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Box 1.  FACET feasibility study research questions 
Reproduced from Snidvongs et al.’s ‘Facet-joint injections for non-specific low 
back pain: a feasibility RCT’ (2017)99 
 
 
 
 
1. Given the multiple sites with potential to generate back pain, can 
patient selection criteria be optimised, using clinical and investigative 
diagnostic methods? 
 
2. Can the method of injection be standardised, and an appropriate sham 
procedure be established? 
 
3. Can justification for further studies to evaluate treatment methods to 
target and attenuate the source of chronic LBP of facet joint origin be 
delivered? 
 
4. Is a sham-controlled trial design acceptable to patients and clinicians? 
 
5. Can sufficient patients be recruited and retained? 
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Contributors to the study design 
 
The FACET feasibility study design was developed by the original grant co-
applicant team, with further revisions made following trial management group 
meetings and on the request of the funders.  I wrote the detailed project 
description and original study protocol; any subsequent changes to the protocol 
are detailed further in this chapter.  The statistical analysis plan, as shown in 
appendix 2, was written by the study statistician Professor Rod Taylor.  
 
The members of original co-applicant team, trial management group and other 
contributors are listed with their contributions in the acknowledgements section 
of the NIHR Journals Library publication.99 
 
Study design 
 
This was a blinded parallel two-arm pilot randomised controlled trial.  
Participants with non-specific LBP who had a positive response to a single 
diagnostic medial branch nerve block were individually randomised in a 1:1 ratio 
to receive either the facet joint injection (active group) or a sham procedure 
(control group).  Participants in both active and sham groups were invited to 
attend a combined physical and psychological (CPP) programme after their 
procedure. 
 
Participants 
 
Potential participants were screened for eligibility to enter the study based on 
the following inclusion and exclusion criteria (see boxes 2 and 3). 
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Box 2.  Inclusion criteria 
Reproduced from Snidvongs et al.’s ‘Facet-joint injections for non-specific low 
back pain: a feasibility RCT’ (2017)99 
 
 
 
 
1. Patients aged 18 to 70 years attending pain clinics identified during 
routine clinical assessment of non-specific LBP. 
 
Clinical indicators for pain of facet joint origin included tenderness over 
the facet joints, referred leg pain above the knees, and worsening pain 
on extension, flexion and rotation of the lumbar spine. 
 
2. LBP of three months’ or greater duration. 
 
3. Average pain intensity score of 4/10 or more in the seven days 
preceding recruitment despite NICE recommended treatment. 
 
NICE clinical guideline CG88 recommended providing patients with 
advice and information to promote self-management of their LBP, and 
offering one of the following treatments, taking into account patient 
preference: an exercise programme, a course of manual therapy, or a 
course of acupuncture.29 
 
4. Dominantly paraspinal (not midline) tenderness at two bilateral lumbar 
levels. 
 
5. At least two components of NICE-recommended best non-invasive 
care completed, including education and one of a physical exercise 
programme, acupuncture, or manual therapy.29 
 
6. Patients are suitable for the facet joint injections. 
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Box 3.  Exclusion criteria 
Reproduced from Snidvongs et al.’s ‘Facet-joint injections for non-specific low 
back pain: a feasibility RCT’ (2017)99 
 
 
 
 
1. Patient refusal to consent. 
 
2. More than four painful lumbar facet joints. 
 
No more than four facet joint joints were to be injected to limit the total dose 
of intra-articular steroids. 
 
3. Patient has not completed at least two components of NICE-
recommended best non-invasive care, including education and one of 
a physical exercise programme, acupuncture, or manual therapy.29 
 
4. ‘Red flag’ signs.a 
 
These are possible indicators of serious spinal pathology, and include 
thoracic pain, fever, unexplained weight loss, bladder or bowel dysfunction, 
progressive neurological deficit, and saddle anaesthesia.139 
 
5. Known hypersensitivity to study medications. 
 
6. Dominantly midline tenderness over the lumbar spine, any other 
dominant pain or radicular pain. 
 
7. Any major systemic disease or mental health illness that may affect 
the patient’s pain, disability and/or their ability to exercise and 
rehabilitate, as judged by the Principal Investigators. 
 
8. Any active neoplastic disease, including primary or secondary 
neoplasm. 
 
                                            
a  These symptoms and signs were assessed by a pain clinician based on 
clinical history and examination. 
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9. Pregnant or breastfeeding patients (verbal confirmation will be 
obtained at screening. Prior to each interventional procedure involving 
x-rays, local hospital procedures will be followed to confirm that female 
participants are not pregnant). 
 
10. Any evidence of previous lumbar facet joint injections, previous lumbar 
spinal surgery or any major trauma or infection to the lumbar spine. 
 
11. Patients with morbid obesity (body mass index of 35 or greater). 
 
12. Participation in another clinical trial of an investigational medicinal 
product or disease related intervention in the past thirty days. 
 
13. Patients unable to commit to the six-month study duration. 
 
14. Patients involved in legal actions or employment or benefit tribunals 
related to their LBP. 
 
15. Patients with a known history of substance abuse. 
 
 
Recruitment procedures 
 
The original study protocol intended to recruit participants from pain clinics at 
three NHS Trusts and their associated community pain clinics.  However, 
recruitment only took place at a single centre, at Barts Health NHS Trust, as the 
study was terminated early by the funder.  Recruitment took place over a nine-
month period, between 22nd January 2016 and 30th September 2016. 
 
Potentially eligible participants were those with non-specific LBP who had been 
referred for further specialist assessment by their general practitioners (GPs).  
The reasons for referral included uncertain diagnosis, failure of conservative 
treatment, or expectation of therapeutic interventions.  Patients were screened 
to enter the study by a pain clinician if they met the inclusion and exclusion 
criteria. 
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As described in the participant information sheet (appendix 3), ‘a decision to 
withdraw from the study at any time will not affect the standard of care that you 
receive now or in the future’.  Participants who withdrew from the study or who 
had a negative response to the diagnostic test would receive a routine pain 
clinic appointment to see a pain consultant. 
 
Informed consent 
 
Participant information sheets (appendix 3) were given to potential participants 
who were considered eligible to enter the study.  A study researcher was 
available to give verbal explanation of its contents, including details of the 
nature of the study, the implications and constraints of the study protocol, and 
any known side effects and risks involved in taking part.  Written informed 
consent, when applicable, was obtained by a medically qualified investigator on 
the delegation log. 
 
Sample size calculation 
 
The statistical analysis plan, written at the outset of the study by the study 
statistician Professor Rod Taylor, stated that 60 patients would be recruited, 
with equal allocation to active and sham groups (see appendix 2).  Twenty-four 
full data sets per arm were expected to be completed, to give an acceptable 
estimate of variance of outcomes; 60 patients would give the ability to estimate 
the precision of an assumed 20% attrition rate with an error of ±5% at the 95% 
confidence level.140 
 
Study interventions 
 
Participants who were screened for eligibility and consented to enter the study 
received diagnostic medial branch nerve blocks.  A positive response was 
defined as a 50% or greater pain reduction measured using a pain intensity 
numerical rating scale lasting over 30 minutes, assessed in the standing 
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position.  If this was achieved, they were then randomised to active or control 
(sham) groups. 
 
All the study interventions were carried out by the Principal Investigator at Barts 
Health NHS Trust, a Fellow of the Faculty of Pain Medicine of the Royal College 
of Anaesthetists in the United Kingdom.  The investigator carrying out the 
injections was not blinded to the active or sham groups.  Strict aseptic 
conditions were adhered to, and local theatre protocols followed with regards to 
admission and discharge criteria.  The locally-adapted WHO Surgical Safety 
Checklist was used to identify the correct patient prior to starting the 
procedure.141 
 
The diagnostic test, facet joint injections and sham procedure are detailed in 
boxes 4, 5 and 6 respectively. 
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Box 4.  Diagnostic test 
Reproduced from Snidvongs et al.’s ‘Facet-joint injections for non-specific low 
back pain: a feasibility RCT’ (2017)99 
 
 
 
 
The diagnostic medial branch nerve injections were carried out at each 
painful lumbar level under radiological guidance.  With the patient lying in the 
prone position on a radiolucent table, the investigator examined the patient’s 
back to elicit paraspinal tenderness and confirmed appropriate landmarks to 
be injected using radiological image intensification.  The C-arm of the image 
intensifier was obliquely rotated as required to facilitate visualisation of the 
target for injection.  A 22G 90mm Quincke spinal needle was used to inject 
0.5 ml 1% lidocaine per level, and six medial branch nerves were injected in 
total in each patient. 
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Box 5.  Lumbar facet joint injections 
Reproduced from Snidvongs et al.’s ‘Facet-joint injections for non-specific low 
back pain: a feasibility RCT’ (2017)99 
 
 
 
 
In the intervention group, each participant received four facet joint injections 
at two bilateral lumbar levels, with 0.5 ml 0.5% bupivacaine (Marcain 
Polyamp Steripack 0.5%, Aspen Pharma Trading Limited, Dublin, Ireland) 
and 20 mg methylprednisolone (Depo-Medrone 40 mg/ml, Pfizer, Kent, UK) 
injected per joint.  No more than four facet joints were to be injected to avoid 
any potential confounding effects attributable to the systematic action of 
exceeding 80 mg methylprednisolone.  The volume of injectate did not 
exceed 1 ml per joint, as it would be possible to rupture the intra-articular 
capsule with greater volumes, spreading the local anaesthetic and steroid to 
other potential pain-generating structures. 
 
Paraspinal tenderness was elicited as described previously.  The skin was 
anaesthetised with 1% lidocaine (Lidocaine Hydrochloride BP 1% w/v, 
Hameln Pharmaceuticals Ltd, Gloucester, UK), and a 22G 90mm Quincke 
spinal needle advanced through the skin, subcutaneous tissue and 
paraspinal muscle towards the facet joint under x-ray guidance.  Entry of the 
needle was confirmed by visualisation of the needle position within the joint 
space, and local anaesthetic and steroid was injected into the joint. 
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Box 6.  Sham procedure 
Reproduced from Snidvongs et al.’s ‘Facet-joint injections for non-specific low 
back pain: a feasibility RCT’ (2017)99 
 
 
 
 
The control group received four injections of 0.5 ml normal saline (0.9% 
sodium chloride) at two bilateral lumbar levels.  A low volume was chosen to 
avoid irritation of any structure that was part of the facet joints, including the 
fibrous capsule, synovial membrane, hyaline cartilage, and bone.  The sham 
group would not receive systematic steroid administration, as it had been 
shown that the addition of parenteral steroid would not contribute to the pain 
relief achieved by targeted injections.142 
 
Paraspinal tenderness was elicited as described previously.  The skin was 
anaesthetised with 1% lidocaine, and a 22G 90mm Quincke spinal needle 
advanced through the skin, subcutaneous tissue and paraspinal muscle 
towards the peri-articular space under x-ray guidance.  Placement of the 
needle in the peri-articular space was confirmed by visualisation of the 
needle position next to the joint space, and normal saline was injected at this 
site. 
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Combined physical and psychological programme 
 
A combined physical and psychological (CPP) programme was delivered to 
both active and sham groups by trained physiotherapists.  The CPP programme 
drew on the methods and evidence from the BeST trial;83 research on CPP 
management of LBP has demonstrated that equally effective management can 
be achieved within a far shorter timeframe than 100 hours as recommended in 
the 2009 NICE guidance.29   
 
 
The study physiotherapists were trained to deliver the Back Skills Training 
Intervention by undertaking approximately ten hours of on-line training at 
www.backskillstraining.co.uk (last accessed 11 November 2017), to receive a 
certificate of completion and a trainer manual which supported CPP programme 
delivery.  Face-to-face meetings took place between the lead physiotherapist 
(Ms Stephanie Poulton) and study physiotherapists to ensure competency and 
standardised delivery.  The CPP programme protocol is shown in box 7. 
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Box 7.  Combined physical and psychological programme 
Reproduced from Snidvongs et al.’s ‘Facet-joint injections for non-specific low 
back pain: a feasibility RCT’ (2017)99 
 
 
 
 
Each participant attended an initial one-to-one hour-long assessment with a 
trained physiotherapist where information was gathered including the impact 
of pain on their activity, and their thoughts and beliefs regarding LBP. 
Individualised goals were identified with one specific to physical activity. 
Participants then selected and practised an individualised exercise 
programme. 
 
Six weekly 1.5 hour sessions of a group-based CPP programme were 
scheduled for each participant.  Completion of the CPP programme was 
defined as having completed a minimum of four out of six sessions.  The 
session contents addressed the following: 
 
§ Understanding pain 
§ Pain fluctuations 
§ Unhelpful thoughts and feelings 
§ Restarting activities or hobbies 
§ When pain worries us 
§ Coping with flare ups 
 
One session per programme was to be observed by the lead physiotherapist 
to assess consistency of delivery and to provide feedback and support for the 
physiotherapists running the course.  Two research physiotherapists 
including the lead delivered the programme to the study participants at Barts 
Health NHS Trust. 
 
Each participant received a Back Skills Training Patient Workbook which 
provided a summary of each week’s content for their reference at home.  
Participants were expected to be in groups of fewer than ten; 4 to 5 groups of 
4 to 5 participants per site were anticipated. 
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Regulatory approvals 
 
The details of the regulatory approvals are detailed in box 8 below. 
 
Box 8.  Regulatory approvals 
Reproduced from Snidvongs et al.’s ‘Facet-joint injections for non-specific low 
back pain: a feasibility RCT’ (2017)99 
 
 
 
 
The study was conducted in compliance with the principles of the Declaration 
of Helsinki (1996)143 and the principles of Good Clinical Practice144 and in 
accord with all applicable regulatory requirements including but not limited to 
the Research Governance Framework145 and the Medicines for Human Use 
(Clinical Trials) Regulations 2004,146 as amended in 2006 and 2008, the 
sponsor’s policies and procedures and any subsequent amendments. 
 
The required regulatory approvals were obtained in the United Kingdom.  The 
study received ethical approval from National Research Ethics Service 
(NRES) Committee London – City & East (Research Ethics Committee 
reference 15/LO/0500) and Clinical Trial Authorisation (CTA) from the 
Medicines and Healthcare products Regulatory Authority (MHRA reference 
14620/0046/001-0001).  The protocol was reviewed by the MHRA’s clinical 
trials team and considered to be a Type A Clinical Trial of an Investigational 
Medicinal Product (CTIMP) i.e. the risks are no higher than that of standard 
medical care.  The summary of product characteristics (SmPCs) for each 
investigational medical product, bupivacaine and methylprednisolone 
acetate, are available to view on the electronic Medicines Compendium.147, 
148  Health Research Authority (HRA) approval was obtained, and the study 
was given permission by the sponsor’s Joint Research Management Office 
(JRMO) to recruit patients at Barts Health NHS Trust. 
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Use of ionising radiation in the study 
 
As all the study participants would receive ionising radiation in the form of x-
rays for the diagnostic injections, facet joint injections and sham procedure, 
imaging authorisation was sought. 
 
The radiation dose and duration from fifteen consecutive lumbar facet joint 
injections were recorded by the Principal Investigator and combined by the 
medical physics expert with local hospital data from 810 patients undergoing 
similar procedures, to calculate a typical total participant dose of 0.4 mSv.  The 
medical physics expert gave approval for the study, and requested an 
amendment to the participant information sheet to reflect this very low risk (see 
appendix 3): 
 
‘The radiation dose received has been assessed by a medical physics expert 
and is considered to be of very low risk, comparable to about 2 months of 
background radiation exposure’. 
 
Imaging authorisation was also given by the clinical radiation expert as the 
participants would receive low levels of radiation exposure. 
 
Use of methylprednisolone in the study 
 
Participants randomised to receive intra-articular lumbar facet joint injections 
would receive a total of 80 mg of methylprednisolone, administered intra-
articularly; this dose was chosen to avoid any potentially confounding effects 
due to systematic absorption (see box 5).  The dose was decided by a modified 
Delphi survey of pain clinicians (appendix 4); the majority of those surveyed 
agreed that a maximum of 20 mg methylprednisolone should be injected into 
each of four joints. 
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Randomisation and blinding 
 
Secure on-line randomisation was provided by the Peninsula Clinical Trials Unit 
(PenCTU), to allocate participants to either intervention or control groups in a 
1:1 ratio.  The randomisation system was stratified by centre with minimisation 
on baseline pain scores (categories). 
 
The operator (Principal Investigator) was not blinded as the injections were 
intentionally given at different sites (intra-articular versus peri-articular) and the 
injections looked different (methylprednisolone is provided as a cloudy 
suspension, whereas the sham injection was clear).  The study participants and 
the remainder of the research team, including the Chief Investigator, research 
nurses conducting the outcome assessments, and data analysts were blinded 
for the duration of the study. 
 
The participants and the research team were unblinded at the end of the study, 
following completion of data analysis.  In accord with sponsor guidelines, a 
standard operating procedure was in place in case of emergency unblinding. 
 
Outcomes 
 
Study participants attended for outcome questionnaire visits in research nurse-
led clinics at baseline (pre-randomisation) and 6 weeks, 3 months and 6 months 
post-randomisation.  A sample case report form (CRF) is shown in appendix 5, 
and the schedule of assessments is detailed in table 8. 
 
The outcome questionnaires were chosen by members of the original co-
applicant team to cover a range of pain and disability-related issues, and are in 
accord with the IMMPACT recommended core outcome measures for chronic 
pain trials.91   Box 9 details the assessment tools used in the study. 
 
  
 109 
Box 9.  Assessment tools and outcome questionnaires 
Reproduced from Snidvongs et al.’s ‘Facet-joint injections for non-specific low 
back pain: a feasibility RCT’ (2017)99 
 
 
 
 
1. Pain intensity and characteristics – Brief Pain Inventory (BPI) (Short 
Form) Modified149 with its 11-point numerical rating scale (NRS), and 
Short Form McGill Pain Questionnaire.150  As movement could 
potentially influence the intervention (lumbar facet joint injections or 
sham procedure), all numerical rating scores were assessed in the 
standing position. 
 
2. Use of co-analgesics in the previous week – participant self-report. 
 
3. Lack of efficacy in pain relief, or, for side effects, early withdrawal from 
the study. 
 
4. Expectation of benefit (asked at baseline only) – measured on a scale 
from 0 to 6, ranging from ‘expect no improvement’ to ‘expect total 
improvement’. 
 
5. Health-related quality of life – EuroQol-5 Dimensions five-level version 
EQ-5D-5L95 and 12-Item Short Form Health Survey (SF-12).94 
 
6. Functional impairment – Oswestry Low Back Pain Disability 
Questionnaire93 and Pain Self Efficacy Questionnaire (PSEQ).151 
 
7. Satisfaction with treatment (after treatment given) – NRS from 0 to 10 
with 0 = ‘extremely dissatisfied’ and 10 = ‘extremely satisfied’. 
 
8. Complications and adverse events – these were the subject of enquiry 
at visits and following procedures, as well as being spontaneously 
reported at any time.  They were acted on as necessary and for the 
patients’ benefit, and were fully documented in case report forms and 
medical notes. 
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9. Co-psychological well-being – Hospital Anxiety and Depression Scale 
(HADS),152 Pain Catastrophizing Scale (PCS),153 SF-12 and BPI. 
 
10. Healthcare utilisation and costs, and impact on productivity – Stanford 
Presenteeism Scale 6,154 self-reported measures of sickness absence 
over the previous 3 months, and healthcare utilisation in the form of 
hospital visits, treatments and medications.  These data were 
collected at each outcome visit in the case report form. 
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Table 8.  Schedule of assessments 
Reproduced from Snidvongs et al.’s ‘Facet-joint injections for non-specific low back pain: a feasibility RCT’ (2017)99 
 
 
 
  Visit 
 
Pre-
screening 
1 2 3 
4 
(6 weeks after 
injections ± 2 
weeks) 
5 
(3 months after 
injections ± 2 
weeks) 
6 
(6 months after 
injections ± 2 
weeks) 
Informed consent  x      
Targeted physical examination x x      
Inclusion/exclusion criteria 
fulfilled 
 x x x x x x 
Medical history recorded  x      
Demographic data recorded  x      
Drug history recorded  x x x x x x 
Breakthrough analgesia 
recorded 
   x x x x 
Adverse events   x x x x x 
Outcome questionnaires  x   x x x 
Expectation of benefit scale  x      
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  Visit 
Brief Pain Inventory (Short 
Form) 
 
 x   x x x 
 
Pre-
screening 
1 2 3 4 5 6 
Short-form McGill Pain 
Questionnaire (SF-MPQ-2) 
 x   x x x 
EQ-5D-5L  x   x x x 
12-item Short Form Health 
Survey (SF-12) 
 x   x x x 
Oswestry Low Back Pain 
Disability Questionnaire 
 x   x x x 
Pain Self Efficacy 
Questionnaire (PSEQ) 
 x   x x x 
Hospital Anxiety and 
Depression Scale (HADS) 
 x   x x x 
Pain Catastrophizing Scale 
(PCS) 
 x   x x x 
Stanford Presenteeism 
Scale (SPS) 
 x   x x x 
Satisfaction with treatment 
scale 
    x x x 
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Adverse events 
 
A blinded study investigator assessed for adverse events at each study visit, 
and when necessary, an adverse event form was completed (see appendix 6).  
The adverse event management policy is shown in box 10 below. 
 
Box 10.  Adverse event management policy 
Reproduced from Snidvongs et al.’s ‘Facet-joint injections for non-specific low 
back pain: a feasibility RCT’ (2017)99 
 
 
 
 
Adverse events are defined as any untoward medical occurrence in a subject 
to whom a medicinal product has been administered; an adverse reaction is 
an untoward and unintended response in a subject to an investigational 
medicinal product (IMP) which is related to any dose administered to that 
subject.  A serious adverse event or reaction results in death, is life-
threatening, requires inpatient hospitalisation or prolongation of existing 
hospitalisation, results in persistent or significant disability or incapacity, or a 
congenital anomaly or birth defect.  A suspected unexpected serious adverse 
reaction is any serious adverse event that is both suspected to be related to 
the IMP and unexpected. 
 
 
Adverse events not already identified locally were recorded at each trial visit, 
and managed in accord with the sponsor’s requirements.  Serious adverse 
events were reported by the investigators within 24 hours of the research 
team becoming aware to the Joint Research Management Office, and 
causality and expectedness confirmed by the Chief Investigator, as the 
sponsor’s medical representative. 
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Study management and committees 
 
The details of the study management and committees are shown in box 11. 
 
Box 11.  Study management and committees 
Reproduced from Snidvongs et al.’s ‘Facet-joint injections for non-specific low 
back pain: a feasibility RCT’ (2017)99 
 
 
 
 
The trial management group (TMG) was responsible for the overall 
management of the project, and included all co-applicants and members of 
the study research team. 
 
A trial steering committee (TSC) provided independent advice and support to 
the study, and aimed to report to the funder on study progress.  It was 
chaired by an independent clinician with experience of pain trials. 
 
A data monitoring committee (DMC) had access to unblinded data and made 
recommendations to the TSC on whether there were any ethical or safety 
reasons why the trial should not continue.  It had independent members who 
were all experts in pain medicine. 
 
 
Patient and public involvement 
 
There was limited patient and public involvement in the running of the trial 
beyond the initial set-up stage; this will be discussed further in chapter 5. 
 
Patient representatives, led by a Patient Liaison Group Member of the British 
Pain Society who was an original study co-applicant, gave advice in the early 
stages of study design during the trial management group meetings, advising 
on the acceptability of study visits and the outcome questionnaires.  The 
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outcome questionnaires were subsequently used on volunteer patients 
attending the pain clinics and deemed to be acceptable.  Patient 
representatives were invited to attend the TSC meetings. 
 
Statistical analysis 
 
A statistical analysis plan was prepared by the study statistician Professor Rod 
Taylor (see appendix 2).  The baseline characteristics of both active and sham 
groups were to be presented descriptively with mean and standard deviations 
(SDs) calculated for all outcomes, and mean recruitment and attrition rates 
presented with 95% confidence intervals (CIs), with no inferential between- or 
within-group comparisons undertaken or reported.  Outcome data were to be 
collected at baseline, then 6 weeks, 3 months and 6 months after 
randomisation.  All statistical analyses were to be performed blinded to group 
allocation following the final data collection after 6 months, with no interim 
analyses. 
 
Health economics analysis 
 
A parallel health economics analysis plan was developed in collaboration with 
the study’s health economist and statistician.  A descriptive analysis of the 
health-related quality of life outcomes is however outside the scope of this 
thesis, but is published in full in the NIHR Journals Library.99 
 
Summary of changes to the study protocol 
 
Table 9 details the minor and major amendments made to the protocol over the 
study’s duration. 
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Table 9.  Summary of changes to the protocol 
Reproduced from Snidvongs et al.’s ‘Facet-joint injections for non-specific low 
back pain: a feasibility RCT’ (2017)99 
 
 
 
Amendment 
Protocol 
version, date 
Summary of changes 
 
Minor 
amendment 
 
4, 4.2.15 
 
Update to schedule of assessment table 
 
Substantial 
amendment 1 
 
5, 2.9.15 
 
Update to patient safety information 
Revised details for the trial steering 
committee and data monitoring 
committee 
 
Substantial 
amendment 2 
 
6, 7.5.16 
 
Change of Chief Investigator and 
Principal Investigator at Barts Health 
NHS Trust 
Lidocaine renamed as a non-IMP 
Additional recruitment from spinal 
orthopaedic and musculoskeletal clinics 
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Chapter 4: Results of the FACET feasibility study 
 
Screening and recruitment 
 
Due to delays in study set up (the timelines and reasons for delay are 
presented at the end of this chapter) the funders requested that screening and 
recruitment take place at one centre only, at Barts Health NHS Trust; the other 
planned recruiting sites were Basildon and Thurrock University Hospitals and 
The Walton Centre in Liverpool.  The recruiting sites at Barts Health NHS Trust 
were the pain clinics at St Bartholomew’s Hospital, the spinal orthopaedic 
(‘fracture’) clinics at The Royal London Hospital, the community pain clinics at 
Essex Lodge GP Surgery, the pain clinics at Whipps Cross University Hospital, 
and the Tower Hamlets Persistent Pain Services at Mile End Hospital.  The first 
participant was recruited from the pain clinic at St Bartholomew’s Hospital on 
22nd January 2016, and the study was terminated on 30th September 2016. 
 
The Consolidated Standards for Reporting Trials (CONSORT) flow diagram 
(figure 11) shows that 50 out of 628 patients who were screened for eligibility to 
enter the study met the inclusion criteria.  Sixteen participants consented to 
take part in the study, with five participants dropping out before receiving the 
diagnostic test; the eleven remaining participants all received diagnostic lumbar 
facet medial branch nerve blocks.  Nine of these eleven participants had a 
positive response to the diagnostic test (82%, 95% confidence interval 48% to 
98%) and were randomised to receive either lumbar facet joint injections with 
steroid, or a sham procedure. 
 
Figure 11 also shows that the actual participant screening to recruitment ratio 
was 70:1 (628:9); the expected screening to recruitment ratio was 17:1 
(1000:60) (see appendix 8 for the pre-study recruitment estimates).  The 
median recruitment rate was 2 participants per month (see figure 10), which 
was lower than expected (figure 12). 
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Table 11 lists the reasons for screening failure, and the screening to recruitment 
ratio for each screening clinic at Barts Health NHS Trust is shown in table 12.
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Figure 11.  CONSORT flow diagram showing the flow of participants 
through the study 
Reproduced from Snidvongs et al.’s ‘Facet-joint injections for non-specific low 
back pain: a feasibility RCT’ (2017)99 
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Table 10.  Screening and recruitment by month 
Reproduced from Snidvongs et al.’s ‘Facet-joint injections for non-specific low 
back pain: a feasibility RCT’ (2017)99 
 
 
 
Outcome 
Recruiting month 
1 2 3 4 5 6 7 8 9 Total 
 
Recruited 
 
1 
 
4 
 
2 
 
0 
 
2 
 
2 
 
0 
 
2 
 
3 
 
16 
 
Screened 
 
8 
 
26 
 
6 
 
37 
 
18 
 
46 
 
78 
 
209 
 
200 
 
628 
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Figure 12.  Actual and expected numbers of participants recruited at Barts Health NHS Trust for each recruitment 
month 
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Table 11.  Reasons for screening failure 
Reproduced from Snidvongs et al.’s ‘Facet-joint injections for non-specific low 
back pain: a feasibility RCT’ (2017)99 
 
 
                                            
b Some participants were in more than one category 
Reasons 
Number of 
patients 
Previous lumbar facet joint injections 192 
 Previous lumbar facet joint injections (163)  
Previous lumbar facet joint injections and no previous 
physiotherapy (3) 
Previous lumbar facet joint injections and 
radiofrequency denervation (18) 
Previous lumbar facet joint injections or 
radiofrequency denervation and aged over 70 (8) 
Other dominant pain, or widespread pain 92 
Radicular pain 64 
Aged over 70b 42 
 Aged over 70 (29)  
Previous lumbar facet joint injections or 
radiofrequency denervation and aged over 70 (8) 
Aged over 70 and has radicular pain (12) 
Aged over 70 and has widespread pain (1) 
Other reasons for not meeting inclusion/exclusion criteria 36 
Did not wish to take part 34 
Previous major trauma to the lumbar spine 29 
‘Red flag’ signs 29 
Previous lumbar spinal surgery 25 
Study team unable to contact 17 
Already taking part in another study 12 
Limited or no English 11 
Active neoplastic disease 7 
No previous physiotherapy 7 
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Morbid obesity (body mass index of 35 or greater) 7 
Learning difficulties or known mental health illness 5 
Known history of substance abuse 2 
Aged under 18 1 
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Table 12.  Locations of screening clinics at Barts Health NHS Trust 
Reproduced from Snidvongs et al.’s ‘Facet-joint injections for non-specific low 
back pain: a feasibility RCT’ (2017)99 
 
 
Clinic location 
Numbers of 
patients 
screened for 
eligibility 
Numbers 
randomised 
Screened/recruited 
fraction % 
 
Pain clinic, St 
Bartholomew’s 
Hospital 
 
413 
 
7 
 
1.69 
 
Spinal orthopaedic 
(‘fracture’) clinic, 
The Royal London 
Hospital 
 
180 
 
0 
 
0 
 
Community pain 
clinic, Essex Lodge 
GP surgery 
 
16 
 
2 
 
12.5 
 
Pain clinic, Whipps 
Cross University 
Hospital 
 
12 
 
0 
 
0 
 
Tower Hamlets 
Persistent Pain 
Services, Mile End 
Hospital 
 
7 
 
0 
 
0 
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Adherence to allocated treatment 
 
Lumbar facet joint injections and sham procedure 
 
The active lumbar facet joint injections and sham procedures were carried out 
according to the study protocol, with no study deviations or adverse events 
reported at the time of the procedure.  The study participants did not receive 
additional interventional pain procedures during their time in the study. 
 
Combined physical and psychological programme 
 
All nine participants, regardless of their allocation group, were invited to attend 
a combined physical and psychological (CPP) programme; these took place 
after they had received their randomised procedure, between study months 12 
and 20.  Completion of the CPP programme was defined in the study protocol 
as having attended at least four out of the six sessions. 
 
Three CPP programmes were scheduled.  There were four participants in the 
first group, three in the second group and two in the final group. 
 
The median number of CPP programme sessions attended by the study 
participants was four.  There were three study deviations (less than four CPP 
programme sessions attended) due to illness, personal reasons relating to 
childcare, and unplanned overseas leave (see figure 13). 
 
Study drop out and attrition 
 
Five participants recruited to the study withdrew before they received their 
diagnostic injections, although all sixteen participants who consented to take 
part completed their baseline assessment questionnaires.  The reasons given 
for drop out at this stage were not formally evaluated but included unsuitable 
dates for the diagnostic injections (one patient already had a date to attend for 
lumbar facet joint injections), and for personal or family reasons. 
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Eight participants completed the study (defined as having completed the final 
set of questionnaires 6 months after the randomised procedure) out of the nine 
participants who were randomised.  The 11% attrition rate (95% confidence 
interval 0.2% to 48%) contrasts with expected attrition rate was 20%. 
 
There were six study deviations; in addition to the three participants who did not 
complete the CPP programme, three participants did not complete all the 
questionnaire sets (see figure 13). 
 
Table 20 of appendix 7 shows that there were low levels of missingness of 
within-questionnaire data.  The study deviations and drop outs are detailed 
further in table 13. 
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Figure 13.  Study deviations and study drop outs 
Reproduced from Snidvongs et al.’s ‘Facet-joint injections for non-specific low 
back pain: a feasibility RCT’ (2017)99 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A ‘study deviation’ is defined as a participant who did not attend a study visit or 
CPP programme session, but did not drop out of the study completely.
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Table 13.   Data missingness, CPP programme attendance and allocation groups 
Reproduced from Snidvongs et al.’s ‘Facet-joint injections for non-specific low back pain: a feasibility RCT’ (2017)99 
 
 
 
Participant 
number 
Questionnaires completed 
Number of CPP programme 
sessions attended 
CPP programme 
group 
Allocation 
group Baseline 
6 
weeks 
3 
months 
6 
months 
1 Y Y Y Y 5 1 Intervention 
2 Y N N Y 0 1 Sham 
3 Y Y Y Y 6 1 Sham 
4 Y Y Y Y 4 1 Intervention 
5 Y Y Y Y 6 2 Sham 
6 Y Y N Y 0 2 Intervention 
7 Y Y Y Y 5 2 Intervention 
8 Y Y Y N 0 3 Sham 
9 Y Y Y Y 4 3 Intervention 
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Baseline characteristics and outcomes 
 
The baseline characteristics and outcomes of those who took part in the study 
are described in box 12 below. 
 
Box 12.  Baseline characteristics and outcomes 
Reproduced from Snidvongs et al.’s ‘Facet-joint injections for non-specific low 
back pain: a feasibility RCT’ (2017)99 
 
 
 
 
The mean age of eligible participants was 45 years, with a similar proportion 
of males and females.  Six out of 14 participants (43%) were not working at 
baseline (see table 14). 
 
Baseline patient-reported outcomes indicate a population with substantial 
levels of pain (mean 8.5 on a 0 to 10 visual analogue scale) that was 
predominantly bilateral (12/16, 75%) and which had a mean duration of 72 
months (see table 14).  High baseline levels of disability and mental ill health, 
and poor overall health-related quality of life were seen (see tables 14 and 
15). 
 
Given the small numbers randomised, not unexpectedly there was evidence 
of imbalance in participant characteristics and patient-reported outcomes 
between the two groups at baseline (see table 15). 
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Table 14.  Participant characteristics in all eligible and randomised participants 
Reproduced from Snidvongs et al.’s ‘Facet-joint injections for non-specific low back pain: a feasibility RCT’ (2017)99 
 
 
 
 
All eligible 
(n=16)c 
Not randomised 
(n=7) 
Sham group 
(n=4) 
Intervention group 
(n=5) 
Age (years), mean (SD) 44.8 (13.2) 44.4 (14.3) 50.5 (14.4) 40.8 (11.5) 
Sex (male), n (%) 9 (56) 2 (28) 2 (50) 3 (60) 
BMI (kg/m2), mean (SD) 27.0 (5.1) 29.9 (5.1) 29.6 (4.7) 27.7 (5.6) 
Baseline pain (0-10 VAS), mean 
(SD) 
8.5 (1.5) 8.0 (1.7) 9.5 (1.0) 8.4 (1.5) 
Duration of pain (months) mean 
(SD) 
71.9 (88.7) 46.0 (53.6) 51.0 (46.3) 124.8 (135.9) 
Location of pain, n (%) 
   Bilateral 
   Unilateral 
 
12 (75) 
4 (25) 
 
5 (71) 
2 (29) 
 
3 (75) 
1 (25) 
 
4 (80) 
1 (20) 
Aware of pain (years), mean (SD) 6.8 (7.6) 5.2 (4.6) 4.2 (3.9) 10.4 (11.3) 
Describe health, n (%) 
   Excellent 
 
0 (0) 
 
0 (0) 
 
0 (0) 
 
0 (0) 
                                            
c Not all eligible and randomised participants contributed data 
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All eligible 
(n=16)c 
Not randomised 
(n=7) 
Sham group 
(n=4) 
Intervention group 
(n=5) 
   Very good  
   Good  
   Fair 
   Poor 
1 (7) 
9 (64) 
1 (7) 
3 (21) 
0 (0) 
3 (60) 
1 (40) 
1 (40) 
0 (0) 
3 (75) 
0 (0) 
1 (25) 
0 (0) 
1 (20) 
3 (60) 
1 (20) 
Work status, n (%) 
   Full time 
   Part time 
   Not working 
   Other 
 
7 (50) 
1 (7) 
4 (29) 
2 (14) 
 
1 (17) 
0 (0) 
3 (50) 
2 (3) 
 
2 (50) 
1 (25) 
0 (0) 
1 (25) 
 
4 (80) 
0 (0) 
1 (20) 
0 (0) 
Illness caused stop working, n (%) 
  Yes 
  No 
 
10 (72) 
4 (28) 
 
1 (20) 
4 (80) 
 
3 (75) 
1 (25) 
 
3 (60) 
2 (40) 
Missed work days, mean (SD) 13.5 (31.1) 0 (0) 30.0 (52.0) 4.5 (3.7) 
Level of activity prior to procedure, 
n (%) 
   Hard manual 
   Lifting 
   Walking 
   Sedentary 
 
 
2 (29) 
1 (14) 
0 (0) 
4 (57) 
 
 
0 (0) 
1 (100) 
0 (0) 
0 (0) 
 
 
1 (33) 
0 (0) 
0 (0) 
2 (66) 
 
 
1 (33) 
0 (0) 
0 (0) 
2 (66) 
Current smoker, n (%)     
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All eligible 
(n=16)c 
Not randomised 
(n=7) 
Sham group 
(n=4) 
Intervention group 
(n=5) 
   Yes  
   No 
11 (79) 
3 (21) 
2 (40) 
3 (60) 
0 (0) 
4 (100) 
1 (20) 
4 (80) 
Alcohol (units per week), mean 
(SD) 
0.7 (1.1) 0.6 (1.3) 0.5 (1.0) 1.0 (1.2) 
Exercise per week, n (%) 
   >5 days 
   3-5 days 
  1-2 days 
  <1 day 
 
2 (14) 
1 (7) 
5 (39) 
6 (43) 
 
0 (0) 
1 (20) 
1 (20) 
3 (60) 
 
1 (25) 
0 
1 (25) 
2 (50) 
 
1 (20) 
0 
3 (60) 
1 (20) 
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Table 15.  Primary and secondary outcomes at baseline 
Reproduced from Snidvongs et al.’s ‘Facet-joint injections for non-specific low back pain: a feasibility RCT’ (2017)99 
 
 
 
 
All eligible 
(n=16)d 
Not randomised 
(n=7) 
Sham group 
(n=4) 
Intervention group 
(n=5) 
BPI (0-10), mean (SD) 
   Worst pain  
   Least pain  
   Average pain 
   Pain now 
Pain severity 
   General activity 
   Mood 
   Walking ability 
   Normal work 
   Relations  
   Sleep 
   Enjoyment 
Interference 
 
8.5 (1.7) 
6.0 (2.7) 
7.4 (1.5) 
6.5 (2.8) 
7.1 (1.6) 
7.7 (2.5) 
6.9 (2.2) 
6.3 (2.8) 
8.1 (2.2) 
6.2 (2.5) 
7.1 (3.0) 
7.4 (3.0) 
7.1 (3.9) 
 
9.0 (0.9) 
6.2 (2.3) 
7.7 (1.5) 
5.2 (2.9) 
7.0 (0.8) 
7.7 (2.6) 
6.7 (2.4) 
6.2 (2.3) 
8.5 (2.1) 
5.3 (3.3) 
5.8 (3.5) 
6.8 (3.9) 
6.7 (4.7) 
 
9.3 (1.5) 
6.0 (2.7) 
7.5 (1.9) 
8.0 (2.3) 
7.7 (1.7) 
9.3 (1.5) 
7.0 (2.4) 
5.5 (2.0) 
8.5 (1.7) 
6.5 (1.9) 
8.8 (1.9) 
8.3 (1.7) 
7.7 (1.8) 
 
7.2 (2.2) 
6.0 (3.5) 
7.0 (1.6) 
6.8 (2.8) 
6.8 (2.4) 
6.6 (1.2) 
7.0 (4.8) 
7.0 (2.7) 
7.2 (2.9) 
7.0 (4.8) 
7.4 (3.0) 
7.4 (3.0) 
7.1 (2.4) 
                                            
d For some outcomes only 14 participants contributed data 
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All eligible 
(n=16)d 
Not randomised 
(n=7) 
Sham group 
(n=4) 
Intervention group 
(n=5) 
McGill Pain Questionnaire, mean (SD) 
   Continuous pain 
   Intermittent pain 
   Neuropathic pain 
   Affective descriptors 
Total 
 
5.2 (2.0) 
4.4 (2.5) 
2.7 (1.9) 
4.0 (2.6) 
4.1 (1.7) 
 
5.6 (0.9) 
4.7 (2.4) 
2.7 (2.2) 
3.9 (2.8) 
4.2 (1.5) 
 
4.5 (3.0) 
4.2 (2.6) 
2.1 (1.8) 
2.0 (1.5) 
3.3 (2.0) 
 
5.3 (2.2) 
4.3 (3.1) 
3.2 (1.7) 
5.6 (2.4) 
4.5 (2.0) 
Oswestry Disability Index, mean (SD)  
Total 
 
49.2 (17.6)  
 
55.8 (19.4) 
 
48.8 (19.9) 
 
43.0 (15.0) 
Pain Self Efficacy Questionnaire, mean 
(SD) 
Total 
 
21.3 (12.8) 
 
16.5 (15.8) 
 
27.0 (7.7) 
 
22.6 (12.2) 
SF-12, mean (SD) 
   PCS 
   MCS 
 
33.5 (5.8) 
35.7 (11.2) 
 
34.5 (5.8) 
34.7 (14.7) 
 
32.7 (6.0) 
43.4 (10.0) 
 
33.1 (6.7) 
30.4 (4.6) 
Hospital Anxiety and Depression Score, 
mean (SD) 
   Anxiety 
   Depression 
 
 
10.1 (4.0) 
9.7 (4.1) 
 
 
10.3 (5.2) 
11.0 (4.8) 
 
 
7.5 (3.4) 
6.8 (3.9) 
 
 
12.0 (1.2) 
10.4 (3.4) 
Pain Catastrophizing Scale, mean (SD) 
   Rumination  
 
12.5 (3.9) 
 
11.7 (4.9) 
 
11.5 (4.0) 
 
14.2 (2.5) 
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All eligible 
(n=16)d 
Not randomised 
(n=7) 
Sham group 
(n=4) 
Intervention group 
(n=5) 
   Magnification  
   Helplessness 
Total 
7.1 (3.3) 
15.7 (4.4) 
35.2 (11.1) 
6.8 (3.3) 
16.3 (4.8) 
34.8 (11.7) 
6.3 (4.3) 
11.7 (4.4) 
29.5 (12.3) 
8.0 (3.2) 
18.0 (4.8) 
40.2 (9.0) 
EQ-5D-5L index, mean (SD) 0.41 (0.30) 0.43 (0.29) 0.40 (0.21) 0.39 (0.35) 
Expectation of benefit, 
mean (SD) 
 
3.3 (1.7) 
 
2.7 (2.4) 
 
3.5 (0.6) 
 
3.8 (1.1) 
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Primary and secondary outcomes at follow-up 
 
The primary and secondary results at 6 weeks’ and 3 and 6 months’ follow-up 
are presented descriptively, according to the statistical analysis plan (see table 
16). 
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Table 16.  Summary of descriptive outcomes at all follow-up points.  Primary and secondary outcomes at follow-up 
Reproduced from Snidvongs et al.’s ‘Facet-joint injections for non-specific low back pain: a feasibility RCT’ (2017)99 
 
 
 
Outcome 
Follow-up time point, mean score (SD) 
 
6 weeks 3 months 6 months 
Sham 
group 
(n=2) 
Intervention 
group (n=5) 
Sham 
group 
(n=3) 
Intervention 
group (n=4) 
Sham 
group 
(n=3) 
Intervention 
group (n=5) 
BPI (0-10), mean (SD) 
   Worst pain  
   Least pain  
   Average pain 
   Pain now 
Pain severity 
   General activity 
   Mood 
   Walking ability 
   Normal work 
 
5.0 (2.8) 
4.0 (1.4) 
4.5 (2.1) 
5.0 (2.8) 
4.6 (2.3) 
5.0 (4.2) 
4.5 (2.1) 
4.0 (1.4) 
5.5 (0.7) 
 
7.8 (1.9) 
5.2 (2.5) 
6.2 (2.5) 
6.6 (2.1) 
6.5 (2.1) 
6.2 (2.4) 
7.2 (1.9) 
7.2 (2.6) 
7.2 (2.6) 
 
7.3 (3.0) 
7.0 (3.6) 
6.0 (2.6) 
6.3 (3.0) 
6.7 (3.0) 
6.7 (2.3) 
7.0 (3.6) 
5.3 (1.5) 
6.0 (2.0) 
 
7.8 (1.7) 
5.3 (2.2) 
6.3 (2.5) 
5.8 (2.1) 
6.3 (2.1) 
7.3 (1.9) 
7.8 (2.1) 
6.0 (2.9) 
6.8 (2.8) 
 
6.3 (4.7) 
5.3 (4.5) 
5.3 (4.5) 
6.0 (4.6) 
5.8 (4.5) 
6.0 (5.3) 
5.3 (5.0) 
4.3 (4.9) 
5.0 (5.0) 
 
6.0 (3.5) 
5.0 (2.8) 
5.6 (2.6) 
5.2 (3.7) 
5.5 (3.1) 
5.6 (3.6) 
5.6 (3.6) 
5.0 (4.6) 
6.0 (4.7) 
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Outcome 
Follow-up time point, mean score (SD) 
 
6 weeks 3 months 6 months 
Sham 
group 
(n=2) 
Intervention 
group (n=5) 
Sham 
group 
(n=3) 
Intervention 
group (n=4) 
Sham 
group 
(n=3) 
Intervention 
group (n=5) 
   Relations  
   Sleep 
   Enjoyment 
Interference 
3.5 (2.1) 
6.5 (4.9) 
4.5 (2.1) 
4.8 (2.1) 
6.2 (3.4) 
8.0 (1.9) 
7.6 (2.3) 
7.1 (1.9) 
5.7 (4.0) 
7.0 (2.6) 
7.7 (2.5) 
6.5 (2.4) 
7.5 (1.9) 
6.3 (2.9) 
7.0 (2.2) 
6.9 (2.2) 
4.0 (5.3) 
4.3 (5.1) 
4.7 (4.7) 
4.8 (4.9) 
5.2 (3.2) 
6.0 (4.7) 
6.2 (3.3) 
5.7 (3.8) 
McGill Pain Questionnaire, 
mean (SD) 
   Continuous pain 
   Intermittent pain 
   Neuropathic pain 
   Affective descriptors 
Total 
 
 
3.8 (3.2) 
4.4 (3.7) 
1.7 (1.8) 
4.4 (4.8) 
3.5 (3.3) 
 
 
4.9 (3.1) 
3.7 (2.5) 
4.0 (3.2) 
4.6 (3.0) 
4.2 (2.3) 
 
 
6.3 (3.4) 
4.9 (3.0) 
2.5 (1.5) 
5.6 (4.0) 
4.8 (2.6) 
 
 
3.9 (1.4) 
3.7 (3.5) 
2.0 (0.9) 
5.4 (1.2) 
3.6 (1.5) 
 
 
4.1 (3.7) 
3.5 (2.9 
3.6 (3.4) 
2.5 (2.5) 
3.5 (2.9) 
 
 
3.3 (2.6) 
3.6 (3.8) 
3.0 (2.9) 
3.7 (2.8) 
3.4 (2.8) 
Oswestry Disability Index, 
mean (SD)  
Total 
 
 
36.0 
(17.0)  
 
 
48.4 (20.2) 
 
 
56.0 
(14.4) 
 
 
39.0 (9.9) 
 
 
42.6 
(34.0) 
 
 
39.9 (26.0) 
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Outcome 
Follow-up time point, mean score (SD) 
 
6 weeks 3 months 6 months 
Sham 
group 
(n=2) 
Intervention 
group (n=5) 
Sham 
group 
(n=3) 
Intervention 
group (n=4) 
Sham 
group 
(n=3) 
Intervention 
group (n=5) 
Pain Self Efficacy 
Questionnaire, mean (SD) 
Total 
 
 
33.5 
(10.6) 
 
 
21.2 (15.3) 
 
 
27.7 (9.6) 
 
 
31.8 (14.1) 
 
 
28.3 
(21.7)  
 
 
33.2 (19.4) 
SF-12, mean (SD) 
   PCS 
   MCS 
 
38.8 
(10.3)  
43.6 
(15.4)           
 
33.7 (8.6)      
31.3 (7.9)       
 
38.5 (6.8)   
35.7 (7.8)           
 
40.8 (11.0) 
37.8 (2.6)             
 
34.4 
(12.5)  
47.2 
(22.1)          
 
39.5 (13.7)  
38.1 (13.5)            
Hospital Anxiety and 
Depression Score, mean 
(SD) 
   Anxiety 
   Depression 
 
 
7.0 (1.4) 
4.0 (4.3)  
 
 
12.8 (4.4) 
10.8 (6.7)  
 
 
8.3 (3.8) 
8.0 (3.5) 
 
 
11.5 (4.6) 
9.5 (5.5) 
 
 
6.7 (5.7) 
7.7 (8.1) 
 
 
10.0 (3.9) 
8.4 (7.1) 
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Outcome 
Follow-up time point, mean score (SD) 
 
6 weeks 3 months 6 months 
Sham 
group 
(n=2) 
Intervention 
group (n=5) 
Sham 
group 
(n=3) 
Intervention 
group (n=4) 
Sham 
group 
(n=3) 
Intervention 
group (n=5) 
Pain Catastrophizing 
Scale, mean (SD) 
   Rumination  
   Magnification  
   Helplessness 
Total 
 
 
11.0 (1.4) 
8.0 (1.4) 
14.0 (2.8) 
33.0 (5.6) 
 
 
12.4 (4.9) 
6.6 (2.9) 
15.0 (7.0) 
34.0 (14.0) 
 
 
15.0 (1.0) 
10.3 (0.6) 
13.7 (6.5) 
19.0 (6.6) 
 
 
11.8 (4.8) 
5.0 (3.5) 
15.0 (8.9) 
32.7 (17.2) 
 
 
15.8 (3.8) 
19.5 (3.5) 
16.7 (6.1) 
16.7 (7.6) 
 
 
14.4 (5.5) 
13.8 (5.9) 
15.5 (9.0) 
16.0 (7.4) 
EQ-5D-5L index, mean 
(SD) 
0.67 
(0.30) 
0.43 (0.33) 0.42 
(0.10) 
0.62 (0.28) 0.60 
(0.50) 
0.51 (0.41) 
Satisfaction, 
mean (SD)  
 
6.3 (3.8) 
 
6.6 (0.9) 
 
7.3 (1.2) 
 
7.5 (0.6) 
 
9.7 (0.6) 
 
6.0 (2.1) 
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Adverse events 
 
Three study participants reported adverse events.  These are detailed further in 
table 17. 
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Table 17.  Summary of adverse events 
Reproduced from Snidvongs et al.’s ‘Facet-joint injections for non-specific low back pain: a feasibility RCT’ (2017)99 
 
 
 
Participant 
number 
Description of adverse 
event 
Relationship to IMP, as 
judged by the Principal 
Investigator 
Seriousness of adverse 
event, as judged by the 
Principal Investigator 
Randomisation 
group 
1 Flare-up of LBP after 
randomised procedure 
Expected reaction, related 
to IMP 
Not serious Sham 
4 Flare-up of LBP 5 
months after 
randomised procedure 
Expected reaction, related 
to IMP 
Not serious Intervention 
7 
 
Urinary incontinence Unexpected reaction, not 
related to IMP 
Serious adverse event 
(required overnight stay in 
hospital) 
Intervention 
Swelling at site of 
injections 
Expected reaction, related 
to the procedure but not to 
the IMP 
Serious adverse reaction 
(required overnight stay in 
hospital) 
Flare-up of LBP after 
randomised procedure 
Expected reaction, related 
to IMP 
Not serious 
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Flare-up of LBP 5 
months after 
randomised procedure 
Expected reaction, related 
to IMP 
Not serious 
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Blinding to treatment allocation 
 
Prior to being unblinded at the end of the study, the eight participants and 
blinded outcome assessor were asked to guess which allocation group they 
thought the participant had belonged to.  One out of eight participants guessed 
correctly, whereas the outcome assessor guessed correctly four out of nine 
times.  The implications of this will be discussed in the following chapter. 
 
Study timelines 
 
The study timelines and Gantt chart are shown in figures 14 and 15 
respectively.  The start date was delayed by 18 months (546 days) from the 
original contract start date, with delays in obtaining NHS permission to recruit.  
The funders granted a no-cost negotiated one-month extension period which 
allowed for timely collection of follow-up data and delivery of the final report.
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Figure 14.  Study timelines and milestones  
Reproduced from Snidvongs et al.’s ‘Facet-joint injections for non-specific low back pain: a feasibility RCT’ (2017)99 
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Figure 15.  Study GANTT chart 
Reproduced from Snidvongs et al.’s ‘Facet-joint injections for non-specific low back pain: a feasibility RCT’ (2017)99 
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Chapter 5: Discussion 
 
Summary of findings 
 
Critical appraisal of systematic reviews 
 
A literature search to identify systematic reviews and meta-analyses of 
randomised controlled trials of intra-articular lumbar facet joint injections for 
chronic LBP management retrieved a total of 14 randomised controlled trials 
across 11 systematic reviews, and no meta-analyses.  None of the review 
authors were able to pool the data due to the level of clinical heterogeneity 
detected across the randomised controlled trials which compared different 
injection procedures, substances and comparators, from a heterogeneous 
population. 
 
No clear conclusions can be drawn from the existing systematic reviews which 
were themselves of variable methodological quality, and the evidence to 
support the use therapeutic lumbar facet joint injections for the management of 
chronic LBP remains lacking despite some limited trial evidence.  Vekaria and 
colleagues, who carried out a well-designed systematic review of randomised 
controlled trials published from inception until April 2015, summarised the 
current evidence base as follows: 
 
‘The studies found here were clinically diverse and precluded any meta-
analysis.  A number of methodological issues were identified.  The positive 
results, whilst interpreted with caution, do suggest that there is a need for 
further high-quality work in this area.’100 
 
The literature search period for the critical appraisal of systematic reviews in 
chapter 2 was between 1966 until May 2017; when this search was repeated 
twelve months later in May 2018, a further 4 randomised controlled trials were 
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identified155-158.  It can however be seen that even these latest trials are diverse 
and any attempts to pool their results will not meaningful (see figure 16). 
 
It is not possible at present to summarise the available evidence for lumbar 
facet joint injections in chronic LBP management.  The randomised controlled 
trials have recruited from a heterogeneous population, with no standardised 
inclusion and exclusion criteria, and there remains no agreement between the 
researchers on how to accurately diagnose pain of lumbar facet joint origin.  
There remain significant challenges in the interpretation of some systematic 
review findings, due to the inclusion of poor quality studies and weak 
methodology.
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Figure 16.  Summary of designs and entry criteria of studies published 
between 1966 until May 2018, adapted from Vekaria et al.’s systematic 
review.100  Clinical = clinical assessment only, radiographic = clinical + 
radiological change, block = clinical + positive diagnostic block, acute = pain of 
less than 3 months’ duration, chronic = pain over 3 months’ duration.  The 
studies in red were published between May 2017 and May 2018. 
This is an open-access article distributed under the terms of the Creative 
Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0./), which permits unrestricted use, 
distribution, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the Creative 
Commons License, and indicate if changes were made. 
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FACET feasibility study 
 
The FACET feasibility study’s overarching aim was to assess the feasibility of 
conducting a definitive study evaluating the clinical- and cost-effectiveness of 
facet joint injections compared with a sham procedure, in patients with non-
specific LBP of more than three months’ duration.  The parallel health 
economics analysis is outside the scope of thesis but is presented separately in 
the NIHR Journals Library’s publication ‘Facet-joint injections for non-specific 
low back pain: a feasibility RCT’.99 
 
No definitive conclusions can be drawn on the clinical effectiveness or cost 
effectiveness of intra-articular lumbar facet joint injections for the management 
of non-specific LBP, due to the constraints of this being a single centre study 
with small patient numbers; the feasibility recruitment target of sixty randomised 
patients at three NHS Trusts was not met, and only nine participants were 
randomised at a single recruiting centre.  The attrition rate was low, although 
the small sample size precludes any definitive conclusions on patient retention.  
No significant adverse events, as judged by the clinical research team,  were 
reported as a consequence of the interventional procedures.   
 
The feasibility study showed good adherence to the statistical analysis plan, 
and many of the clinical outcomes were successfully collected over the duration 
of the study.  The sample size however meant that it was not possible to 
interpret the numerical differences in outcomes observed between the two 
treatment arms. 
 
Many of the feasibility objectives, listed in box 13, were met.  The detailed 
objectives will be discussed further in this section.  
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Box 13.  Feasibility objectives achieved by the FACET feasibility study 
Adapted from Snidvongs et al.’s ‘Facet-joint injections for non-specific low back 
pain: a feasibility RCT’ (2017)99 
 
 
1. Selection of patients into the study using a joint clinical and diagnostic 
approach. 
 
2. Successful standardisation of the methods of facet joint injection and 
the sham procedure, using a modified Delphi method to generate 
consensus amongst interventional pain specialists in the United 
Kingdom. 
 
3. Ability to carry out the sham procedure (peri-articular injections with 
saline) in participants randomised to the control group. 
 
4. The sham-control study design was accepted by the clinicians involved 
in the study, and was also deemed acceptable by patients. 
 
5. Participants were retained over the 6-month follow-up period. 
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To assess the eligibility criteria, recruitment and retention of patients in 
the two treatment arms 
 
The considerable delays in obtaining permission to recruit participants to the 
study (see figure 14) resulted in a funder-led decision to terminate the study 
early.  Recruitment therefore only took place at a single centre, as there was 
insufficient time available to open the other two sites.  Some of the reasons for 
delay will be discussed further in this chapter. 
 
One striking finding of the feasibility study was the high screening to recruitment 
ratio of approximately 70:1; 628 participants were screened to randomise nine 
participants.  It can be seen in appendix 8 that the pre-study screening to 
recruitment ratio estimate was 17:1 (1000:60).  A lack of formal process 
evaluation meant that this discrepancy was discussed instead at each trial 
management group meeting, when the screening logs were also reviewed.  It 
was noted that patients who were aged over 70 who would otherwise have 
been suitable were excluded from the study; table 11 shows that out 628 
patients screened, 42 were aged over 70 and 29 met the entry criteria.  
Although a decision was made not to amend the existing study protocol, a 
future trial may wish to broaden the entry criteria by increasing or removing the 
upper age limit.  The screening to recruitment ratio derived from this feasibility 
study has some precision in the context of the hospital pain and spinal 
orthopaedic clinics at Barts Health NHS Trust and is applicable to this patient 
sub-group, but may not apply to other centres or to primary care. 
 
The expected level of attrition was 20%, as defined in the statistical analysis 
plan and protocol; five participants dropped out of the study after giving consent 
but prior to receiving the diagnostic test, and one randomised participant did not 
complete the study i.e. did not complete the final set of questionnaires six 
months post-randomisation.  Although this feasibility study shows an apparently 
high level of participant retention, the sample size is too imprecise to calculate 
the attrition rate with any degree of precision (11% attrition rate, 95% 
confidence interval 0.2% to 48%). 
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To assess the feasibility and acceptability of the two treatment arms from 
the point of view of patients and their pain teams 
 
A modified Delphi survey of approximately 250 pain specialists in the United 
Kingdom was undertaken to achieve a consensus on the choice and maximum 
dose of steroid for the facet joint injections, the volume to inject into each joint, 
and on the technique for the sham procedure (see appendix 4); the facet joint 
injections and sham procedure can therefore be considered acceptable to pain 
clinicians as 42 took part in the survey.  The pain and spinal orthopaedic teams 
and research physiotherapists at Barts Health NHS Trust all screened and 
recruited participants to the study, indicating its feasibility and acceptability to 
clinicians. 
 
The CONSORT flow diagram, shown in figure 7, illustrates that 34 patients 
referred to the pain clinics by their GPs with LBP met the eligibility criteria but 
declined to take part in the study.  Although a formal process evaluation was 
not undertaken, the two treatment arms were not cited as a reason for not 
wishing to take part. 
 
To assess the feasibility of the proposed definitive study design 
 
Many aspects of the proposed definitive study design were shown to be feasible 
within the constraints of this study.  The research team received training to use 
the web-based randomisation system, with no reports of technical difficulties or 
unintentional unblinding.  Some fidelity of blinding was demonstrated as nearly 
50% of the allocation groups were correctly guessed by the blinded outcome 
assessor, and only one out of eight participants who completed the study 
correctly guessed their allocation group. 
 
Appropriate active intra-articular lumbar facet joint injections and sham peri-
articular saline injection techniques were developed using a consensus 
technique, and no protocol deviations were reported in their delivery. 
 
The outcomes proposed for the main trial were collected in the majority of 
participants; however, eleven participants returned incomplete questionnaire 
 154 
sets, as shown in table 20 of appendix 7.  The level of missingness ranged from 
individual questions being omitted or spoiled (illegible), to missed questionnaire 
visits.  Feasibility was demonstrated in study data collection, as baseline data 
was collected in all participants who consented to take part in the study, and in 
most participants at six weeks, three months and six months’ post-
randomisation.  High quality data entry was ensured by the use of manual 
double data entry onto the electronic database by two independent research 
team members.159 
 
The feasibility study protocol and detailed project description was written in 
2012; the 2009 NICE guidelines for the early management of persistent non-
specific LBP (NICE CG88) had recommended around 100 hours of a CPP 
programme over a maximum of eight weeks to those who had already received 
at least one less intensive treatment such as an exercise programme, manual 
therapy or acupuncture, and with ‘high disability and/or significant psychological 
distress’.29  It was however decided by the trial management group to draw on 
the evidence from the BeST trial as a 100-hour CPP programme was not usual 
NHS practice at the time of the commissioned call; this would allow for the CPP 
programme to be effectively delivered to groups of six to ten participants within 
a far shorter timeframe.83 
 
The NICE guidelines for LBP management was updated in November 2016, 
two months after the feasibility study’s recruitment period had ended.25  This 
guidance similarly followed the evidence from the BeST trial and did not 
prescribe the length and duration of the CPP programme; a programme was to 
be considered in those with LBP or sciatica when there were ‘significant 
psychosocial obstacles to recovery’, and when previous treatments were 
ineffective.  The CPP programme delivered in the FACET feasibility study can 
therefore be considered to be well aligned with this current guidance. 
 
Delivery of the CPP programme proved to be feasible at the single recruiting 
centre; all the study physiotherapists across the three planned recruiting sites 
were trained by the lead physiotherapist (Ms Stephanie Poulton) to deliver the 
CPP programme, with no protocol deviations.  Three programmes were 
delivered at Barts Health NHS Trust although fewer participants attended per 
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group than expected, with between one and three participants per group.  The 
protocol defined successful completion of the CPP programme as having 
attended at least four out of the six sessions; six out nine randomised 
participants completed the CPP programme.  The reasons given for incomplete 
or non-attendance included illness, undisclosed personal reasons, and travel 
abroad. 
 
To estimate outcome standard deviation to inform the power calculation 
for a definitive study 
 
Good adherence to the statistical analysis plan was demonstrated, despite the 
small final sample size.  As shown in chapter 4, the participant characteristics 
for all study participants were described, with mean and standard deviation for 
the primary and secondary outcomes reported at baseline and follow-ups. 
 
It is however not advisable to use these outcome standard deviations to inform 
the power calculation for a definitive study.  The study statistician (Professor 
Rod Taylor) used a calculation based on a simulation study by Teare and 
colleagues, which recommended at least 35 participants per group to estimate 
a standard deviation for a continuous outcome in an external pilot or feasibility 
study; the larger the sample size, the more precise the estimate.160 
 
To finalise the protocol design, statistical plan, number of centres 
required and study duration of the definitive study 
 
It was not possible to finalise the protocol design for the definitive trial on the 
basis of this feasibility study, as the recruitment target was not reached, and 
participants were recruited from a single centre only.  However, important 
lessons have been learned here which should be considered by future 
researchers when planning a trial of injection therapy for chronic LBP 
management; the implications of the FACET feasibility study for future research 
will be discussed later in this chapter. 
Issues encountered and how they were resolved 
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The following section outlines the regulatory and staffing issues encountered, 
and the challenges experienced with recruitment including with clinician and 
patient participation and with the study population itself.  The importance of trial 
management and trial mentorship will also be discussed. 
 
Regulatory issues 
 
Figure 14 illustrates the delays experienced by the research team in particular 
at a local level, in part due to the length of time taken for any issues to be 
addressed.  System errors caused delays in gaining NIHR portfolio adoption 
and NHS permission to recruit.  There were additional delays in obtaining 
signed contracts between the proposed collaborating centres. 
 
The processes required for gaining research governance approval to carry out a 
clinical trial can lead to significant delays in a study’s schedule.  Thompson and 
France presented a narrative case study where unexplained delays in obtaining 
Research Management and Governance approval in England but not Scotland, 
for a multicentre observational study, were caused in part by the research 
governance teams offering contradictory advice, lack of familiarity with the new 
systems and processes, and by a lack of clear training and guidance.161  
Consequently, the researchers had to revise and scale down their objectives, 
which they were unable to fully deliver within the funding timescale.  Difficulties 
were also experienced in recruiting from general practices in England, as the 
Primary Care Research Networks would not allow the practices to be used as 
Patient Identification Centres until governance approvals had been granted. 
 
Kearney and colleagues investigated and analysed the delays in opening 
research sites for multicentre clinical trials in the United Kingdom, which the 
group identified as a high priority and potential barrier in improving the country’s 
research profile in a competitive market.162  The group noted that the United 
Kingdom may not at present be an attractive location to conduct clinical trials, 
due to these perceived barriers and delays, although the delays may be 
reduced by government-initiated targets and the National Institute for Health 
Research Clinical Research Network initiatives.  This prospective study found 
that the median time to open the participating sites from the date of the ethics 
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letter confirming the sites’ participation in the trial was 10.5 months (interquartile 
range 7.3 to 15.2), which increased to 14.5 months (interquartile range 11.4 to 
16) for the first 17 sites.  The authors noted that research applications were not 
being reviewed during the period of NHS restructuring and the formation of 
Clinical Commissioning Groups which came into effect in April 2013. 
 
The inconsistencies found across the NHS in gaining research permission, with 
considerable duplication in the application processes and multiple requests for 
information led to the development of a new process to streamline the research 
regulatory pathway, with Health Research Authority (HRA) Approval replacing 
the previous NHS Permissions from 2014 with a full roll out of all NHS studies in 
England from the end of March 2016.  Although single centre studies (where 
the sponsor is also the recruiting site) were initially excluded during the early roll 
out phase, HRA Approval is now required of all trials. 
 
Many of the regulatory issues experienced were out of the research team’s 
control; the study’s timescale coincided with a time of change within research 
governance, and lack of guidance and clear dissemination of information from 
the local research governance team meant that the clinical research team were 
unaware of the changes in the permissions process, further delaying the start of 
the study whilst waiting to obtain HRA Approval. 
 
Staffing issues 
 
Key members of the original co-applicant team withdrew from the study as the 
projected study period was delayed during the regulatory approval processes.  
Both the Chief Investigator (Professor Richard Langford) and lead 
physiotherapist (Professor Paul Watson) retired from clinical practice, a new 
trial co-ordinator was appointed, and other key members including the lead 
psychologist (Professor Amanda Williams) had conflicting interests and 
priorities. 
 
Staffing issues were noted also within the local research governance team; this 
included several changes of trial pharmacist and a change of trial monitor 
immediately prior to gaining NHS permission to recruit.  The turnover rate of 
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research staff caused duplication of work due to inadequate handover.  The 
new trial monitor requested further substantial amendments to the trial protocol 
which delayed the start of study recruitment. 
  
Recruitment challenges 
 
A significant proportion of patients referred by their GP to the pain clinics with 
persistent LBP did not meet the eligibility criteria, for the reasons detailed in 
table 11.  The low recruitment rate led to a request from the funders to appoint 
a trial mentor who was an experienced triallist; the trial mentor led a recruitment 
drive within the last two months of the recruitment phase and the resulting 
increase in numbers of patients screened is illustrated in figure 17.  The 
strategies employed to improve recruitment included minor protocol 
amendments within the constraints of the existing study entry criteria to screen 
and recruit from community pain clinics, physiotherapy-based musculoskeletal 
clinics and spinal orthopaedic clinics, and the appointment of additional 
research assistants to assist with the screening process.  The trial mentor also 
negotiated a no-cost recruitment extension period which was granted by the 
funder. 
 
It may be possible to avoid some of these recruitment challenges by the early 
addition of a recruitment co-ordinator to the core study team, to closely monitor 
the recruitment rate at each site, and to implement a priori contingency plans 
with the sites’ Principal Investigators should the recruitment rate fall below the 
predicted rate.  Some of the strategies successfully implemented by the trial 
mentor for the FACET feasibility study could be used by future researchers to 
improve the recruitment rate. 
 
Recruitment problems have been identified as one of the most difficult 
challenges in conducting a clinical trial; Dal-Ré and colleagues have called for 
greater transparency in the disclosure of recruitment performance of each site 
investigator, which could potentially highlight differences in standards of care at 
each site.163  This group noted that many clinical trials, both publicly-funded and 
industry-sponsored, do not achieve the expected sample size before 
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termination, and are unable to test the proposed hypothesis.  However, 
improved transparency will not necessarily improve recruitment. 
 
The Strategies for Trial Enrolment and Participation Study (STEPS) was a 
three-part study aimed at identifying factors associated with good or poor 
recruitment in multicentre trials.164  Successful trial recruitment was observed 
more commonly in trials with a dedicated trial manager, in cancer or drug trials, 
and in trials with interventions that were exclusive to that particular study.  
McDonald and colleagues (the STEPS group) reviewed 114 trials funded in the 
United Kingdom by the Medical Research Council (MRC) and the Health 
Technology Assessment (HTA) programme between 1994 and 2002, and 
concluded that only 31% of trials achieved their planned recruitment target, and 
45% did not recruit to within 80% of target.  Furthermore, 54% of trials were 
awarded an extension to recruit, most with a supplementary grant.165  Delays 
related to the central trial staff and local research staff were identified.  It was 
found than 17 trials had pre-identified trial centres that did not participate as 
originally planned, for reasons such as funding problems and delays in the 
recruitment of trial staff.  Internal problems for example with trial staff were also 
discussed as a factor contributing towards delays in later recruitment. 
 
A number of strategies to improve recruitment have previously been identified 
by McDonald and colleagues; these include further promotion of the study (such 
as via newsletters or posters), changes to the inclusion criteria and protocol, 
and presentations to appropriate groups.165  Recruitment strategies can 
therefore change as a result of pilot or feasibility phases of a study. 
 
Sundaresen and colleagues described the concept of the ‘apparent recruitment 
fraction’ in their narrative discussion of an oncology trial’s recruitment progress, 
in contrast to the ‘true recruitment fraction’, as shown in box 14.166 
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Box 14.  Apparent versus true recruitment fractions 
Adapted from Sundaresan et al.’s ‘Do screening trial recruitment logs accurately 
reflect the eligibility criteria of a given clinical trial?  Early lessons from the 
RAVES 0803 trial’ (2014)166 
 
 
Apparent recruitment fraction = [number of patients recruited to the study] / 
[number who met the eligibility criteria and attended for assessment at a trial 
site] 
 
True recruitment fraction = [number of patients recruited to the study] / 
[number of patients who satisfied the eligibility criteria, regardless of whether 
the attended an assessment at a trial site or not] 
 
 
They have suggested that differences in the apparent and true recruitment 
fractions (33% versus 18% respectively, in their trial) can be improved through 
close collaboration with the referring clinicians, as screening or recruitment logs 
may not accurately represent the study’s target population; patients with non-
specific LBP or more than three months’ duration may not necessarily be 
referred to the pain clinic from primary care, and are instead being  
managed by their GPs or referred to other specialists.  A number of local GPs 
were identified and had given agreement to be involved and to aid recruitment, 
but were not represented at the trial management group meetings.  This 
feasibility study has demonstrated the need for more primary care involvement 
at all stages of the study, from protocol design and patient screening and 
recruitment, to dissemination of the results. 
 
The trial co-ordinator kept and maintained a recruitment log which recorded 
anonymised details of all the patients who were screened for eligibility to enter 
the study, whether they were randomised or not.  Details of ineligibility or non-
participation were also recorded.  Further analysis of the recruitment logs could 
be used to refine the protocol for future studies, for example by identifying 
certain inclusion or exclusion criteria which could potentially be modified to 
allow more patients to be eligible to enter the study.  The reasons for ineligibility 
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to enter this study are detailed in table 11; these potentially modifiable barriers 
to recruitment, such as increasing or removing the upper age limit, should be 
reviewed prior to consideration of trial progression to a definitive study. 
 
A retrospective audit at each of the three recruiting centres was carried out at 
the start of the feasibility study, to estimate a recruitment rate of eleven 
participants a week; five participants weekly from Barts Health NHS Trust, and 
three participants each from Basildon and Thurrock University Hospitals and 
The Walton Centre in Liverpool.  This target was not met however at the single 
recruiting centre, as shown in appendix 8 which illustrates the actual versus the 
estimated numbers of participants recruited per week. 
 
The feasibility study has shown that the greatest challenges to recruitment can 
largely be attributed to the patient population presenting to the hospital pain and 
spinal orthopaedic clinics, as an increase in the screening rate did not improve 
the rate of participant recruitment.  The experiences of the research team can 
be used to guide future researchers to perhaps look elsewhere other than these 
clinics to recruit suitable participants.  The patient population presenting to the 
pain and spinal orthopaedic clinics at Barts Health NHS Trust will be discussed 
later in this section. 
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Figure 17.  Number of patients screened versus the recruitment rate, by recruitment month
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Clinician and patient participation 
 
Clinician participation in a study may be affected by time constraints, lack of 
staff and training, in addition to competing priorities during the study recruitment 
period, for example from involvement in other trials; these factors were 
identified by Prescott and colleagues in their systematic review paper ‘Factors 
that limit the quality, number and progress of randomised controlled trials’.167  
Many of these factors also applied to the FACET feasibility study, where clinical 
staff recruited and consented participants from pain clinics alongside routine 
NHS work.  The pain consultants involved in the study were all full-time 
clinicians and no additional time was allowed for the study interventions to take 
place, or for the consultant-led follow-up appointments which were often 
overbooked into routine clinical sessions.  Based on the experiences of this 
study, a large-scale definitive trial may require substantial ring-fenced research 
time for any additional trial activity. 
 
Patients attending the pain clinics at St Bartholomew’s Hospital at Barts Health 
NHS Trust, located in Central London, are referred by their GPs via the NHS e-
Referral Service (formerly Choose and Book) from a wide catchment area 
across the United Kingdom.  A future definitive trial may consider remuneration 
of travel costs to increase attendance for study visits.  A process evaluation 
could additionally be employed to look into other reasons that might affect 
compliance to the study protocol, such as work commitments or caring for 
dependents. 
 
Schultz and Grimes have stated that 5% loss to follow-up is probably of little 
concern, whereas 20% or greater loss is likely to introduce a greater risk of bias 
in randomised trials, affecting the validity of the results.168  A future trial may 
wish to compare the baseline characteristics of those participants who dropped 
out with those who completed the study, to identify the true effects of attrition 
within the study.  The authors proposed a number of approaches to maximise 
participant follow-up, listed in box 15 below.  Although the article was published 
in 2002, many of these factors remain relevant today and may need to be 
considered in any preliminary discussions of feasibility trial progression towards 
a definitive trial. 
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Suggested updates to maintain patient participation include the use of text 
message reminders or social media to return for study visits and follow-up 
appointments; however, as many text messaging platforms are not encrypted, 
this can limit what information can be sent to comply with information 
governance regulations.  One Cochrane review on the use of text message 
reminders has shown that there is low to moderate quality evidence to support 
their use, as they can increase attendance at healthcare appointments 
compared to no reminders or postal reminders.169  The Facet Injection Study 
used a text messaging system to collect daily and weekly pain scores with 
some degree of success, although a paper alternative was also recommended 
to improve compliance amongst older participants.98 
 
More patient and public involvement at all stages of the research cycle could 
also help to recruit and retain participants in the study, for example by making 
the study protocol more acceptable and sensitive to those taking part, and by 
ensuring that the patient and public’s interests and concerns remain the focus 
of the trial.  The importance of patient and public involvement will be discussed 
further in this chapter. 
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Box 15.  Proposals to maximise participant follow-up. 
Adapted from Schulz and Grimes’ ‘Sample size slippages in randomised trials: 
exclusions and the lost and wayward’ (2002)168 
 
 
§ Hire a person to manage and encourage follow-up 
§ Hire personnel to call participants or to visit participants at their home 
or place of work, if participants are not returning for follow-up 
§ Exclude before randomisation those likely to be unwilling to return 
§ Exclude before randomisation those likely to move 
§ Obtain contact information to prompt participants to return for follow-
up and to facilitate location of participants if they do not return e.g. via 
mail, telephone, and e-mail for enrolled participants, for close friends 
or relatives who do not live with the participant, and for the 
participant’s family doctor  
§ Obtain an identification number, such as a national healthcare number  
§ Establish follow-up venues suited to participants rather than to 
investigators and trial implementers e.g., more locations than just the 
central clinic or hospital, close to where participants live, convenient to 
access, and sensitive to waiting times  
§ Streamline trial procedures to move participants quickly through 
follow-up visits  
§ Keep data collection instruments short so as to not overburden the 
participant  
§ Provide excellent and free medical care  
§ Provide monetary subsidies, primarily for time and travel costs 
incurred by participants 
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Study population 
 
The limited data shows that the patients screened for inclusion and presenting 
to pain clinics at Barts Health NHS Trust had high levels of disability related to 
their pain condition, often with co-existing psychological distress and low health-
related quality of life.  Approximately 1050 patients are referred to the pain 
clinics at St Bartholomew’s Hospital each year as a new referral,170 although 
many of these ‘new’ patients had already received spinal injections or surgery 
and were therefore ineligible to enter the study, as shown in table 11.  Many of 
the patients referred to the spinal orthopaedic clinics also did not meet the 
study’s entry criteria due to the presence of radicular pain, which could suggest 
pain of lumbar disc origin. 
 
The Tower Hamlets Persistent Pain Services is located at Mile End Hospital 
and serves the population of the London Borough of Tower Hamlets in East 
London.  Tower Hamlets is one of the most deprived boroughs in England with 
low average health deprivation scores, and has a diverse ethnic population with 
many residents born outside the United Kingdom.171  One general practice-
based survey within Tower Hamlets found that the commonest site of pain of 
those surveyed was in the low back, and that chronic widespread pain lasting 
for more than three months was more common and more severe in the 
Bangladeshi population compared to the White population.172 
 
The reasons that no participants from Tower Hamlets were recruited to the 
study warrants further investigation even despite the small sample size; a future 
trial should make all efforts to include an adequate representation of the 
population, to make the results applicable and relevant.  Translation and 
advocacy services are readily available for routine NHS visits, but not for non-
NHS study-related visits.  Previous researchers have shown that language 
barriers may affect an individual’s decision to take part in a research study;173 
this however could be an area for further exploration in a future trial, for 
example by more patient and public involvement with representation from the 
South Asian population, to make the research more accessible to the diverse 
local population. 
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The highest proportion of participants recruited relative to the numbers 
screened was from the community pain clinic at the Essex Lodge GP surgery in 
Plaistow, East London, which is co-located within the GP surgery itself.  Despite 
the very small sample size, it was observed that these patients were referred for 
specialist care earlier in their pain trajectory compared with the other recruiting 
clinics; this relative ease of referral to the pain services indicates that strong 
links and lines of communication between primary and secondary care is 
possible and feasible. 
 
Trial management and mentoring 
 
A trial manager or co-ordinator is essential for the delivery of high-quality trials; 
the NIHR Health Technology Assessment (HTA) programme has recommended 
that a dedicated trial manager is appointed to all clinical trials.  The desirable 
qualities of a trial manager are detailed in the NIHR’s generic job description for 
a clinical trials manager: 
 
‘The post holder will have the leading role in planning, co-ordinating and 
completing the project.  They will have excellent communication and 
presentation skills, together with the ability to organise and motivate others.  
They will demonstrate flair, enthusiasm, innovation and leadership when faced 
with challenges and will provide strategic, tactical and operational management 
skills in the planning and execution of the project.’174 
 
Successful trial delivery requires not only a well-designed trial from a scientific 
perspective, but also a structured, practical and business-like approach to its 
management.  Farrell and colleagues have suggested that trials fail due to poor 
management, and that successful completion of a trial can be dependent on 
active management of every trial aspect.175  Trials with a dedicated trial 
manager have been shown to have a higher chance of achieving the target 
sample size; the STEPS study found that trials with a dedicated trial manager 
had increased chances of successful recruitment (odds ratio 3.80, 98% 
confidence interval 0.79% to 36.14%, p value 0.087).164 
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A number of resources and support processes are available to provide 
guidance to trial managers in the United Kingdom.  The on-line forum UKTMN 
Trial Managers’ Network (http://www.tmn.ac.uk, last accessed 11th November 
2017) seeks membership from trial managers of academic, non-commercial 
trials, to improve the delivery of high quality clinical trials within the United 
Kingdom by promoting best practice.  The Trial Managers’ Network (TMN) 
offers formal courses in clinical trial management, in addition to one day 
workshops.  A professional accreditation scheme is in development. 
 
The reference tool ‘Trial Managers’ Network Guide to Efficient Trial 
Management’ has been produced by a group of volunteer TMN members.176  
The authors’ objective was to produce an inclusive resource of trial 
management framework, providing pragmatic advice to those involved in clinical 
trial management.  Currently in its fifth edition, this guide can be used as an 
induction tool for newly appointed trial staff and as a reference guide for more 
experienced trialists. 
 
Prescott and colleagues have recommended, based on anecdotal evidence, 
that inexperienced trialists should be supported by experienced trialists.167  A 
recent scoping literature review has identified mentorship as a key influence in 
the career progression of early career clinical academics; effective mentors 
were seen to provide moral and institutional support, leading to greater career 
satisfaction and confidence of the mentee.177 
 
Strengths and limitations 
 
Critical appraisal of systematic reviews 
 
A critical appraisal is defined as the process of ‘carefully and systematically 
examining research to judge its trustworthiness, and its value and relevance in 
a particular context.’178  A strength of the critical appraisal of systematic reviews 
was in the methodology and in the composition of the review team; an 
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information specialist (librarian trained in systematic reviews) helped to develop 
the relevant search terms and search strategies, and two independent 
reviewers screened and assessed the retrieved articles.  A third reviewer, 
acting as a tiebreaker, was available in case of disagreements.  The primary 
reviewer had attended relevant training courses on systematic review 
methodology and software.  The PRISMA-P guidelines were used as a basis for 
carrying out the search and presenting the results and discussion,106 and the 
AMSTAR checklist, a validated measurement tool to assess the methodological 
quality of the systematic reviews, was applied independently by each 
assessor.105 
 
It was originally intended to carry out a new systematic review and meta-
analysis of lumbar facet joint injections for the management of LBP.  However, 
a high quality systematic review had been published recently,100 and an 
informal literature search revealed that very few relevant trials had been 
published in the intervening period.  A weakness of the process was the inability 
to combine data from the randomised controlled trials identified from systematic 
reviews, as the studies were heterogeneous to provide any meaningful 
analysis. 
 
The systematic review protocol was not prospectively registered.  It is 
recommended that systematic review protocols with a health-related outcome 
are prospectively published in an international database such as the 
International Prospective Register of Systematic Reviews (PROSPERO); this 
would improve transparency and reduce any reporting bias, and avoid 
duplication of work.179 
 
FACET feasibility study 
 
The FACET feasibility study successfully addressed many of the study 
objectives, as detailed earlier in this chapter.  
 
One strength of the study was the use of the modified Delphi survey to obtain a 
consensus amongst interventional pain specialists in the United Kingdom on the 
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procedural techniques including a sham procedure.  No significant adverse 
events were reported as a result of the diagnostic medial branch blocks, lumbar 
facet joint injections and sham procedure, and the techniques themselves were 
reproducible.  Some accuracy of assessment was demonstrated by the clinical 
team in determining pain of lumbar facet joint origin based on history and 
clinical examination alone, as shown by the positive response to diagnostic 
blocks in nine out of eleven participants (82%, 95% confidence interval 48% to 
98%).  Most the recruited participants were retained for the study’s duration.  
However, the response to diagnostic injections and the attrition rate are 
imprecise due to the low number of participants recruited to the study. 
 
CPP programme delivery was shown to feasible within the constraints of this 
single-centre study; it was delivered according to the protocol and all the study 
physiotherapists at each the three planned recruitment centres were trained to 
deliver the programme.  However, the group sizes were smaller than 
anticipated; a more clinical- and cost-effective delivery could be achieved by 
having between six to ten participants per group, as shown in the BeST trial.  
This group size has been shown to be popular in clinical practice in that it 
allows for group discussion and problem solving.83 
 
Good adherence to the statistical analysis plan has been demonstrated (see 
appendix 2); it was intended at the outset to present the available data by 
group, and not to carry out any formal statistical analyses.  Although the data 
was limited due to small numbers of participants, it was deemed inappropriate 
to pool the data with other studies as no other published randomised controlled 
trials recruited from a comparable patient population with the same entry criteria 
and use of diagnostic block, and the previous trials have been of variable 
scientific quality (see figure 16).  Other trials of lumbar facet joint injections have 
not tested the same hypotheses as different comparators have been used 
(usual care or physiotherapy instead of a sham procedure for example), with 
dissimilar techniques for the lumbar facet joint injections themselves described, 
no standardised sham or control injections, and different outcome measures.  
Pooling any limited data may increase the statistical precision of a definitive 
study by increasing the sample size and power, but only when used judiciously; 
combining heterogeneous studies could lead to flawed and misleading results.  
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In studies with a sham or placebo control, success in blinding can be better 
understood by the differences in correct guesses between the two groups.180  
None of the five participants in the active group correctly guessed their 
allocation, and one out of three participants who completed the study in the 
sham group correctly guessed their allocation.  The blinded outcome assessor 
correctly guessed 4 out of 9 allocation groups (44.4%, 95% confidence interval 
10% to 79%).  This indicates some success in maintaining fidelity of blinding as 
a 50% accuracy is considered successful for a two-arm trial; however, the small 
sample size has resulted in wide confidence intervals which means that caution 
is advised when interpreting these results. 
 
The study’s main weakness was the failure to recruit sufficient participants from 
the pain and spinal orthopaedic clinics, which let to early closure by the funder 
and permission was not granted to open more than one recruiting site.  The 
factors contributing to the slow study set-up, in particular in gaining research 
governance approvals, were largely out of the research team’s control and have 
been detailed earlier in this chapter. 
 
Although a patient representative was an original study co-applicant, another 
weakness of the study was the limited patient and public involvement once 
recruitment had commenced, beyond the initial set-up stage.  The advantages 
of patient and public involvement and suggestions for a future trial are 
discussed in the following sections. 
 
Amendments to the study protocol were made on the request of the newly-
appointed trial monitor; this included the addition of inclusion criterion 6, 
‘Patients are suitable for the facet joint injections’ and the re-wording of 
exclusion criterion 4, ‘‘Red-flag’ signs’ (see boxes 2 and 3).  Although the 
research team approved these changes to gain permission for recruitment to 
commence, the involvement of less experienced research staff at a later stage 
in the approvals process resulted in some potentially unnecessary and 
confusing additions to the inclusion and exclusion criteria. 
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Any results arising from this feasibility study should be interpreted tentatively as 
they may not be representative of a wider population; in addition to the small 
sample size, recruitment took place within secondary care only, from the pain 
clinics at Barts Health NHS Trust in London.  Many of the patients seen in these 
clinics were not suitable, and it is possible that patients who would have met the 
entry criteria had not yet been referred from primary care services.  The 
feasibility has identified several key areas which would benefit from a formal 
qualitative process evaluation; these are discussed in later in this chapter. 
 
Implications for clinical practice and policy 
 
A recent report by The King’s Fund, an independent charity with the aim of 
improving health and care in England, has investigated the financial pressures 
on the NHS (largely attributed to a slowing down in funding growth over recent 
years) and has identified additional independent factors that affect the access 
and quality of patient care.181  These factors affecting healthcare services and 
patient care (in terms of access and quality) can also be applied to the 
commissioning process of lumbar facet joint injections for chronic LBP 
management, and include spending decisions at a national and local level, 
workforce capacity, ongoing service development, patient choice, the use of 
targets and guidelines to regulate and manage performance, the use of new 
technologies, marketing incentives, and patient demand. 
 
Clinical Commissioning Groups (CCGs) were set up in England in 2012 with a 
statutory duty to improve the quality of NHS services, and an aim of obtaining 
the best possible health outcomes at a local level.  The 2013 National Pain 
Audit has already identified stark variations across England in patient care and 
outcomes.10  It can also be seen that variations in CCG funding of facet joint 
injections in secondary care exist, which change with emerging and updated 
guidelines; for example, the Bristol, North Somerset and South Gloucestershire 
CCGs Commissioning Group did not routinely fund facet joint injections 
following the publication of NICE clinical guideline CG88,42, 182 and in line with 
NICE guideline NG59,25 do not routinely fund facet joint injections but will give 
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approval, based on certain criteria, to fund for single diagnostic medial branch 
blocks and radiofrequency denervation.183  Treatments that are not routinely 
funded by the CCGs require an NHS England Individual Funding Request 
which is completed by a clinician on behalf of a patient in ‘exceptional clinical 
circumstances’.184 
 
The 2013 document ‘Pain management services: planning for the future’ was 
produced by the Royal College of Physicians and endorsed by the British Pain 
Society, Chronic Pain Policy Coalition and Faculty of Pain Medicine of the 
Royal College of Anaesthetists; this publication aimed to give support and 
guidance to clinicians, in particular those leading pain management services, to 
appropriately engage with commissioners in order to provide optimal 
services.185  The stakeholders have highlighted pain as a commissioning priority 
and propose that each CCG has a duty to consult experts in the services it 
commissions.  The results of the FACET feasibility study and critical appraisal 
of systematic reviews may therefore be taken forward in any discussion of local 
pain services commissioning, as high quality evidence to support the use of 
lumbar facet joint injections in LBP management remains lacking, and there are 
no published studies of cost-effectiveness.   
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Implications for future research 
 
Critical appraisal of systematic reviews 
 
The heterogeneity demonstrated across the existing randomised controlled 
trials of facet joint injections, in terms of scope and quality, indicate that there is 
no indication at present to carry out an updated or de novo systematic review; a 
future systematic review must however combine new and existing data from 
randomised controlled trials, in order to provide definitive evidence to guide 
clinical practice. 
 
Drawing on the strengths and limitations of previous systematic reviews, the 
composition of any review team should be taken into consideration; any future 
multidisciplinary review group must involve appropriate expertise and 
experience, consisting of experts in interventional pain management in addition 
to experts in systematic review methods, relevant evidence searching and 
quantitative methods.  Patient and public involvement could help to focus the 
research question, improving its clinical relevance.  A team leader, with 
knowledge of protocol implementation, may be required to facilitate the review 
process.186 
 
Heterogeneity within the patient population was frequently cited as a reason for 
inability to carry out data synthesis.  Some reviewers subdivided the studies 
according to the comparator, or therapeutic agent used.  The updated method 
guideline for systematic reviews in the Cochrane Back and Neck Group has 
included mandatory and optional recommendations for review authors based on 
new methodological evidence; a homogenous population is recommended for 
inclusion in a future review, with the type of back or spinal disorder clearly 
described.  This group also advised on the inclusion of comparators with a clear 
contrast for the index intervention, to independently assess the effects.119 
 
Amundsen and colleagues have reported heterogeneity of the entry criteria of 
non-specific LBP randomised controlled trials in their systematic review of trials 
 175 
published between 2006 and 2012.187  This diversity amongst trials was noted 
even between studies of similar populations, and was cited as a contributing 
factor towards the difficulties of carrying out between-trial comparisons.  
Consistent use of their suggested inclusion and exclusion criteria in future trials 
could result in studies of homogeneous populations that would allow for pooling 
of results in meta-analyses. 
 
The research recommendations for the future systematic review are 
summarised in box 16 below. 
 
Box 16.  Research recommendations: the future systematic review 
 
 
§ The review team needs appropriate expertise and experience 
§ Steps must be taken to minimise methodological and reporting bias 
and to improve transparency, by using relevant checklists and method 
guidelines for systematic reviews 
§ The systematic review protocol should be prospectively registered with 
an international database 
§ Future high quality systematic reviews of randomised controlled trials 
intra-articular lumbar facet joint injections are required to objectively 
summarise the evidence for decision makers 
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FACET feasibility study 
 
The two research teams funded by NIHR to answer the research question, ‘Is a 
definitive study to assess the effectiveness and cost-effectiveness of facet joint 
injections compared to best non-invasive care for people with persistent non-
specific low back pain feasible?’ were led by Professor Martin Underwood, 
University of Warwick,97 and Professor Richard Langford, Barts Health NHS 
Trust.96  The two trial protocols are compared in table 18 below.
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Table 18.  Comparison of the FACET feasibility study and Facet Feasibility study protocols 
 
 FACET feasibility study (Langford team)99  Facet Feasibility study (Underwood team)122  
Primary 
objective 
 
To assess the feasibility of conducting a definitive trial 
to evaluate the clinical- and cost-effectiveness of 
lumbar facet joint injections compared to a sham 
procedure, in patients with non-specific LBP of more 
than 3 months’ duration 
 
To explore the feasibility of running a randomised 
controlled trial to test the clinical and cost-
effectiveness of intra-articular lumbar facet joint 
injections in addition to best usual non-invasive 
care 
Trial design 
 
Multicentre (3 sites) 
Double-blind randomised controlled trial 
2 arms – intervention (facet joint injections + best 
usual care) versus control (sham + best usual care) 
 
Multicentre (up to 6 sites) 
Non-blinded randomised controlled trial 
2 arms –  intervention (facet joint injections + best 
usual care) versus control (best usual care only) 
Inclusion 
criteria 
 
LBP of three months’ or greater duration 
At least 2 components of NICE-recommended best 
non-invasive care completed, including education and 
one of a physical exercise programme, acupuncture, 
or manual therapy 
 
LBP for at least six months 
Has had registered health-professional delivered 
treatment for LBP in the past 2 years 
No radicular symptoms 
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 FACET feasibility study (Langford team)99  Facet Feasibility study (Underwood team)122  
Exclusion 
criteria 
Previous spinal injections or spinal surgery 
Other dominant pain, or widespread pain 
Radicular pain 
Previous spinal injections or spinal surgery 
Corticosteroid usage in the preceding 3 months 
 
 
Estimated 
sample size 
 
60 participants 
 
150 participants 
 
Recruitment 
period 
 
6 months 
 
6 months 
Diagnostic 
criteria 
 
Diagnostic lumbar facet medial branch nerve 
injections with lidocaine – a positive response is a 
50% or greater pain reduction lasting for over 30 
minutes 
 
Physiotherapist assessment (based on agreed 
criteria following a consensus conference)64 
Outcome 
measures 
 
6 weeks, 3 months and 6 months post randomisation 
Pain intensity and characteristics, use of co-
analgesics, early withdrawal from study, expectation 
of benefit, health-related quality of life, functional 
impairment, satisfaction with treatment, complications 
 
3, 6 and 12 months post randomisation 
Medications, satisfaction with health state, 
troublesomeness questionnaire, back pain-related 
disability, back pain severity, psychological 
distress, pain self-efficacy, health-related quality of 
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 FACET feasibility study (Langford team)99  Facet Feasibility study (Underwood team)122  
and adverse events, co-psychological well-being, 
healthcare utilisation and costs 
life, health utilities, well-being, current work status, 
health and social service resource use 
Follow-up 
period 
 
6 months post randomisation 
 
12 months post randomisation 
Usual care 
components 
 
CPP programme delivered by study physiotherapists 
using the Back Skills Training Programme 
Initial 1-hour one-to-one session after the intervention, 
followed by between 4 and 6 90 minute sessions with 
2 study physiotherapists in small groups 
 
 
Bespoke package of physical and behavioural 
rehabilitation tailored to individual patients 
Initial 1-hour session prior to intervention, followed 
by 5 30 minute one-to-one sessions with a study 
physiotherapist 
Intervention 
group 
 
4 lumbar facet joints injected at 2 bilateral lumbar 
levels 
0.5 ml 0.5% bupivacaine + 20 mg methylprednisolone 
(1 ml total volume) per joint 
 
Up to six lumbar facet joints injected 
1 ml 0.5% bupivacaine + 1 ml triamcinolone 10 mg 
(2 ml total volume) per joint 
Comparator 
 
Sham procedure – 4 peri-articular injections at 2 
bilateral lumbar levels 
0.5 ml normal saline per site 
 
‘Best usual care package’ 
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The target recruitment rate was not met by either of the two research teams 
funded by the NIHR HTA programme to investigate the feasibility of carrying out 
a definitive study assessing the use of lumbar facet joint injections for persistent 
non-specific LBP, with both groups experiencing significant delays in study set-
up; Professor Underwood’s team recruited 26 participants (the study aimed to 
recruit approximately 150 participants) and the FACET feasibility study 
randomised 9 participants (60 participants were expected to be randomised).  
Professor Underwood’s team has concluded that a definitive study to explore 
the addition of facet joint injections to usual care is indeed feasible, but that 
recruitment from the pain clinics alone was insufficient.98  The FACET feasibility 
study has concluded that a definitive study comparing facet joint injections to a 
sham procedure is potentially feasible, with adjustments in the target population 
and increased primary care involvement, to screen patients earlier in their pain 
trajectory.99  Some considerations for future research are detailed below. 
 
Future trial designs 
 
An evaluation of the two failed feasibility studies calls for an assessment of the 
study designs themselves.  A trial comparing usual care only to the addition of 
facet joint injections, the trial design used in Professor Underwood’s study,100 
could allow for a more pragmatic evaluation, by providing evidence of improved 
effectiveness of an intervention over best existing practice that already been 
endorsed by national guidelines.  The comparison of an active intra-articular 
injection with a sham procedure in a double-blinded randomised controlled trial 
design, as utilised by Professor Langford’s team,99 may be considered more 
scientifically rigorous,188 with the advantage that established best usual care 
could also be provided to both groups.  The authors of the superseded 
Cochrane review of injection therapy for chronic LBP management proposed 
that placebo-controlled trials of spinal injections should be a priority over trials 
that compared injections to other treatments, and that future randomised 
controlled trials must be methodologically sound with more focus on long-term 
treatment effects (Nelemans).111  However, large sample sizes may be 
necessary to detect any effect size due to variations between and within the 
groups. 
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In 2003, Horng and Miller published an ethical framework on the use of sham 
procedures in clinical trials; the authors stated that the use of a sham control is 
often methodologically necessary to show that any outcome changes can be 
attributed to the active procedure itself and not due to its mode of administration 
or a placebo response due to study participant’s expectations and 
psychosomatic effects.189  The risks of the sham procedure itself must however 
be taken into consideration, and need to be justified in any well-conducted 
study. 
 
A published systematic review of LBP trials has shown that placebo-controlled 
trials can give biased results; the use of placebos that are potentially not inert, 
and a failure to achieve acceptable blinding were a common finding in these 
trials where an imperfect placebo was used.180  The use of a two-arm trial may 
not control for any improvement in LBP due to its natural history i.e. any 
improvement seen in both groups could be unrelated to the treatment 
allocation. 
 
A future trial could consider the use of a three-arm trial design, simultaneously 
comparing lumbar facet joint injections, a sham procedure, and usual care (no 
injections).  Such a trial would allow the following research questions to be 
addressed: whether facet joint injections are superior to a sham procedure, and 
whether facet joint injections are superior to usual care.  A three-arm trial could 
also for the first time in a trial of facet joint injections compare a sham treatment 
against usual care in a homogeneous population. 
 
The findings of such a study could be more scientifically relevant and 
statistically robust as it would demonstrate any associations between the 
groups with a greater degree of reliability than a two-arm trial.  Any independent 
effects from the different allocation groups could potentially be evaluated, and 
any outcome changes due to the natural history and progression of LBP and 
other incidental factors are controlled for.  Selection from a homogeneous 
patient population by utilising standardised inclusion and exclusion criteria, as 
suggested by Amundsen and colleagues, would also allow for further 
comparisons with other future trials utilising the same guidelines for trial 
entry.187 
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Another future research direction could be the evaluation of lumbar facet joint 
medial branch radiofrequency denervation procedures, as the current evidence 
for their use has similarly been muddled by flawed study design and the 
inclusion of a heterogeneous patient population in trials and meta-analyses of 
radiofrequency denervation.  The use of diagnostic injections to more 
accurately diagnose pain of lumbar facet joint origin is another area for future 
researchers to consider as there remains no clear consensus on what medicinal 
product to inject, how many blocks are required, and what a positive response 
should be.  However, despite these controversies, the latest NICE guidance 
recommends consideration for assessment for radiofrequency denervation 
those with a positive response to a diagnostic medial branch block; the referral 
criteria are detailed further in table 1.25 
 
Use of a consensus approach 
 
Both the Langford and Underwood teams utilised a consensus approach to 
decide on the technique for lumbar facet joint injections.  Professor Langford’s 
group carried out a web-based survey of approximately 250 interventional pain 
specialists in the United Kingdom, of whom 42 took part.  The questions and 
answer choices were pre-determined in an early trial management group 
meeting (see appendix 4), and the final decisions were made by the trial 
management group members.  Professor Underwood’s team published a 
transparent and inclusive approach by inviting professionals and lay people with 
an interest in LBP management to attend a one-day conference, which took the 
form of a nominal group technique where fourteen different aspects of injection 
technique were discussed.64  Fifty-two people attended on the day, of whom 
nineteen with pain consultants and physicians.  The uncertainty about the 
injectate was later resolved by email (eleven responses). 
 
Future reviewers may wish to consider a true Delphi method to gain consensus 
on the injection techniques, where questionnaires are answered anonymously 
by expert panellists then fed back to the researchers.  This technique may have 
advantages in this area with limited research and lack of clarity, by involving 
national and international experts in LBP management as panellists for a more 
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accurate representation of ‘expert consensus’.  The process also means that 
the views of stronger panellists do not necessarily dominate the process.  
Based on the experiences of Professor Underwood’s team, experts in finalising 
the consensus will be required.64 
 
Patient and public involvement 
 
The involvement of patients and members of the public can improve the quality 
and relevance of clinical research, by providing personal knowledge and 
experience of the medical condition under investigation, and a different 
viewpoint.190  The INVOLVE programme is a national advisory group set up in 
1996 to support greater public involvement in the NHS, public health and social 
care research in England; the group defines public (this term includes patients, 
potential patients, carers, healthcare users and relevant representing 
organisations) involvement as research carried out ‘with’ or ‘by’ members of the 
public, as opposed to ‘to’, ‘about’ or ‘for’ them.191  Patient and public 
involvement is increasingly a requirement to receive funding and is considered 
best practice; the INVOLVE programme has recommended a number of ways 
that the public can be involved in the research process, from identifying and 
prioritising the research topic to commissioning the study, involvement in the 
design and running of the trial itself, undertaking the research (for example in 
highlighting the findings that are most relevant to the public), dissemination of 
results, implementing the research, and evaluating its impact. 
 
A future definitive trial must therefore consider stronger patient and public 
involvement at all stages of the research cycle.  This could include the early 
appointment of a study co-applicant as a lead for public involvement and 
recruiting members of the public to help identify research priorities and as 
members of the trial steering committee; these members could be identified via 
the hospital pain clinics or GP practices, and through organisations such as the 
British Pain Society’s Patient Liaison Committee, and Back Care (the National 
Back Pain Association).  Members of the public could also be asked to 
comment on questionnaire design and on the participant information sheets, to 
make the research as appropriate and accessible as possible.  Members of the 
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public could also be consulted on how best to report and disseminate the 
research findings. 
 
Recruitment sites and primary care collaboration 
 
The choice of recruitment site was dictated by the funders, who requested in 
the commissioning brief that recruitment should take place in ‘secondary care 
centres, e.g. pain or orthopaedic, possibly also primary care’.96  Both feasibility 
studies have shown that in the current climate in the United Kingdom, it is not 
possible to recruit sufficient patients meeting the eligibility criteria from such 
secondary care clinics. 
 
An evaluation of the recruitment methods and recruiting sites of other trials may 
be required; for example, the thirteen randomised controlled trials of lumbar 
facet joint injections identified from the systematic review papers in chapter 2 
recruited a median of 80 participants per study (this ranged from 18 to 120).  
One recently published study of radiofrequency denervation published in the 
Netherlands recruited 251 patients to the facet joint arm; the relatively large 
number of participants recruited could be attributed the suspension of all regular 
national reimbursement programmes due to the absence of rigorous scientific 
evidence, meaning that only those who took part in the study would receive 
these interventional pain procedures.77  Furthermore, only those who had a 
positive response to a diagnostic block would be reimbursed.  This may have 
contributed towards a selection bias and a relatively high positive responder 
rate to the diagnostic block.80  The FACTS study was a multicentre 
comparative-effectiveness study in the United States comparing facet joint 
injections with medial branch blocks and a placebo injection, recruiting 229 
participants between March 2014 and August 2017.192  Both studies had 
relatively lax entry criteria which could have produced smaller effect sizes; their 
results may therefore not apply to real-world conditions or an NHS setting. 
 
The current guidance in the United Kingdom does not recommend lumbar facet 
joint injections for chronic LBP management;25 patients with persistent LBP who 
have not responded to conservative treatment may therefore only be offered 
these injections as part of a research study.  A future study should consider 
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recruitment from GP practices and musculoskeletal physiotherapy services 
alongside hospital pain clinics; a definitive study should therefore build in a pilot 
phase to estimate the screening to recruitment ratio from this patient population, 
with pre-defined criteria for study progression i.e. an acceptable screening to 
recruitment ratio.  Other feasibility outcomes, including an estimation of the 
outcome standard deviations to inform a power calculation, and an accurate 
assessment of blinding, could also be answered by this pilot study. 
 
Future researchers must engage with GP practices and commissioners for any 
future collaborative work, for example working alongside the Trauma 
Programme of Care Board Pathfinder Project (where spinal injections are not 
recommended)41; potential participants, for example those with high levels of 
disability, may benefit from such interventions and rehabilitation at an early 
stage and could be identified and considered for inclusion in a trial without 
having to be first referred to a pain or spinal orthopaedic clinic.  Some feasibility 
of this process has already been demonstrated by the Facet Injection Study, 
referrals were later being taken directly from physiotherapy departments and 
from primary care in order to improvement the recruitment rate.98  A parallel 
process evaluation (see below) would be essential to recognise any contextual 
factors that might affect the implementation and outcomes of patients recruited 
from primary care, compared to those recruited from hospital clinics. 
 
Process evaluation 
 
The Medical Research Council (MRC) produced guidance on the evaluation of 
complex interventions in 2000, which was updated in 2008 and has called for a 
researchers to provide a more definitive evaluation of processes as well as 
outcomes in their studies.193, 194  Although a process evaluation was not 
proposed as part of this feasibility study, it is hoped that the preparatory work 
may pave the way for a future definitive study which would incorporate a 
parallel process evaluation alongside an evaluation of outcomes.  Moore and 
colleagues, on behalf of the MRC Population Health Science Research 
Network, defined a process evaluation as: 
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‘A study which aims to understand the functioning of an intervention, by 
examining implementation, mechanism of impact, and contextual factors.  
Process evaluation is complementary to, but not a substitute for, high quality 
outcomes evaluation.’195 
 
The guidance, which draws on evidence from literature reviews, consultation 
with stakeholders and case studies, offers a number of key recommendations in 
the planning, design, analysis and conduct of a process evaluation.  These 
recommendations could be included in a definitive trial proposal by utilising a 
mixed-methods approach incorporating both quantitative (including structured 
observations and self-report questionnaires) and qualitative (one-to-one 
interviews and groups interviews or focus groups) methods.  It is increasingly 
being recognised that trial success is dependent on the context and 
environment, as well as the intervention being tested; a process evaluation 
could further allow researchers and analysts to explore the definitive trial’s 
fidelity of implementation and adherence to the study protocol, and to identify 
any possible predictors or mediators of change. 
 
Professor Underwood’s team did carry out a formal process evaluation of 
patient experience within their trial; although the data may not have been fully 
representative due to low patient numbers, the researchers were able to 
describe in detail the reasons for slow recruitment, and insight was gained into 
some aspects of study implementation. 
 
One area for further exploration highlighted by the FACET feasibility study was 
the long duration of pain awareness amongst all the study participants (mean 
6.8 years, see table 14), which could indicate the time taken to be referred from 
primary care to specialist centres.  The feasibility study also showed 34 out of 
fifty eligible patients declined to take part, and five of the remaining sixteen 
dropped out after giving consent (figure 11).  Incorporating a parallel process 
evaluation into the study protocol, with regulatory approvals in place to contact 
patients once they have left the study, could explore these reasons for study 
drop out in more details.  A process evaluation could also be used to improve 
the quality of outcome data by exploring the reasons into why some 
questionnaire datasets were incomplete or spoiled, and whether the use of 
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injection therapy might improve compliance with a CPP programme.  
Furthermore, this process could explore with more formality the acceptability of 
the two treatment arms (active facet joint injection with steroid, versus a sham 
procedure) to both study participants and research clinicians, using structured 
questionnaires. 
 
The MRC has stated that the guidance for complex intervention evaluation will 
be jointly updated with NIHR in 2019, due to significant developments in the 
field. 
 
Research recommendations 
 
The research recommendations for a future definitive study are summarised in 
box 17. 
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Box 17.  Research recommendations: the future definitive study 
 
 
§ A definitive trial is feasible with adjustments to the target population 
§ A definitive trial needs to draw on lessons learned from both teams 
and involve future collaborations between the research groups 
§ One proposed trial design is a three-arm trial comparing facet joint 
injections, a sham procedure and usual care 
§ An internal pilot phase, with pre-defined criteria for progression, could 
assess whether patients in primary care are more suitable for trial 
inclusion than those referred for specialist care 
§ Future researchers should utilise standardised inclusion and exclusion 
criteria to reduce heterogeneity in the study population 
§ A parallel process evaluation should be incorporated into the protocol 
and consent for follow-up from all participants should be obtained at 
trial entry 
§ Future definitive trials of intra-articular injections and radiofrequency 
denervation in the management of chronic low back pain are required 
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Chapter 6: Conclusions 
 
The existing evidence to support the use of facet joint injections is equivocal 
and the published research findings are controversial, with methodological 
variability detected across the studies and reviews.  Fundamentally flawed 
research has caused confusion and disappointment to researchers, 
commissioners and patients themselves.  As it is not possible to summarise the 
evidence, which currently consists of both good and poor quality research, there 
remains a future need for high quality randomised controlled trials in a 
homogeneous population, incorporating the latest trial methods which would 
lead towards a new systematic review with meta-analyses.  Any emerging 
research therefore has the potential to change the recommendations for the 
management of persistent non-specific LBP at a national and international level. 
 
Despite the equivocal evidence to support their use, both intra-articular facet 
joint injections and radiofrequency denervation of their medial branch nerves 
are currently being offered to selected patients with persistent non-specific LBP 
in the United Kingdom at the time of writing.  However, some Clinical 
Commissioning Groups (CCGs), who are decision makers responsible in 
England for the planning and commissioning of local healthcare services, have 
classified lumbar facet joint injections as a ‘procedure of limited clinical value’; 
lumbar facet joint injections are therefore no longer being routinely funded by 
certain CCGs due to financial constraints on the NHS.  It is very possible that 
their future use may be restricted to research studies only. 
 
CCGs are currently routinely funding for radiofrequency denervation, on the 
recommendation on the 2016 NICE guidelines, to those patients with persistent 
LBP who have had a positive response to a single diagnostic block and who 
have not responded to more conservative management.25  However, some of 
the published trials of radiofrequency denervation including those used in 
guideline development have been criticised for poor methodology, for example 
their inclusion of a heterogeneous population; there additionally remains no 
consensus on the definition of a ‘positive diagnostic block’, and no high quality 
evidence for their long-term clinical- and cost-effectiveness. 
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The FACET feasibility study met many of the intended feasibility objectives but 
failed to achieve the target recruitment rate.  Lessons have been learnt here, 
which can be used to guide future definitive studies of facet joint injections and 
radiofrequency denervation.  Based on the experiences of both feasibility 
studies, one proposed trial design which could more accurately reflect best 
usual practice is a three-arm pragmatic comparative effectiveness trial 
comparing facet joint injections with a sham procedure and usual care.  The 
successful elements of both teams should be built upon in a future collaboration 
combining national and international expertise, for example incorporating the 
recruitment enhancement strategies and consensus methodology.  Embedding 
an internal pilot phase into a definitive trial could aid in optimising the 
recruitment sites by investigating whether suitable participants can be screened 
earlier in their pain trajectories from GP surgeries and primary care-based 
musculoskeletal physiotherapy services.  The addition of a parallel process 
evaluation could provide invaluable information on whether certain aspects of 
the research cycle can be improved, and by exploring any barriers in the 
referral pathway from primary to secondary care.  
 
The FACET feasibility study did not set out to answer the research question, 
‘Are lumbar facet joint injections with steroid superior to a sham procedure in 
the management of persistent non-specific low back pain?’, but instead aimed 
to explore the feasibility of carrying out a definitive study within an NHS setting.  
Lumbar facet joint injections for the management of chronic LBP may indeed be 
proven to be financially and clinically justifiable in selected patients, by adding 
value and improving quality of life, but the evidence remains lacking.  The thesis 
has however identified key areas in chronic LBP management that require 
further exploration; future research must however focus not only on high quality 
clinical trials, but also on methodologically robust systematic reviews and meta-
analyses which have the potential to inform clinical practice and alter current 
healthcare policies. 
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Appendix 1.  Search strategies for the literature search 
of systematic reviews and meta-analyses of 
randomised controlled trials of intra-articular lumbar 
facet joint injections for chronic low back pain 
management 
Reproduced from Snidvongs et al.’s ‘Facet-joint injections for non-specific low 
back pain: a feasibility RCT’ (2017)99 
 
 
 
 
Medline (date range searched: 1966 to 6th February 2017) 
 
# Database Search term Results 
1 Medline exp *LOW BACK PAIN/ 13733 
2 Medline ("low back pain").ti,ab 21120 
3 Medline exp *ZYGAPOPHYSEAL 
JOINT/ 
961 
4 Medline ("facet joint").ti,ab 2227 
5 Medline exp *CHRONIC PAIN/ OR exp 
*PAIN/ 
218391 
6 Medline (lumbar OR paravertebral).ti,ab 91494 
7 Medline exp *LUMBAR VERTEBRAE/ 26956 
8 Medline 1 OR 2 24954 
9 Medline 3 OR 4 2683 
10 Medline 6 OR 7 98948 
11 Medline 5 AND 10 9560 
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12 Medline 8 OR 9 OR 10 OR 11 117090 
13 Medline exp *INJECTIONS, INTRA-
ARTICULAR/ 
809 
14 Medline ("intra articular*").ti,ab 12196 
15 Medline (facet ADJ2 injection).ti,ab 143 
16 Medline (facet ADJ2 joint).ti,ab 2299 
17 Medline exp *FLUOROSCOPY/ 5060 
18 Medline (fluoroscop*).ti,ab 21046 
19 Medline exp *THERAPEUTICS/ 2895415 
20 Medline (therap*).ti,ab 2169176 
21 Medline ("percutaneous spinal").ti,ab 94 
22 Medline 13 OR 14 12630 
23 Medline 15 AND 16 120 
24 Medline 17 OR 18 23098 
25 Medline 19 OR 20 4590592 
26 Medline exp *INJECTIONS/ 20026 
27 Medline (injection*).ti,ab 496795 
28 Medline 26 OR 27 505646 
29 Medline 21 AND 28 7 
30 Medline 22 OR 23 OR 24 OR 25 OR 29 4610334 
31 Medline 12 AND 30 49755 
32 Medline ("systematic review*").ti,ab 94141 
33 Medline 31 AND 32 1138 
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34 Medline ("meta analysis").ti,ab 88442 
35 Medline 31 AND 34 521 
36 Medline ("control* trial*" OR RCT).ti,ab 13597 
37 Medline 31 AND 36 179 
38 Medline 33 OR 35 OR 37 1504 
39 Medline (facet).ti,ab 10869 
40 Medline 32 AND 39 123 
 
Embase (date range searched: 1966 to 6th February 2017) 
 
# Database Search term Results 
1 EMBASE exp *LOW BACK PAIN/ 23697 
2 EMBASE ("low back pain").ti,ab 28245 
3 EMBASE exp *ZYGAPOPHYSEAL 
JOINT/ 
509 
4 EMBASE ("facet joint").ti,ab 2999 
5 EMBASE exp *CHRONIC PAIN/ OR exp 
*PAIN/ 
386200 
6 EMBASE (lumbar OR paravertebral).ti,ab 123427 
7 EMBASE exp *LUMBAR VERTEBRAE/ 7855 
8 EMBASE 1 OR 2 35444 
9 EMBASE 3 OR 4 3251 
10 EMBASE 6 OR 7 125759 
11 EMBASE 5 AND 10 16010 
12 EMBASE 8 OR 9 OR 10 OR 11 151862 
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13 EMBASE exp *INJECTIONS, INTRA-
ARTICULAR/ 
1884 
14 EMBASE ("intra articular*").ti,ab 15071 
15 EMBASE (facet ADJ2 injection).ti,ab 193 
16 EMBASE (facet ADJ2 joint).ti,ab 3056 
17 EMBASE exp *FLUOROSCOPY/ 6811 
18 EMBASE (fluoroscop*).ti,ab 34353 
19 EMBASE exp *THERAPEUTICS/ 3002010 
20 EMBASE (therap*).ti,ab 3111511 
21 EMBASE ("percutaneous spinal").ti,ab 138 
22 EMBASE 13 OR 14 16232 
23 EMBASE 15 AND 16 165 
24 EMBASE 17 OR 18 35845 
25 EMBASE 19 OR 20 5235530 
26 EMBASE exp *INJECTIONS/ 33580 
27 EMBASE (injection*).ti,ab 635413 
28 EMBASE 26 OR 27 639110 
29 EMBASE 21 AND 28 11 
30 EMBASE 22 OR 23 OR 24 OR 25 OR 29 5270243 
31 EMBASE 12 AND 30 38627 
32 EMBASE ("systematic review*").ti,ab 118882 
33 EMBASE 31 AND 32 867 
34 EMBASE ("meta analysis").ti,ab 117968 
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35 EMBASE 31 AND 34 428 
36 EMBASE ("control* trial*" OR RCT).ti,ab 231428 
37 EMBASE 31 AND 36 2362 
38 EMBASE 33 OR 35 OR 37 2906 
39 EMBASE (facet).ti,ab 12624 
40 EMBASE 32 AND 39 149 
 
Cochrane Central Register of Controlled Trials (date range searched: 1966 to 
6th February 2017) 
 
ID Search  
#1 MeSH descriptor: [Back Pain] explode all trees 
#2 back near pain  
#3 dorsalgia  
#4 back disorder*  
#5 backache  
#6 MeSH descriptor: [Low Back Pain] explode all trees 
#7 (lumbar next pain)  
#8 (#1 or #2 or #3 or #4 or #5 or #6 or #7)  
#9 MeSH descriptor: [Zygapophyseal Joint] explode all trees 
#10 facet near joints  
#11 zygapophysial*  
#12 (#9 or #10 or #11)  
#13 (#8 and #12)
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A multicentre double-blind randomised controlled trial to assess the clinical- 
and cost-effectiveness of facet-joint injections in selected patients with non-
specific low back pain: a feasibility study.  
 
Statistical Analysis Plan (SAP) 
 
Trial short title Facet-joint feasibility study  
Trial registration number ISRCTN12191542 
Trial chief investigator Dr Vivek Mehta 
Trial manager Ms. Alia Ahmad 
Trial statistician Prof Rod Taylor 
SAP author Prof Rod Taylor 
CTU involvement (name of CTU and 
role, e.g. data management, 
randomisation) 
PenCTU (data management, 
randomisation) 
 
 
Date of SAP SAP version 
number 
Date 
presented to 
Trial 
management 
group/Trial 
steering 
committee 
Significant 
amendments 
since previous 
version 
Date approved 
14th June 2016 1.1    
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1. Abbreviations and definitions 
Abbreviation Full terminology/definition 
  
  
  
  
 
2. Statistical guidelines 
Analyses are to be conducted in accordance with International Conference on 
Harmonisation (ICH) statistical guidelines for clinical trials and Consolidated 
Standards for Reporting Trials (CONSORT) reporting checklist for trials [1,2].  
 
3. Trial background 
Pain of lumbar facet-joint origin is a common cause of low back pain in adults [3], 
and may lead to chronic pain and disability, with associated health and 
socioeconomic implications.  At present there is no definitive research to support the 
use of targeted lumbar facet-joint injections (FJIs) to manage this pain.  Due to the 
lack of high quality, robust clinical evidence the National Institute for Health and Care 
Excellence (NICE) clinical guidelines published in 2009 did not recommend 
injections of therapeutic substances into the back for non-specific low back pain [3], 
despite their potential to reduce pain intensity and rehabilitation.  As a result, NICE 
called for further research to be undertaken to clarify the clinical effectiveness and 
cost-effectiveness of interventional pain procedures for the treatment of low back 
pain.  
Before undertaking a definitive trial to assess clinical effectiveness and cost 
effectiveness of FJIs compared to sham (placebo) procedure for non-specific low 
back pain, there are a number of questions that first need to be within this a 
feasibility study. The facet-joint feasibility study (reference number HTA - 11/31/02) 
is an NIHR HTA programme funded project.  
This statistical analysis plan (SAP) relates to the Study Protocol Version 6, 25th April 
2016. 
 
4. Trial information 
4.1 Interventions 
Facet-joint injection (FJIs) (intervention) or sham injection (control).  
4.2 Phase of trial 
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Single feasibility stage.  
The definitive trial will be deemed feasible if: successful standardisation of the 
method of injection and the test-run of the sham procedure, study design is deemed 
acceptable by patients and clinicians, and able to recruit and retain sufficient 
patients. 
4.3 Randomisation level 
Patients will be randomised on 1:1 ratio to intervention and control groups using 
minimisation to ensure between group balance by centre and baseline pain scores.   
4.4 Study design 
Two-arm parallel randomised controlled trial. Administration of injections will be 
carried out by the operator (the site’s Principal Investigator) who cannot be blinded. 
Patients and all other members of the research visits, including research nurse 
performing outcome assessments, will be blinded. Randomisation will take place 
following provision of informed consent and provision of baseline data. Follow-up 
data collection will take place at 6 weeks, and 3 and 6 months post-randomisation.  
4.5 Purpose of the analyses 
As this is a feasibility study, it is not proposed to formally inferentially test differences 
in outcomes or costs between or within the groups.  The purposes of the statistical 
analyses are as follows: 
1. to report recruitment rates (and 95% confidence intervals) 
2. to provide descriptive summarises of baseline and follow up data for all 
outcomes; 
3. to report attrition rates (and 95% confidence intervals) at all follow-up time 
points; 
4. to report individual data missingness at all follow-up timepoints; 
5. to provide descriptive data on adverse events. 
4.6 Sample size calculation 
A total of 60 patients will be recruited (equally allocated to either intervention and 
control groups).  Assuming a 20% attrition rate, we expect 24 full data sets per arm 
will be completed at the end of the study. This sample size will allow us to achieve 
our various feasibility objectives.  For example, 60 patients gives the ability to 
estimate the precision of our assumed attrition rate with error of error of ±5% at 95% 
confidence level and 24 patients per arm is acceptable for a reasonable estimate of 
variance of outcomes [4].  
4.7 Study populations 
Full inclusion/exclusion criteria are set out in the protocol.  
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5. Study objectives and endpoints 
5.1 Aims and objectives 
The study aim is to assess the feasibility of conducting a definitive trial to evaluate 
the clinical- and cost-effectiveness of facet-joint injections compared to a sham 
procedure, in patients with non-specific low back pain of more than three months’ 
duration. 
Specific objectives are: 
1. To assess the eligibility criteria, recruitment and retention of patients in the 
two treatment arms (FJI versus sham procedure) by 
a. Assessing the feasibility of recruitment in the three centres, with regards to 
a potential definitive trial. 
b. Reviewing the number of completed patient data sets. 
c. Auditing the quality of data entry at the centres. 
d. Assessing and analysing any protocol violations (such as failure to deliver 
the combined physical and psychological programme), side effects and 
other adverse outcomes. 
2.  To assess the feasibility and acceptability of the two treatment arms from the 
point of view of patients and their pain teams. 
3. To assess the feasibility of the proposed definitive trial design including: 
4. Testing of randomisation and blinding procedures. 
5. Development of an appropriate active and sham procedure for FJIs. 
6. Assessment of the consistency of the trial sites to deliver the combined 
physical and psychological programme. 
7. Ability to collect the outcomes proposed for the main trial (pain, functioning, 
health-related quality of life, anxiety and depression, health care resource 
utilisation, complications, and adverse events). 
8. To estimate outcome standard deviation to inform the power calculation for a 
definitive trial. 
9. To finalise the protocol design, statistical plan, number of centres required 
and study duration of the definitive trial. 
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5.2 Endpoints 
Endpoints, with their source and time points collected, are set out in Table 3.  
Table 3. Outcomes 
Endpoint Scoring Source Timepoints collected 
Brief Pain Inventory 
[BPI] (Short Form) 
Continuous 2 domains  
• BPI severity  
• BPI interference 
Each 0-10 
Baseline, 6 weeks, 3 months, 6 
months	
Short-form McGill 
Pain Questionnaire 
(SF-MPQ-2) 
Continuous	 3 pain domains 
• Sensory 
• Affective 
• Total 
Each 0-10 
	
Baseline, 6 weeks, 3 months, 6 
months	
EQ-5D-5L Continuous	 Single total utility score (-
0.594 to 1.000)	
Baseline, 6 weeks, 3 months, 6 
months	
12-item Short Form 
Health Survey (SF-
12) 
Continuous	 2 domains 
• Physical 
component score 
(PCS) 
• Mental component 
score (MCS) 
Both 0-100 
Baseline, 6 weeks, 3 months, 6 
months	
Oswestry Low Back 
Pain Disability 
Questionnaire 
Continuous	 8 items 
• pain intensity 
• personal care 
• walking/running 
sitting, standing 
sleeping 
• traveling 
Each scored 8-48 
Baseline, 6 weeks, 3 months, 6 
months	
Pain Self Efficacy 
Questionnaire 
(PSEQ) 
Continuous	 Single score 
Score 0-60	
Baseline, 6 weeks, 3 months, 6 
months	
Hospital Anxiety 
and Depression 
Score (HADS) 
Continuous	 2 domains 
• HADS anxiety 
• HADS depression 
Both scored 0-21	
Baseline, 6 weeks, 3 months, 6 
months	
Pain 
Catastrophizing 
Scale (PCS) 
Continuous	 • Total (0-52) & 3 
subscales 
rumination (0-16) 
• magnification (0-
12) 
• helplessness (0-24)	
Baseline, 6 weeks, 3 months, 6 
months	
Stanford 
Presenteeism Scale 
Continuous	 Single scale 
Score 6-30	
Baseline, 6 weeks, 3 months, 6 
months	
Satisfaction with 
treatment scale 
??? ???	 6 weeks, 3 months, 6 months	
Expectation of 
benefit scale 
??? ???	 Baseline	
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5.3 Derived variables 
No analyses of derived variables are planned. 
 
6. General analysis considerations 
6.1 Timing of analyses 
All analyses will be performed following collection of data at 6  months , and 
finalisation and tidying of the database. No interim analyses are planned. 
6.2 Types of analyses 
The descriptive analysis of primary and outcomes at baseline and follow up will 
based on the intention to treat analysis, i.e. according to initial random allocation) 
using complete case data. .  
6.3 Covariates and subgroups 
No covariate adjustment or subgroup analyses will be reported. Baseline 
characteristics of both groups will presented descriptively with no inferential 
comparison of groups.  
6.4 Presentation of inferential analyses 
Not relevant.  
6.5 Missing data 
The level of data missingness for each outcome will be reported for both groups at 
each of the 3 assesssment points. No imputation of missing data will be performed.   
6.6 Adverse events 
Data on serious adverse events will be set out descriptively by group.  
6.7 Reporting conventions 
Quantiles, such as the median, or minimum and maximum, will be reported to the 
same number of decimal places as the original data. The mean, standard deviation 
and other statistics will be reported to one decimal place greater than the original 
data. . 
6.8 Mediation analyses 
No mediational analysis will be conducted 
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6.9 Execution of analyses 
The initial ITT analyses will be performed by a statistician who is blinded to 
intervention allocation.. All analyses will be performed using Stata v.14.1. 
 
8. Tables and figures 
Proposed dummy tables and figure templates are shown in the Appendix.  
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10. Appendix  
Figure 1. CONSORT study patient flow 
 
 
 
  
	
Assessed for eligibility (n=  ) 
Excluded  (n=   ) 
¨			Not meeting inclusion criteria (n=  ) 
¨			Declined to participate (n=  ) 
¨			Other reasons (n=  ) 
Analysed  (n=  ) 
¨	Excluded from analysis (give reasons) (n=  )	
Lost to follow-up (give reasons) (n=  ) 
Discontinued intervention (give reasons) (n=  ) 
Allocated to intervention (n=  ) 
¨	Received allocated intervention (n=  )	
¨	Did not receive allocated intervention (give 
reasons) (n=  )	
Lost to follow-up (give reasons) (n=  ) 
Discontinued intervention (give reasons) (n=  ) 
Allocated to intervention (n=  ) 
¨	Received allocated intervention (n=  )	
¨	Did not receive allocated intervention (give 
reasons) (n=  )	
Analysed  (n=  ) 
¨	Excluded from analysis (give reasons) (n=  )	
	
Allocation 
Analysis 
Follow-Up 
Randomized (n=  ) 
Enrollment 
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Table 1. Summary of patient baseline characteristics and outcomes 
 Intervention  Control 
Characteristics 
Gender, % male   
Age, mean (standard 
deviation) 
  
[etc]   
Outcomes 
Expectation of benefit 
scale 
  
Brief Pain Inventory (Short 
Form) 
  
Short-form McGill Pain 
Questionnaire (SF-MPQ-
2) 
  
EQ-5D-5L   
12-item Short Form Health 
Survey (SF-12) 
  
Oswestry Low Back Pain 
Disability Questionnaire 
  
Pain Self Efficacy 
Questionnaire (PSEQ) 
  
Hospital Anxiety and 
Depression Score (HADS) 
  
Pain Catastrophizing 
Scale (PCS) 
  
Stanford Presenteeism 
Scale 
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Table 2. Summary of descriptive outcomes at all follow up points 
 6-weeks 
N Mean (SD) 
3-months 
N Mean (SD) 
6-months 
N Mean (SD) 
 Intervention Control Intervention Control Intervention Control 
Brief Pain 
Inventory (Short 
Form) 
      
Short-form McGill 
Pain Questionnaire 
(SF-MPQ-2) 
      
EQ-5D-5L       
12-item Short Form 
Health Survey (SF-
12) 
      
Oswestry Low 
Back Pain 
Disability 
Questionnaire 
      
Pain Self Efficacy 
Questionnaire 
(PSEQ) 
      
Hospital Anxiety       
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and Depression 
Score (HADS) 
Pain 
Catastrophizing 
Scale (PCS) 
      
Stanford 
Presenteeism 
Scale 
      
Satisfaction with 
treatment scale 
      
Expectation of 
benefit scale 
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Table 3. Complications and adverse events up to 6-months 
 Intervention  Control 
Complication 1   
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Appendix 3.  Participant information sheet 
Reproduced from Snidvongs et al.’s ‘Facet-joint injections for non-specific low 
back pain: a feasibility RCT’ (2017)99 
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Appendix 4.  Delphi exercise 
Pain specialists in the United Kingdom took part in a modified Delphi survey to 
agree on the choice of steroid, volume of injectate into the facet joint, and site of 
placement of the needle for the sham procedure (see table 19).  There were 
forty-two responders out of approximately 250 pain specialists consulted. 
  
 216 
Table 19.  Results of the Delphi exercise 
 
Reproduced from Snidvongs et al.’s ‘Facet-joint injections for non-specific low 
back pain: a feasibility RCT’ (2017)99 
 
 
 
Appendix 6 Delphi exercise
A web-based survey of pain specialists in the UK utilised the Delphi method to determine the choice ofneedle, injectate and volume of injection, as well as the choice of steroid, dose and volume and the
maximum dose of steroid. Of approximately 250 pain specialists consulted, 42 took part in the survey.
TABLE 21 Results of the Delphi exercise
Question Response (%)
Response
count
1. At what maximum steroid dose, do you think, reviewers and general sceptics could claim that a positive result for a
facet-joint injection was due to systematic action, rather than local benefit?
60 mg of methylprednisolone 25.0 10
80mg of methylprednisolone 22.5 9
100mg of methylprednisolone 20.0 8
120mg of methylprednisolone 32.5 13
Response (%)
Response
count
2. Which volume is closest to your choice in each facet-joint?
< 1ml 28.6 12
1ml 38.1 16
1.5 ml 21.4 9
Response (%)
Response
count
3. Assuming that we keep to a maximum of four joints, what steroid dose should we use in each joint?
10 mg of methylprednisolone per joint 40.5 17
20mg of methylprednisolone per joint 57.1 24
30mg of methylprednisolone per joint 2.4 1
Most likely,
% (n)
Likely,
% (n)
Not likely,
% (n)
Does not affect the
outcome, % (n) Rating average
Response
count
4. If we were not to use methylprednisolone, which of these two steroids would you prefer?
Triamcinolone 85.7 (36) 9.5 (4) 2.4 (1) 2.4 (1) 1.21 42
Dexamethasone 12.5 (4) 34.4 (11) 50.0 (16) 3.1 (1) 2.44 32
Response (%)
Response
count
5. The sham group should have a fluoroscopic guided needle placed
Next to the periarticular surface with no injection 38.1 16
Next to the periarticular surface with saline injected (same volume as the active group) 28.6 12
Intra-articular placement with only contrast injected 21.4 9
Intra-articular placement with contrast and placebo (saline) injection (same volume as the
active group)
11.9 5
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Appendix 5.  Sample case report form 
Reproduced from Snidvongs et al.’s ‘Facet-joint injections for non-specific low 
back pain: a feasibility RCT’ (2017)99 
Appendix 7 Sample case report form
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
 
CASE REPORT FORM 
A multicentre double-blind randomised controlled trial to assess the clinical- 
and cost-effectiveness of facet-joint injections in selected patients with non-
specific low back pain: a feasibility study. 
Short title:     Facet-joint feasibility study 
Sponsor: Barts Health NHS Trust  
Representative of the Sponsor: 
 Dr Sally Burtles 
 Director of Research Services 
JRMO 
QM Innovation Building 
 5 Walden Street 
 London 
 E1 2EF 
 Phone: 020 7882 7265 
 Email: sponsorsrep@bartshealth.nhs.uk 
Chief investigator:   Dr Vivek Mehta 
Site principal investigator: 
Co-investigators:
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Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
Patient eligibility – inclusion criteria 
 
 
 
Inclusion criteria 
 Yes No 
1. Patient aged 18 to 70 years attending pain clinics identified during routine clinical 
assessment of non-specific low back pain 
  
2. Low back pain of greater than three months’ duration   
3. Average pain intensity score of 4/10 or more in the seven days preceding recruitment 
despite NICE recommended treatment 
  
4. Dominantly paraspinal (not midline) tenderness at two bilateral lumbar levels   
5. At least two components of NICE-recommended best non-invasive care completed, 
including education and one of a physical exercise programme, acupuncture, and 
manual therapy 
  
6. Patient is suitable for the facet- joint feasibility study   
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Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
Patient eligibility – exclusion criteria 
 
 
 
Exclusion criteria 
 Yes No 
1. Patient refusal to consent   
2. More than four painful lumbar facet-joints   
3. Patient has not completed at least two components of NICE-recommended best non-
invasive care, including education and one of a physical exercise programme, 
acupuncture, and manual therapy 
  
‘Red flag’ signs including thoracic pain, fever, unexplained weight loss, bladder or bowel 
dysfunction, progressive neurological deficit, and saddle anaesthesia 
  
5. Hypersensitivity to study medications   
6. Dominantly midline tenderness over the lumbar spine, any other dominant pain or 
radicular pain. 
  
7. Any major systemic disease or mental health illness that may affect the patient’s pain, 
disability and/or their ability to exercise and rehabilitate, as judged by the Principal 
Investigators 
  
8. Any active neoplastic disease, including primary or secondary neoplasm   
9. Pregnant or breastfeeding   
10. Previous lumbar facet-joint injections, spinal surgery or any major trauma or infection 
to lumbar spine. 
  
11. Patient with morbid obesity (body mass index of 35 or greater)   
12. Participation in another clinical trial of a investigational medicinal product or disease 
related intervention in the past thirty days 
  
13. Patient unable to commit to the six-month study duration   
14. Patient involved in legal actions or employment or benefit tribunals related to their low 
back pain 
  
15. Patient with a history of substance abuse   
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Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
Consent 
 
 
Date of patient consent 
 
_________________ 
Version of consent form used 
 
_________________ 
Baseline pain score (NRS)  up 7 
days preceding recruitment 
                 date taken: 
 
I confirm that this patient is eligible to enter the study  
–––––––––––––––––––––––––––––––––––––– 
 (signature of medical doctor on delegation log) 
Patient visit schedule 
 
 
 Date of visit(s) 
 
Visit 1 
 
Screening and informed consent 
Outcome questionnaires at baseline 
 
 
Visit 2 
 
Diagnostic test (medial branch nerve blocks) 
 
 
Visit 3 
 
Study procedure (facet-joint injections or sham 
procedure) 
 
 
 Combined physical and psychological programme 
 
Date of first session: 
 
Date of last session: 
 
Number of sessions attended: 
 
Visit 4 
 
Outcome questionnaires at 6 weeks 
 
 
Visit 5 
 
Outcome questionnaires at 3 months 
 
 
Visit 6  
Outcome questionnaires at 6 months 
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Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
Patient history 
To be completed by research assistant 
 
 
General health 
 
How long has the patient been aware of his/her non-specific low back pain? 
 
_______ 
 
_______ 
 Years Months 
   
 
In general, would the patient describe his/her health as: (tick box) 
  
 
Excellent  
 
Very good  
 
Good  
 
Fair  
 
Poor  
   
Occupation information 
 
What is the patient’s current work status? (tick box) 
 
 
 
 
Full time  
 
Part time  
 
Volunteer  
 Modified 
duties 
 
 
Disabled  
 Not 
working 
 
 
Homemaker  
 
Retired  
 Not 
applicable 
 
   
Type of work or occupation: 
_____________________________________________________________ 
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Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
Patient history 
To be completed by research assistant 
 
Did the patient’s illness cause him/her to stop working? Yes 
 
 No 
 
 Not 
applicable 
 
  
 Other (give reason): 
  
_______________________________________________________________ 
  
If the patient continued working, how many work days in the past 3 
months, prior to the procedure, did he/she miss due to pain? 
 
_______ days 
   
What was the patient’s level of activity prior to the procedure?   
 Hard 
manual 
work 
 
 
Lifting  
 
Walking  
 
Sedentary  
   
Social history 
 
Smoking 
Current 
smoker 
 
 
_______ 
cigarettes/day 
 
 
 
Ex-smoker 
 
 
 date stopped 
 
 Never 
smoked 
 
   
 
Alcohol 
 
_______ 
 
 Units consumed per week 
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Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
 
Patient history 
To be completed by research assistant 
 
 
Exercise per week: (tick box) >5 days 
 
 3-5 day 
 
 1-2 days 
 
 Less than 1 
day 
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Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
 
 
 
Visit 1 
 
Baseline 
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Visit 1- Baseline 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
Patient questionnaire 
To be completed by research assistant 
 
Treatments/hospitalisations/medications 
 
Has the patient seen a healthcare professional within the 
past 4 weeks due to pain? 
 
 
 
 _______ 
Emergency 
department visits 
_______ 
Length of stay in hospital 
  
_______ GP appointments 
  
_______ pain clinic 
 
 
 Other (give details): 
  
_______________________________________________________________ 
 
Current analgesics (name of medication, dosage and frequency) 
 
 
 
 
 
 
 
 
Other medications (name of medication, dosage and frequency) 
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Visit 1- Baseline 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
Patient’s expectation of benefit 
 
How much improvement in pain does the patient expect from the procedure?  (circle one) 
 
 
1 2 3 4 5 6 
 
 
Outcome questionnaires 
 
Has the questionnaire pack (set 1) been completed? Yes 
 
 No 
 
 
 
 
 
 
 
 
Expect no improvement Expect total improvement 
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Visit 1- Baseline 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
 
 
 
Visit 2 
 
Diagnostic test 
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Visit 1- Baseline 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
Diagnostic test (medial branch nerve blocks) 
To be completed by PI 
 
 
 
Study centre 
 
____________________________ 
 
 
Date of procedure 
 
____________________________ 
 
 
Time of procedure 
 
____________________________ 
 
 
Operator 
 
____________________________ 
 
 
Procedure details 
 
Number of injections 
 
____________________________ 
 
IMP injected 
 
1% lidocaine 0.5% per site 
 
  
Levels injected  
 
 
 
 
 
  
 
Post injection evaluation 1 (20 to 40 minutes after injection) 
To be completed by PI 
 
 
 
Time of evaluation 
 
____________________________ 
 
 
Minutes after injection 
 
____________________________ 
 
 
Please rate the patient’s current level of pain on a numerical rating scale (NRS) of 0-10. (0 is no pain and 10 is worst 
pain): 
 
Patient’s current pain score = 
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Visit 1- Baseline 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
 
Post injection evaluation 2 (180 to 240 minutes after injection) 
To be completed by PI 
 
 
 
Time of evaluation 
 
____________________________ 
 
 
Minutes after injection 
 
____________________________ 
 
 
Please rate the patient’s current level of pain on a numerical rating scale (NRS) of 0-10. (0 is no pain and 10 is worst 
pain): 
 
Patient’s current pain score =  
 
 
 
 
 
Investigator decision: positive test is a 50% or greater pain relief lasting more than 30 minutes (circle one) 
 
Positive (for randomisation)               Date of randomisation ________________ 
 
Negative (end of study) 
 
 
Visit 3- Study procedures form the ‘blinded CRF' 
This section is to be completed by the PI and kept separately in a locked filing cabinet until unblinding 
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Patient identification number __________ 
 
Patient initials __________ 
Investigator’s initials __________ 
 
Date __________ 
 
CASE REPORT FORM 
A multicentre double-blind randomised controlled trial to assess the clinical- 
and cost-effectiveness of facet-joint injections in selected patients with non-
specific low back pain: a feasibility study. 
Short title:     Facet-joint feasibility study 
Sponsor: Barts Health NHS Trust 
Representative of the Sponsor: 
 Dr Sally Burtles 
 Director of Research Services 
JRMO 
QM Innovation Building 
 5 Walden Street 
 London 
 E1 2EF 
 Phone: 020 7882 7265 
 Email: sponsorsrep@bartshealth.nhs.uk 
Chief investigator: Dr Vivek Mehta 
Site principal investigator: 
 
This section is the ‘blinded CRF' to be completed by the PI and kept separately in a locked filing cabinet 
until unblinding 
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Patient identification number __________ 
 
Patient initials __________ 
Investigator’s initials __________ 
 
Date __________ 
 
 
Visit 3 
 
Study procedure 
 
Study procedure (facet-joint injections or sham procedure) 
To be completed by PI 
 
 
 
Study centre 
 
____________________________ 
 
 
Date of procedure 
 
____________________________ 
 
 
Time of procedure 
 
____________________________ 
 
 
Operator 
 
____________________________ 
 
 
Procedure details 
 
Number of injections 
 
____________________________ 
  
Levels injected  
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CPP 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
 
 
 
 
Combined physical and 
psychological 
programme 
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CPP 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
Combined physical and psychological programme 
 
 
 
Study centre 
 
____________________________ 
 
 
  
Date attended 
 
Outcomes delivered 
 
Session 1 
 
____________________________ 
Y/N 
 
Session 2 
 
____________________________ 
Y/N 
 
Session 3 
 
____________________________ 
 
 
Session 4 
 
____________________________ 
 
 
Session 5 
 
____________________________ 
 
 
Session 6 
 
____________________________ 
 
 
If all outcomes not delivered please provide further details: 
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Visit 4 – Outcome measures at 6 weeks 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
 
 
 
Outcomes 
  
6 Weeks Post 
Intervention 
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Visit 4 – Outcome measures at 6 weeks 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
Patient questionnaire 
To be completed by research assistant 
 
 
Treatments/hospitalisations/medications 
 
Has the patient seen a healthcare professional within the 
past 4 weeks due to pain? 
 
 
 
 _______ 
Emergency 
department visits 
_______ 
Length of stay in hospital 
  
_______ GP appointments 
  
_______ pain clinic 
 
 
 Other (give details): 
  
_______________________________________________________________ 
 
Current analgesics (name of medication, dosage and frequency) 
 
 
 
 
 
 
 
 
Other medications (name of medication, dosage and frequency) 
 
 
 
 
 
 
 
Patient’s expectation of benefit 
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Visit 4 – Outcome measures at 6 weeks 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
 
How satisfied is the patient with the treatment received?  (circle one) 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
Outcome questionnaires 
 
Has the questionnaire pack (set 2) been completed? Yes 
 
 No 
 
 
 
Adverse events 
 
Have there been any adverse events since the intervention? Yes 
 
 No 
 
If yes, please complete the adverse event log at the end of the CRF  
 
 
 
Changes to medications 
 
Have there been any changes in medication since the intervention? Yes 
 
 No 
 
If yes, please complete in box below:  
 
 
Extremely dissatisfied Extremely satisfied 
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Visit 5 – Outcome measures at 3 months 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
 
 
 
Outcomes 
 
3 Months Post 
Intervention 
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Visit 5 – Outcome measures at 3 months 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
Patient questionnaire 
To be completed by research assistant 
 
 
Treatments/hospitalisations/medications 
 
Has the patient seen a healthcare professional within the 
past 4 weeks due to pain? 
 
 
 
 _______ 
Emergency 
department visits 
_______ 
Length of stay in hospital 
  
_______ GP appointments 
  
_______ pain clinic 
 
 
 Other (give details): 
  
_______________________________________________________________ 
 
Current analgesics (name of medication, dosage and frequency) 
 
 
 
 
 
 
 
 
Other medications (name of medication, dosage and frequency) 
 
 
 
 
 
 
 
Patient’s expectation of benefit 
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Visit 5 – Outcome measures at 3 months 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
 
How satisfied is the patient with the treatment received?  (circle one) 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
Outcome questionnaires 
 
Has the questionnaire pack (set 3) been completed? Yes 
 
 No 
 
 
 
Adverse events 
 
Have there been any adverse events since the last visit? Yes 
 
 No 
 
If yes, please complete the adverse event log at the end of the CRF  
 
 
 
Changes to medications 
 
Have there been any changes in medication since the last visit? Yes 
 
 No 
 
If yes, please complete in box below:  
 
 
 
Extremely dissatisfied Extremely satisfied 
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Visit 6 – Outcome measures after 6 months 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
 
 
 
Outcomes 
 
6 Months Post 
Intervention 
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Visit 6 – Outcome measures after 6 months 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
Patient questionnaire 
To be completed by research assistant 
 
 
Treatments/hospitalisations/medications 
 
Has the patient seen a healthcare professional within the 
past 4 weeks due to pain? 
 
 
 
 _______ 
Emergency 
department visits 
_______ 
Length of stay in hospital 
  
_______ GP appointments 
  
_______ pain clinic 
 
 
 Other (give details): 
  
_______________________________________________________________ 
 
Current analgesics (name of medication, dosage and frequency) 
 
 
 
 
 
 
 
 
Other medications (name of medication, dosage and frequency) 
 
 
 
 
 
 
 
Patient’s expectation of benefit 
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Visit 6 – Outcome measures after 6 months 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
 
How satisfied is the patient with the treatment received?  (circle one) 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
Outcome questionnaires 
 
Has the questionnaire pack (set 4) been completed? Yes 
 
 No 
 
 
 
Adverse events 
 
Have there been any adverse events since the last visit? Yes 
 
 No 
 
If yes, please complete the adverse event log at the end of the CRF  
 
 
Changes to medications 
 
Have there been any changes in medication since the last visit? Yes 
 
 No 
 
If yes, please complete in box below:  
 
 
 
 
 
Extremely dissatisfied Extremely satisfied 
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End of study 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
 
 
 
 
End of study 
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End of study 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
End of study 
To be completed by research assistant 
 
 
 
Date of final study contact with patient ________________ 
 
Reason (circle one) 
 
Completed study 
Withdrawn from study 
Other 
 
Reason for withdrawal from study (circle one) 
 
Drop out 
Protocol non-compliance 
Adverse event (please complete AE form at the end of the CRF) 
Other 
 
If other, provide further details: 
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End of study 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
 
 
 
 
Adverse events 
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End of study 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
Adverse events 1 
 
 
Date adverse event occurred ________________ 
 
Date investigator become aware of the event ________________ 
 
Location of adverse event 
________________________________________________________________ 
 
Event details: 
 
 
 
 
 
 
 
 
 
 
 
Is the adverse event related to the procedure? (circle one only) 
 
Unrelated 
Unlikely 
Possible 
Probably 
Related 
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End of study 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
Was the adverse event a serious adverse event (SAE)? 
 
Yes 
No (move on to action plan) 
Serious criteria (circle all that apply) 
 
The AE led or could have led to a congenital anomaly/birth defect 
The AE led or could have led to death 
Resulted in medical or surgical intervention to prevent permanent impairment to a body 
structure 
Life-threatening illness or injury 
Resulted in permanent impairment of a body structure or body function 
Required inpatient hospitalisation 
Other 
 
Action plan 
 
No action required 
Amend consent form 
Amend protocol 
Inform current subjects 
Terminate or suspend protocol 
Other 
 
Has the Sponsor been informed? 
 
Yes 
No 
 
If other, provide further details: 
 
 
 
 
 
 
 
 
 
APPENDIX 7
NIHR Journals Library www.journalslibrary.nihr.ac.uk
108
  248 
	
End of study 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
Adverse events 2 
 
 
Date adverse event occurred ________________ 
 
Date investigator become aware of the event ________________ 
 
Location of adverse event 
________________________________________________________________ 
 
Event details: 
 
 
 
 
 
 
 
 
 
 
 
Is the adverse event related to the procedure? (circle one only) 
 
Unrelated 
Unlikely 
Possible 
Probably 
Related 
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End of study 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
Was the adverse event a serious adverse event (SAE)? 
 
Yes 
No (move on to action plan) 
Serious criteria (circle all that apply) 
 
The AE led or could have led to a congenital anomaly/birth defect 
The AE led or could have led to death 
Resulted in medical or surgical intervention to prevent permanent impairment to a body 
structure 
Life-threatening illness or injury 
Resulted in permanent impairment of a body structure or body function 
Required inpatient hospitalisation 
Other 
 
Action plan 
 
No action required 
Amend consent form 
Amend protocol 
Inform current subjects 
Terminate or suspend protocol 
Other 
 
Has the Sponsor been informed? 
 
Yes 
No 
 
If other, provide further details: 
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Appendix 6.  Sample adverse event log 
Reproduced from Snidvongs et al.’s ‘Facet-joint injections for non-specific low back pain: a feasibility RCT’ (2017)99 
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Appendix 7.  Missing or incomplete questionnaire data 
Reproduced from Snidvongs et al. Facet-joint injections for non-specific low 
back pain: a feasibility RCT (2017)99 
 
Eleven participants did not complete, or incorrectly completed certain 
components of each questionnaire; this is detailed in table 20 below. 
 
Table 20.  Missing or incomplete questionnaire data 
 
Appendix 11 Missing or incomplete
questionnaire data
E leven participants did not complete, or completed incorrectly, the different components of eachquestionnaire; this is detailed in Table 30 .
TABLE 30 Missing or incomplete questionnaire data
Participant
number
Missing data
DetailsBaseline 6 weeks 3 months 6 months
1002 All All
1003 BPI ‘What treatments or medications are you receiving
for your pain?’ – missing
1004 BPI ‘Please mark on the diagram the area of your
pain’ – spoiled
1005 SF-12 ‘Climbing several flights of stairs’ – missing
1006 All
1007 Oswestry ‘Social life’ – spoiled
1009 All
1009 SF-12 ‘Physical health, limited to work, emotional
problems, did work less carefully’ – missing
1010 SF-MPQ-2 ‘Hot burning pain, splitting pain’ – missing
SF-12 ‘Did work less carefully’ – missing
Oswestry ‘Personal care, sleeping’ – spoiled; ‘sex life’ –
missing
1011 SPS 6 ‘I felt hopeless about finishing certain work tasks,
due to my health problems’, ‘At work, I was able
to focus on achieving my goals despite my health
problem’ and ‘Despite having my health problem,
I felt energetic enough to complete all my work’ –
missing
1014 EQ-5D-5L ‘Pain/discomfort’ – missing
Oswestry ‘Sex life’ – missing
Oswestry, Oswestry Low Back Pain Disability Questionnaire.
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Appendix 8.  CONSORT flow diagram showing the 
actual and estimated flow of participants through the 
study 
Reproduced from Snidvongs et al.’s ‘Facet-joint injections for non-specific low 
back pain: a feasibility RCT’ (2017)99 
 
  254 
References 
 
1. Hoy D, Bain C, Williams G, March L, Brooks P, Blyth F, et al. A 
systematic review of the global prevalence of low back pain. Arthritis Rheum. 
2012;64(6):2028-37. 
2. Hoy D, March L, Brooks P, Blyth F, Woolf A, Bain C, et al. The global 
burden of low back pain: estimates from the Global Burden of Disease 2010 
study. Ann Rheum Dis. 2014;73(6):968-74. 
3. International Association for the Study of Pain. Declaration of Montreal; 
2010. Available from: https://www.iasp-pain.org/DeclarationofMontreal. Last 
accessed 2nd August 2018. 
4. Jackson T, Thomas S, Stabile V, Shotwell M, Han X, McQueen K. A 
Systematic Review and Meta-Analysis of the Global Burden of Chronic Pain 
Without Clear Etiology in Low- and Middle-Income Countries: Trends in 
Heterogeneous Data and a Proposal for New Assessment Methods. Anesth 
Analg. 2016;123(3):739-48. 
5. Global, regional, and national incidence, prevalence, and years lived with 
disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the 
Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1545-602. 
6. Global, regional, and national incidence, prevalence, and years lived with 
disability for 328 diseases and injuries for 195 countries, 1990-2016: a 
systematic analysis for the Global Burden of Disease Study 2016. Lancet. 
2017;390(10100):1211-59. 
7. Global, regional, and national disability-adjusted life-years (DALYs) for 
315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a 
systematic analysis for the Global Burden of Disease Study 2015. Lancet. 
2016;388(10053):1603-58. 
  255 
8. Babu AN, McCormick Z, Kennedy DJ, Press J. Local, national, and 
service component cost variations in the management of low back pain: 
Considerations for the clinician. J Back Musculoskelet Rehabil. 2016;29(4):685-
92. 
9. Maniadakis N, Gray A. The economic burden of back pain in the UK. 
Pain. 2000;84(1):95-103. 
10. National Pain Audit. National Pain Audit: final report 2010-2012; 2012. 
Available from: www.nationalpainaudit.org. Last accessed 13th June 2017. 
11. Dagenais S, Caro J, Haldeman S. A systematic review of low back pain 
cost of illness studies in the United States and internationally. Spine J. 
2008;8(1):8-20. 
12. McMahon S.B. KM, Tracey I., Turk D.C. Wall & Melzack's Textbook of 
Pain: Saunders, an imprint of Elsevier Ltd; 2013. 
13. Balague F, Mannion AF, Pellise F, Cedraschi C. Non-specific low back 
pain. Lancet. 2012;379(9814):482-91. 
14. Koes BW, van Tulder MW, Thomas S. Diagnosis and treatment of low 
back pain. Bmj. 2006;332(7555):1430-4. 
15. Chou R, Shekelle P. Will this patient develop persistent disabling low 
back pain? Jama. 2010;303(13):1295-302. 
16. Freburger JK, Holmes GM, Agans RP, Jackman AM, Darter JD, Wallace 
AS, et al. The rising prevalence of chronic low back pain. Arch Intern Med. 
2009;169(3):251-8. 
17. Grotle M, Foster NE, Dunn KM, Croft P. Are prognostic indicators for 
poor outcome different for acute and chronic low back pain consulters in 
primary care? Pain. 2010;151(3):790-7. 
  256 
18. Karran EL, McAuley JH, Traeger AC, Hillier SL, Grabherr L, Russek LN, 
et al. Can screening instruments accurately determine poor outcome risk in 
adults with recent onset low back pain? A systematic review and meta-analysis. 
BMC Med. 2017;15(1):13. 
19. Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, et al. A 
classification of chronic pain for ICD-11. Pain. 2015;156(6):1003-7. 
20. Hancock MJ, Maher CG, Latimer J, Spindler MF, McAuley JH, Laslett M, 
et al. Systematic review of tests to identify the disc, SIJ or facet joint as the 
source of low back pain. Eur Spine J. 2007;16(10):1539-50. 
21. Chou R, Fu R, Carrino JA, Deyo RA. Imaging strategies for low-back 
pain: systematic review and meta-analysis. Lancet. 2009;373(9662):463-72. 
22. Norton G, McDonough CM, Cabral HJ, Shwartz M, Burgess JF, Jr. 
Classification of patients with incident non-specific low back pain: implications 
for research. Spine J. 2016;16(5):567-76. 
23. Deyo RA, Dworkin SF, Amtmann D, Andersson G, Borenstein D, 
Carragee E, et al. Report of the NIH Task Force on research standards for 
chronic low back pain. J Pain. 2014;15(6):569-85. 
24. Agency for Healthcare Research and Quality. Methods Guide for 
Effectiveness and Comparative Effectiveness Reviews. AHRQ Publication No. 
10(14)-EHC063-EF. Chapters available at: www.effectivehealthcare.ahrq.gov 
Rockville, MD; January 2014. Available from: 
https://effectivehealthcare.ahrq.gov/ehc/products/60/318/CER-Methods-Guide-
140109.pdf. Last accessed 27th September 2017. 
25. National Institute for Health and Clinical Excellence. Low back pain and 
sciatica in over 16s: assessment and management.  NICE guideline (NG59). 
November 2016. 
26. National Institute for Health and Clinical Excellence. Low back pain in 
adults: early management.  Clinical guideline (CG88). May 2009. 
  257 
27. Boswell MV, Colson JD, Sehgal N, Dunbar EE, Epter R. A systematic 
review of therapeutic facet joint interventions in chronic spinal pain. Pain 
Physician. 2007;10(1):229-53. 
28. Carette S, Marcoux S, Truchon R, Grondin C, Gagnon J, Allard Y, et al. 
A controlled trial of corticosteroid injections into facet joints for chronic low back 
pain. N Engl J Med. 1991;325(14):1002-7. 
29. Savigny P, Watson P, Underwood M, Guideline Development G. Early 
management of persistent non-specific low back pain: summary of NICE 
guidance. BMJ. 2009;338:b1805. 
30. Royal College of Anaesthetists. NICE clinical guideline 88: Low back 
pain; June 2011 updated 14th June 2017. Available from: 
http://www.rcoa.ac.uk/news-and-bulletin/rcoa-news-and-statements/nice-
clinical-guideline-88-low-back-pain. Last accessed 27th September 2017. 
31. Rawlins M. LP. NICE outraged by ousting of BPS President. BMJ 
2009;338:b1805 [Internet]. 2009. Available from: http://www.bmj.com/rapid-
response/2011/11/02/nice-outraged-ousting-bps-president. Last accessed 13th 
June 2017. 
32. Wells C. Re: NICE outraged by ousting of BPS President, but the real 
outrage is the planned reduction in Pain Clinic services. BMJ 2009;338:b1805 
[Internet]. Available from: http://www.bmj.com/rapid-response/2011/11/02/re-
nice-outraged-ousting-bps-president-real-outrage-planned-reduction-pain. Last 
accessed 13th June 2017. 
33. British Pain Society statement on the NICE Guidelines for the early 
management of persistent non-specific low back pain. Pain News. Autumn 
2009:18. 
34. Fuchs S, Erbe T, Fischer HL, Tibesku CO. Intraarticular hyaluronic acid 
versus glucocorticoid injections for nonradicular pain in the lumbar spine. J 
Vasc Interv Radiol. 2005;16(11):1493-8. 
  258 
35. Jackson RP. The facet syndrome. Myth or reality? Clin Orthop Relat 
Res. 1992(279):110-21. 
36. Lilius G, Laasonen EM, Myllynen P, Harilainen A, Gronlund G. Lumbar 
facet joint syndrome. A randomised clinical trial. J Bone Joint Surg Br. 
1989;71(4):681-4. 
37. Mayer TG, Gatchel RJ, Keeley J, McGeary D, Dersh J, Anagnostis C. A 
randomized clinical trial of treatment for lumbar segmental rigidity. Spine (Phila 
Pa 1976). 2004;29(20):2199-205; discussion 206. 
38. Kawu AA, Olawepo A, Salami AO. Facet joints infiltration: a viable 
alternative treatment to physiotherapy in patients with low back pain due to 
facet joint arthropathy. Niger J Clin Pract. 2011;14(2):219-22. 
39. Low back pain and sciatica in over 16s: assessment and management.   
NICE guideline NG59.  Appendices A - G National Institute for Health and Care 
Excellence; November 2016. Available from: 
https://www.nice.org.uk/guidance/ng59/evidence/appendices-ag-pdf-
2726157999. Last accessed 2nd August 2018. 
40. Staal JB, de Bie R, de Vet HC, Hildebrandt J, Nelemans P. Injection 
therapy for subacute and chronic low-back pain. Cochrane Database Syst Rev. 
2008(3):Cd001824. 
41. NHS England Trauma Programme of Care. National Low Back and 
Radicular Pain Pathway 2017. Available from: 
http://www.ukssb.com/assets/PDFs/2017/February/National-Low-Back-and-
Radicular-Pain-Pathway-2017_final.pdf. Last accessed 8th July 2017. 
42. National Institute for Health and Clinical Excellence. Low back pain: early 
management of persistent non-specific low back pain.  NICE clinical guideline 
88.  Quick reference guide. May 2009. 
43. National Institute for Health and Care Excellence. Managing low back 
pain and sciatica.  Interactive flowchart (NG59); 2017. Available from: 
  259 
http://pathways.nice.org.uk/pathways/low-back-pain-and-sciatica. Last 
accessed 6th May 2017. 
44. Chou R, Loeser JD, Owens DK, Rosenquist RW, Atlas SJ, Baisden J, et 
al. Interventional therapies, surgery, and interdisciplinary rehabilitation for low 
back pain: an evidence-based clinical practice guideline from the American Pain 
Society. Spine (Phila Pa 1976). 2009;34(10):1066-77. 
45. Manchikanti L, Datta S, Gupta S, Munglani R, Bryce DA, Ward SP, et al. 
A critical review of the American Pain Society clinical practice guidelines for 
interventional techniques: part 2. Therapeutic interventions. Pain Physician. 
2010;13(4):E215-64. 
46. Manchikanti L, Abdi S, Atluri S, Benyamin RM, Boswell MV, 
Buenaventura RM, et al. An update of comprehensive evidence-based 
guidelines for interventional techniques in chronic spinal pain. Part II: guidance 
and recommendations. Pain Physician. 2013;16(2 Suppl):S49-283. 
47. Slade SC, Kent P, Patel S, Bucknall T, Buchbinder R. Barriers to Primary 
Care Clinician Adherence to Clinical Guidelines for the Management of Low 
Back Pain: A Systematic Review and Metasynthesis of Qualitative Studies. Clin 
J Pain. 2016;32(9):800-16. 
48. Manchikanti L, Pampati V, Hirsch JA. Utilization of Interventional 
Techniques in Managing Chronic Pain In Medicare Population from 2000 to 
2014: An Analysis of Patterns of Utilization. Pain Physician. 2016;19(4):E531-
46. 
49. Beckworth WJ, Jiang M, Hemingway J, Hughes D, Staggs D. Facet 
injection trends in the Medicare population and the impact of bundling codes. 
Spine J. 2016;16(9):1037-41. 
50. Manchikanti L, Hirsch JA. Inaccurate information on facet joint injections 
in the Medicare population. Spine J. 2016;16(9):1157-8. 
  260 
51. NHS Digital. Hospital Episode Statistics - admitted patient care, England. 
Available from: https://digital.nhs.uk/data-and-
information/publications/statistical/hospital-admitted-patient-care-activity/2016-
17. Last accessed 1st December 2017. 
52. Cavanaugh JM, Lu Y, Chen C, Kallakuri S. Pain generation in lumbar 
and cervical facet joints. J Bone Joint Surg Am. 2006;88 Suppl 2:63-7. 
53. van Kleef M, Vanelderen P, Cohen SP, Lataster A, Van Zundert J, 
Mekhail N. 12. Pain originating from the lumbar facet joints. Pain Pract. 
2010;10(5):459-69. 
54. Cohen SP, Hurley RW, Christo PJ, Winkley J, Mohiuddin MM, Stojanovic 
MP. Clinical predictors of success and failure for lumbar facet radiofrequency 
denervation. Clin J Pain. 2007;23(1):45-52. 
55. Revel M, Poiraudeau S, Auleley GR, Payan C, Denke A, Nguyen M, et 
al. Capacity of the clinical picture to characterize low back pain relieved by facet 
joint anesthesia. Proposed criteria to identify patients with painful facet joints. 
Spine (Phila Pa 1976). 1998;23(18):1972-6; discussion 7. 
56. Laslett M, Oberg B, Aprill CN, McDonald B. Zygapophysial joint blocks in 
chronic low back pain: a test of Revel's model as a screening test. BMC 
Musculoskelet Disord. 2004;5:43. 
57. Cid J, De La Calle JL, Lopez E, Del Pozo C, Perucho A, Acedo MS, et al. 
A modified Delphi survey on the signs and symptoms of low back pain: 
indicators for an interventional management approach. Pain Pract. 
2015;15(1):12-21. 
58. Kalichman L, Li L, Kim DH, Guermazi A, Berkin V, O'Donnell CJ, et al. 
Facet joint osteoarthritis and low back pain in the community-based population. 
Spine (Phila Pa 1976). 2008;33(23):2560-5. 
  261 
59. Schwarzer AC, Aprill CN, Derby R, Fortin J, Kine G, Bogduk N. The 
false-positive rate of uncontrolled diagnostic blocks of the lumbar zygapophysial 
joints. Pain. 1994;58(2):195-200. 
60. Cohen SP, Williams KA, Kurihara C, Nguyen C, Shields C, Kim P, et al. 
Multicenter, randomized, comparative cost-effectiveness study comparing 0, 1, 
and 2 diagnostic medial branch (facet joint nerve) block treatment paradigms 
before lumbar facet radiofrequency denervation. Anesthesiology. 
2010;113(2):395-405. 
61. Falco FJ, Manchikanti L, Datta S, Sehgal N, Geffert S, Onyewu O, et al. 
An update of the systematic assessment of the diagnostic accuracy of lumbar 
facet joint nerve blocks. Pain Physician. 2012;15(6):E869-907. 
62. Boswell MV, Manchikanti L, Kaye AD, Bakshi S, Gharibo CG, Gupta S, 
et al. A Best-Evidence Systematic Appraisal of the Diagnostic Accuracy and 
Utility of Facet (Zygapophysial) Joint Injections in Chronic Spinal Pain. Pain 
Physician. 2015;18(4):E497-533. 
63. Manchikanti L, Hirsch JA, Falco FJ, Boswell MV. Management of lumbar 
zygapophysial (facet) joint pain. World J Orthop. 2016;7(5):315-37. 
64. Mars T, Ellard DR, Antrobus JH, Cairns M, Underwood M, Haywood K, 
et al. Intraarticular Facet Injections for Low Back Pain: Design Considerations, 
Consensus Methodology to Develop the Protocol for a Randomized Controlled 
Trial. Pain Physician. 2015;18(5):473-93. 
65. Wu T, Zhao WH, Dong Y, Song HX, Li JH. Effectiveness of Ultrasound-
Guided Versus Fluoroscopy or Computed Tomography Scanning Guidance in 
Lumbar Facet Joint Injections in Adults With Facet Joint Syndrome: A Meta-
Analysis of Controlled Trials. Arch Phys Med Rehabil. 2016;97(9):1558-63. 
66. Kidd BL. Osteoarthritis and joint pain. Pain. 2006;123(1-2):6-9. 
  262 
67. Ribeiro LH, Furtado RN, Konai MS, Andreo AB, Rosenfeld A, Natour J. 
Effect of facet joint injection versus systemic steroids in low back pain: a 
randomized controlled trial. Spine (Phila Pa 1976). 2013;38(23):1995-2002. 
68. Manchikanti L, Kaye AD, Boswell MV, Bakshi S, Gharibo CG, Grami V, 
et al. A Systematic Review and Best Evidence Synthesis of the Effectiveness of 
Therapeutic Facet Joint Interventions in Managing Chronic Spinal Pain. Pain 
Physician. 2015;18(4):E535-82. 
69. Schutz U, Cakir B, Dreinhofer K, Richter M, Koepp H. Diagnostic value of 
lumbar facet joint injection: a prospective triple cross-over study. PLoS One. 
2011;6(11):e27991. 
70. International Spine Intervention Society. Practice Guidelines.  Spinal 
diagnostic and treatment procedures. Bogduk N. 2004. 
71. American Pain Society. Guideline for the evaluation and management of 
low back pain.  Evidence review. Glenview IL; 2009. Available from: 
http://americanpainsociety.org/uploads/education/guidelines/evaluation-
management-lowback-pain.pdf. Last accessed 27th September 2017. 
72. Falco FJ, Manchikanti L, Datta S, Sehgal N, Geffert S, Onyewu O, et al. 
An update of the effectiveness of therapeutic lumbar facet joint interventions. 
Pain Physician. 2012;15(6):E909-53. 
73. Datta S, Lee M, Falco FJ, Bryce DA, Hayek SM. Systematic assessment 
of diagnostic accuracy and therapeutic utility of lumbar facet joint interventions. 
Pain Physician. 2009;12(2):437-60. 
74. Gauci C. Manual of RF techniques.  A practical manual of radiofrequency 
procedures in chronic pain management.  2nd edition. Amsterdam, the 
Netherlands: FlivoPress BV; 2008. 
75. Maas ET, Ostelo RW, Niemisto L, Jousimaa J, Hurri H, Malmivaara A, et 
al. Radiofrequency denervation for chronic low back pain. Cochrane Database 
Syst Rev. 2015(10):Cd008572. 
  263 
76. Lee CH, Chung CK, Kim CH. The efficacy of conventional 
radiofrequency denervation in patients with chronic low back pain originating 
from the facet joints: a meta-analysis of randomized controlled trials. Spine J. 
2017. 
77. Juch JNS, Maas ET, Ostelo R, Groeneweg JG, Kallewaard JW, Koes 
BW, et al. Effect of Radiofrequency Denervation on Pain Intensity Among 
Patients With Chronic Low Back Pain: The Mint Randomized Clinical Trials. 
Jama. 2017;318(1):68-81. 
78. North American Spine Society. Multisociety Statement on Effect of 
Radiofrequency Denervation on Pain Intensity Among Patients with Chronic 
Low Back Pain: The Mint Randomized Clinical Trials by Juch et al.; 2017. 
Available from: 
https://www.spine.org/Portals/0/Documents/ResearchClinicalCare/Comments/S
cientificPolicy112117.pdf. Last accessed 2nd August 2018. 
79. Provenzano DA, Buvanendran A, de Leon-Casasola OA, Narouze S, 
Cohen SP. Interpreting the MINT Randomized Trials Evaluating 
Radiofrequency Ablation for Lumbar Facet and Sacroiliac Joint Pain: A Call 
From ASRA for Better Education, Study Design, and Performance. Reg Anesth 
Pain Med. 2018;43(1):68-71. 
80. van Kuijk SMJ, Van Zundert J, Hans G, Van Boxem K, Vissers K, van 
Kleef M, et al. Flawed Study Design and Incorrect Presentation of Data 
Negatively Impact Potentially Useful Interventional Treatments for Patients with 
Low Back Pain: A Critical Review of JAMA's MinT Study. Pain Pract. 
2018;18(3):292-5. 
81. Andronis L, Kinghorn P, Qiao S, Whitehurst DG, Durrell S, McLeod H. 
Cost-Effectiveness of Non-Invasive and Non-Pharmacological Interventions for 
Low Back Pain: a Systematic Literature Review. Appl Health Econ Health 
Policy. 2017;15(2):173-201. 
82. The National Spinal Taskforce. Commissioning spinal services – getting 
the service back on track.  A guide for commissioners of spinal services; 
  264 
January 2013. Available from: 
http://www.nationalspinaltaskforce.co.uk/pdfs/NHSSpinalReport_vis7 
30.01.13.pdf. Last accessed 20th February 2017. 
83. Lamb SE, Lall R, Hansen Z, Castelnuovo E, Withers EJ, Nichols V, et al. 
A multicentred randomised controlled trial of a primary care-based cognitive 
behavioural programme for low back pain. The Back Skills Training (BeST) trial. 
Health Technol Assess. 2010;14(41):1-253, iii-iv. 
84. Back Skills Training (BeST) online course. Available from: 
www.backskillstraining.co.uk. Last accessed 13th June 2017. 
85. Chou R, Deyo R, Friedly J, Skelly A, Weimer M, Fu R, et al. Systemic 
Pharmacologic Therapies for Low Back Pain: A Systematic Review for an 
American College of Physicians Clinical Practice Guideline. Ann Intern Med. 
2017;166(7):480-92. 
86. Qaseem A, Wilt TJ, McLean RM, Forciea MA. Noninvasive Treatments 
for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline 
From the American College of Physicians. Ann Intern Med. 2017;166(7):514-30. 
87. Kaiser U, Neustadt K, Kopkow C, Schmitt J, Sabatowski R. Core 
Outcome Sets and Multidimensional Assessment Tools for Harmonizing 
Outcome Measure in Chronic Pain and Back Pain. Healthcare (Basel). 
2016;4(3). 
88. Deyo RA, Battie M, Beurskens AJ, Bombardier C, Croft P, Koes B, et al. 
Outcome measures for low back pain research. A proposal for standardized 
use. Spine (Phila Pa 1976). 1998;23(18):2003-13. 
89. Bombardier C. Outcome assessments in the evaluation of treatment of 
spinal disorders: summary and general recommendations. Spine (Phila Pa 
1976). 2000;25(24):3100-3. 
  265 
90. Turk DC, Dworkin RH, Allen RR, Bellamy N, Brandenburg N, Carr DB, et 
al. Core outcome domains for chronic pain clinical trials: IMMPACT 
recommendations. Pain. 2003;106(3):337-45. 
91. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz 
NP, et al. Core outcome measures for chronic pain clinical trials: IMMPACT 
recommendations. Pain. 2005;113(1-2):9-19. 
92. Roland M, Morris R. A study of the natural history of back pain. Part I: 
development of a reliable and sensitive measure of disability in low-back pain. 
Spine (Phila Pa 1976). 1983;8(2):141-4. 
93. Mapi Research Trust. Oswestry Disability Index; 2000. Available from: 
https://eprovide.mapi-trust.org/instruments/oswestry-disability-index. Last 
accessed 14th November 2017. 
94. Optum. 12-Item Short Form Health Survey (SF-12v2® Health Survey). 
Available from: https://campaign.optum.com/content/optum/en/optum-
outcomes/what-we-do/health-surveys/sf-12v2-health-survey.html. Last 
accessed 14th November 2017. 
95. EuroQol. EQ-5D-5L; 2014. Available from: http://www.euroqol.org/eq-5d-
products/eq-5d-5l.html Last accessed 6th May 2017. 
96. National Institute for Health Research Journals Library. HTA 11/31/02: A 
multicentre double-blind randomised controlled trial to assess the clinical- and 
cost-effectiveness of facet-joint injections in selected patients with non-specific 
low back pain: A feasibility study. Available from: 
https://www.journalslibrary.nihr.ac.uk/programmes/hta/113102/ - /. Last 
accessed 13th June 2017. 
97. National Institute for Health Research Journals Library. HTA 11/31/01: 
Facet Feasibility (FF). Available from: 
https://www.journalslibrary.nihr.ac.uk/programmes/hta/113101/ - /. Last 
accessed 13th June 2017. 
  266 
98. Ellard DR, Underwood M, Achana F, Antrobus JH, Balasubramanian S, 
Brown S, et al. Facet joint injections for people with persistent non-specific low 
back pain (Facet Injection Study): a feasibility study for a randomised controlled 
trial. Health Technol Assess. 2017;21(30):1-184. 
99. Snidvongs S, Taylor RS, Ahmad A, Thomson S, Sharma M, Farr A, et al. 
Facet-joint injections for non-specific low back pain: a feasibility RCT. Health 
Technol Assess. 2017;21(74):1-130. 
100. Vekaria R, Bhatt R, Ellard DR, Henschke N, Underwood M, Sandhu H. 
Intra-articular facet joint injections for low back pain: a systematic review. Eur 
Spine J. 2016;25(4):1266-81. 
101. Manchikanti L. Evidence-based medicine, systematic reviews, and 
guidelines in interventional pain management, part I: introduction and general 
considerations. Pain Physician. 2008;11(2):161-86. 
102. Atkins D, Chang, S; Gartlehner G.; Buckley D. I.;Whitlock, E. P.; Berliner, 
E.; Matchar, D. Assessing the applicability of studies when comparing medical 
interventions.  In Methods guide for comparative effectiveness reviews. Quality 
AfHRa, editor2014. 
103. Higgins J. P. T.; Green S. Cochrane Handbook for Systematic Reviews 
of Interventions Version 5.1.0 [updated March 2011]. Available from: 
www.handbook.cochrane.org. Last accessed 13th June 2017. 
104. Institute of Medicine Committee on Standards for Systematic Reviews of 
Comparative Effectiveness R. In: Eden J, Levit L, Berg A, Morton S, editors. 
Finding What Works in Health Care: Standards for Systematic Reviews. 
Washington (DC): National Academies Press (US); 2011. 
105. Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, et 
al. Development of AMSTAR: a measurement tool to assess the methodological 
quality of systematic reviews. BMC Med Res Methodol. 2007;7:10. 
  267 
106. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. 
Preferred reporting items for systematic review and meta-analysis protocols 
(PRISMA-P) 2015: elaboration and explanation. Bmj. 2015;349:g7647. 
107. Slipman CW, Bhat AL, Gilchrist RV, Issac Z, Chou L, Lenrow DA. A 
critical review of the evidence for the use of zygapophysial injections and 
radiofrequency denervation in the treatment of low back pain. Spine J. 
2003;3(4):310-6. 
108. Chou R, Atlas SJ, Stanos SP, Rosenquist RW. Nonsurgical 
interventional therapies for low back pain: a review of the evidence for an 
American Pain Society clinical practice guideline. Spine (Phila Pa 1976). 
2009;34(10):1078-93. 
109. Henschke N, Kuijpers T, Rubinstein SM, van Middelkoop M, Ostelo R, 
Verhagen A, et al. Injection therapy and denervation procedures for chronic 
low-back pain: a systematic review. Eur Spine J. 2010;19(9):1425-49. 
110. Boswell MV, Colson JD, Spillane WF. Therapeutic facet joint 
interventions in chronic spinal pain: a systematic review of effectiveness and 
complications. Pain Physician. 2005;8(1):101-14. 
111. Nelemans PJ, de Bie RA, de Vet HC, Sturmans F. Injection therapy for 
subacute and chronic benign low back pain. Cochrane Database Syst Rev. 
2000(2):Cd001824. 
112. Staal JB, de Bie RA, de Vet HC, Hildebrandt J, Nelemans P. Injection 
therapy for subacute and chronic low back pain: an updated Cochrane review. 
Spine (Phila Pa 1976). 2009;34(1):49-59. 
113. Manchikanti L, Nampiaparampil DE, Manchikanti KN, Falco FJ, Singh V, 
Benyamin RM, et al. Comparison of the efficacy of saline, local anesthetics, and 
steroids in epidural and facet joint injections for the management of spinal pain: 
A systematic review of randomized controlled trials. Surg Neurol Int. 
2015;6(Suppl 4):S194-235. 
  268 
114. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for 
systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 
2009;6(7):e1000097. 
115. Moher D, Tetzlaff J, Tricco AC, Sampson M, Altman DG. Epidemiology 
and reporting characteristics of systematic reviews. PLoS Med. 2007;4(3):e78. 
116. Page MJ, Shamseer L, Altman DG, Tetzlaff J, Sampson M, Tricco AC, et 
al. Epidemiology and Reporting Characteristics of Systematic Reviews of 
Biomedical Research: A Cross-Sectional Study. PLoS Med. 
2016;13(5):e1002028. 
117. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, 
et al. The PRISMA statement for reporting systematic reviews and meta-
analyses of studies that evaluate healthcare interventions: explanation and 
elaboration. Bmj. 2009;339:b2700. 
118. Shea BJ, Hamel C, Wells GA, Bouter LM, Kristjansson E, Grimshaw J, et 
al. AMSTAR is a reliable and valid measurement tool to assess the 
methodological quality of systematic reviews. J Clin Epidemiol. 
2009;62(10):1013-20. 
119. Furlan AD, Malmivaara A, Chou R, Maher CG, Deyo RA, Schoene M, et 
al. 2015 Updated Method Guideline for Systematic Reviews in the Cochrane 
Back and Neck Group. Spine (Phila Pa 1976). 2015;40(21):1660-73. 
120. Faggion CM, Jr. Critical appraisal of AMSTAR: challenges, limitations, 
and potential solutions from the perspective of an assessor. BMC Med Res 
Methodol. 2015;15:63. 
121. A Measurement Tool to Assess Systematic Reviews. AMSTAR checklist. 
Available from: https://amstar.ca/Amstar_Checklist.php. Last accessed 13th 
June 2017. 
122. Sandhu H, Ellard DR, Achana F, Antrobus JH, Balasubramanian S, 
Brown S, et al. Facet-joint injections for people with persistent non-specific low 
  269 
back pain (FIS): study protocol for a randomised controlled feasibility trial. 
Trials. 2015;16:588. 
123. PROSPERO 2015 CRD42015018991. Facet joint injections for low back 
pain. Available from: 
http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD420150189
91. Last accessed 11th August 2018. 
124. DeAngelis CD, Fontanarosa PB. Impugning the integrity of medical 
science: the adverse effects of industry influence. Jama. 2008;299(15):1833-5. 
125. Nash TP. Facet joints: intra-articular steroids or nerve blocks? Pain 
Clinic. 1990;3:77-82. 
126. Marks RC, Houston T, Thulbourne T. Facet joint injection and facet 
nerve block: a randomised comparison in 86 patients with chronic low back 
pain. Pain. 1992;49(3):325-8. 
127. Manchikanti L, Pampati V, Bakhit CE, Rivera JJ, Beyer CD, Damron KS, 
et al. Effectiveness of lumbar facet joint nerve blocks in chronic low back pain: a 
randomized clinical trial. Pain Physician. 2001;4(1):101-17. 
128. Manchikanti L, Singh V, Falco FJ, Cash KA, Pampati V. Lumbar facet 
joint nerve blocks in managing chronic facet joint pain: one-year follow-up of a 
randomized, double-blind controlled trial: Clinical Trial NCT00355914. Pain 
Physician. 2008;11(2):121-32. 
129. Celik B, Er U, Simsek S, Altug T, Bavbek M. Effectiveness of lumbar 
zygapophysial joint blockage for low back pain. Turk Neurosurg. 
2011;21(4):467-70. 
130. Yun DH, Kim HS, Yoo SD, Kim DH, Chon JM, Choi SH, et al. Efficacy of 
ultrasonography-guided injections in patients with facet syndrome of the low 
lumbar spine. Ann Rehabil Med. 2012;36(1):66-71. 
  270 
131. Lakemeier S, Lind M, Schultz W, Fuchs-Winkelmann S, Timmesfeld N, 
Foelsch C, et al. A comparison of intraarticular lumbar facet joint steroid 
injections and lumbar facet joint radiofrequency denervation in the treatment of 
low back pain: a randomized, controlled, double-blind trial. Anesth Analg. 
2013;117(1):228-35. 
132. Van Boxem K, Cahana A, Van Zundert J. Injection therapy and 
denervation procedures for chronic low back pain: a systematic review--clinical 
value? Eur Spine J. 2011;20(5):820-1; author reply 2-3. 
133. Boxem KV, Zundert JV, van Kleef M. Re: Staal JB, de Bie R, de Vet HC, 
et al. Injection therapy for subacute and chronic low-back pain. Cochrane 
Database Syst Rev 2008:CD001824. Spine (Phila Pa 1976). 2009;34(15):1628-
9; author reply 9. 
134. Norris S, Atkins D, Bruening W, Fox S, Johnson E, Kane R, et al. AHRQ 
Methods for Effective Health Care.  Selecting Observational Studies for 
Comparing Medical Interventions.  Methods Guide for Effectiveness and 
Comparative Effectiveness Reviews. Rockville (MD): Agency for Healthcare 
Research and Quality (US); 2008. 
135. Garner P, Hopewell S, Chandler J, MacLehose H, Schunemann HJ, Akl 
EA, et al. When and how to update systematic reviews: consensus and 
checklist. Bmj. 2016;354:i3507. 
136. Vekaria R, Bhatt R, Ellard DR, Henschke N, Underwood M, Sandhu H. 
Intra-articular facet joint injections for low back pain: a systematic review. 
Available from: https://link.springer.com/article/10.1007%2Fs00586-016-4455-y. 
Last accessed 10th July 2017. 
137. Pieper D, Mathes T. Survey of instructions for authors on how to report 
an update of a systematic review: guidance is needed. Evid Based Med. 
2017;22(2):45-8. 
  271 
138. Furlan AD, Pennick V, Bombardier C, van Tulder M. 2009 updated 
method guidelines for systematic reviews in the Cochrane Back Review Group. 
Spine (Phila Pa 1976). 2009;34(18):1929-41. 
139. Greenhalgh SS, J. Red flags II: a guide to solving serious pathology of 
the spine. 2nd ed. London: Churchill Livingstone; 2010. 
140. Browne RH. On the use of a pilot sample for sample size determination. 
Stat Med. 1995;14(17):1933-40. 
141. World Health Organisation. Surgical Safety Checklist; 2009. Available 
from: http://www.who.int/patientsafety/safesurgery/checklist/en/. Last accessed 
28th July 2017. 
142. Bogduk N. A narrative review of intra-articular corticosteroid injections for 
low back pain. Pain Med. 2005;6(4):287-96. 
143. World Medical Association. World Medical Association Declaration of 
Helsinki; 1996. Available from: 
http://www.chcuk.co.uk/pdf/Declaration_of_Helsinki_1996_version.pdf. Last 
accessed 2nd November 2017. 
144. International Conference of Harmonisation Steering Committee. 
International Conference of Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use. Guideline for Good Clinical 
Practice E6 (R1); 10 June 1996. Available from: 
https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Effica
cy/E6/E6_R1_Guideline.pdf, . Last accessed 14th November 2017. 
145. Department of Health. Research Governance Framework for Health and 
Social Care, Second Edition London; 2005. Available from: 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/1
39565/dh_4122427.pdf. Last accessed 14th November 2017. 
146. The Stationery Office, Great Britain. The Medicines for Human Use 
(Clinical Trials) Regulations 2004 London; 2004. Available from: 
  272 
http://www.legislation.gov.uk/uksi/2004/1031/pdfs/uksi_20041031_en.pdf. Last 
accessed 14th November 2017. 
147. electronic Medicines Compendium. Summary of Product Characteristics 
for Marcain Polyamp Steripack 0.5%;  updated 7th February 2017. Available 
from: http://www.medicines.org.uk/emc/medicine/6013. Last accessed 11th 
September 2017. 
148. electronic Medicines Compendium. Summary of Product 
Characeteristics for Depo-Medrone 40mg/ml;  updated 1st February 2017. 
Available from: http://www.medicines.org.uk/emc/medicine/3549. Last accessed 
11th September 2017. 
149. The University of Texas M. D. Anderson Cancer Center. Brief Pain 
Inventory (Short Form) Houston, Texas; 1991. Available from: 
https://www.mdanderson.org/documents/Departments-and-Divisions/Symptom-
Research/BPI-SF_English-24h_Original_SAMPLE.pdf. Last accessed 14th 
November 2017. 
150. Mapi Research Trust. Short-Form McGill Pain Questionnaire (SF-MPQ-
2); 2009. Available from: https://eprovide.mapi-trust.org/instruments/short-form-
mcgill-pain-questionnaire. Last accessed 14th November 2017. 
151. Paper presented at the annual conference of the British Psychological 
Society. Self-efficacy and chronic painSt Andrews, Scotland. 1989. 
152. GL Assessment. Hospital Anxiety and Depression Scale (HADS). 
Available from: https://www.gl-assessment.co.uk/products/hospital-anxiety-and-
depression-scale-hads/. Last accessed 14th November 2017. 
153. Mapi Research Trust. Pain Catastrophizing Scale; 1995. Available from: 
https://eprovide.mapi-trust.org/instruments/pain-catastrophizing-scale. Last 
accessed 14th November 2017. 
  273 
154. Koopman C, Pelletier KR, Murray JF, Sharda CE, Berger ML, Turpin RS, 
et al. Stanford presenteeism scale: health status and employee productivity. J 
Occup Environ Med. 2002;44(1):14-20. 
155. Do KH, Ahn SH, Cho YW, Chang MC. Comparison of intra-articular 
lumbar facet joint pulsed radiofrequency and intra-articular lumbar facet joint 
corticosteroid injection for management of lumbar facet joint pain: A randomized 
controlled trial. Medicine (Baltimore). 2017;96(13):e6524. 
156. Annaswamy TM, Armstead C, Carlson L, Elkins NJ, Kocak D, Bierner 
SM. Intra-articular Triamcinolone Versus Hyaluronate Injections for Low Back 
Pain With Symptoms Suggestive of Lumbar Zygapophyseal Joint Arthropathy: 
A Pragmatic, Double-Blind Randomized Controlled Trial. Am J Phys Med 
Rehabil. 2018;97(4):278-84. 
157. Sae-Jung S, Jirarattanaphochai K. Outcomes of lumbar facet syndrome 
treated with oral diclofenac or methylprednisolone facet injection: a randomized 
trial. Int Orthop. 2016;40(6):1091-8. 
158. Kennedy DJ, Huynh L, Wong J, Mattie R, Levin J, Smuck M, et al. 
Corticosteroid Injections into Lumbar Facet Joints: A Prospective, Randomized, 
Double-Blind Placebo-Controlled Trial. Am J Phys Med Rehabil. 2018. 
159. Paulsen A, Overgaard S, Lauritsen JM. Quality of data entry using single 
entry, double entry and automated forms processing--an example based on a 
study of patient-reported outcomes. PLoS One. 2012;7(4):e35087. 
160. Teare MD, Dimairo M, Shephard N, Hayman A, Whitehead A, Walters 
SJ. Sample size requirements to estimate key design parameters from external 
pilot randomised controlled trials: a simulation study. Trials. 2014;15:264. 
161. Thompson AG, France EF. One stop or full stop? The continuing 
challenges for researchers despite the new streamlined NHS research 
governance process. BMC Health Serv Res. 2010;10:124. 
  274 
162. Kearney A, McKay A, Hickey H, Balabanova S, Marson AG, Gamble C, 
et al. Opening research sites in multicentre clinical trials within the UK: a 
detailed analysis of delays. BMJ Open. 2014;4(9):e005874. 
163. Dal-Re R, Moher D, Gluud C, Treweek S, Demotes-Mainard J, Carne X. 
Disclosure of investigators' recruitment performance in multicenter clinical trials: 
a further step for research transparency. PLoS Med. 2011;8(12):e1001149. 
164. Campbell MK, Snowdon C, Francis D, Elbourne D, McDonald AM, Knight 
R, et al. Recruitment to randomised trials: strategies for trial enrollment and 
participation study. The STEPS study. Health Technol Assess. 2007;11(48):iii, 
ix-105. 
165. McDonald AM, Knight RC, Campbell MK, Entwistle VA, Grant AM, Cook 
JA, et al. What influences recruitment to randomised controlled trials? A review 
of trials funded by two UK funding agencies. Trials. 2006;7:9. 
166. Sundaresan P, Turner S, Kneebone A, Pearse M, Fraser-Browne C, 
Woo HH. Do screening trial recruitment logs accurately reflect the eligibility 
criteria of a given clinical trial? Early lessons from the RAVES 0803 trial. Clin 
Oncol (R Coll Radiol). 2014;26(6):348-52. 
167. Prescott RJ, Counsell CE, Gillespie WJ, Grant AM, Russell IT, Kiauka S, 
et al. Factors that limit the quality, number and progress of randomised 
controlled trials. Health Technol Assess. 1999;3(20):1-143. 
168. Schulz KF, Grimes DA. Sample size slippages in randomised trials: 
exclusions and the lost and wayward. Lancet. 2002;359(9308):781-5. 
169. Gurol-Urganci I, de Jongh T, Vodopivec-Jamsek V, Atun R, Car J. Mobile 
phone messaging reminders for attendance at healthcare appointments. 
Cochrane Database Syst Rev. 2013(12):Cd007458. 
170. Barts Health NHS Trust. Pain Management Service; 2017. Available 
from: https://www.bartshealth.nhs.uk/pain-management-service. Last accessed 
27th September 2017. 
  275 
171. Tower Hamlets Council. Tower Hamlets borough statistics; 2015. 
Available from: 
http://www.towerhamlets.gov.uk/lgnl/community_and_living/borough_statistics/b
orough_statistics.aspx. Last accessed 6th May 2017. 
172. Choudhury Y, Bremner SA, Ali A, Eldridge S, Griffiths CJ, Hussain I, et 
al. Prevalence and impact of chronic widespread pain in the Bangladeshi and 
White populations of Tower Hamlets, East London. Clin Rheumatol. 
2013;32(9):1375-82. 
173. Newington L, Metcalfe A. Factors influencing recruitment to research: 
qualitative study of the experiences and perceptions of research teams. BMC 
Med Res Methodol. 2014;14:10. 
174. National Institute for Health Research. Generic job description – Clinical 
Trials Manager. Available from: https://www.nihr.ac.uk/funding-and-
support/documents/funding-for-research-studies/manage-my-study/clinical-
trials-manager-generic-job-description.pdf. Last accessed 27th September 
2017. 
175. Farrell B, Kenyon S, Shakur H. Managing clinical trials. Trials. 
2010;11:78. 
176. UK Trial Managers’ Network. The Guide to Efficient Trial Management.  
Effectively managing clinical trials; Fifth edition 2016. Available from: 
http://www.tmn.ac.uk/?page=Guide. Last accessed 27th September 2017. 
177. Ranieri V, Barratt H, Fulop N, Rees G. Factors that influence career 
progression among postdoctoral clinical academics: a scoping review of the 
literature. BMJ Open. 2016;6(10):e013523. 
178. Burls A. What is a critical appraisal?2009. Available from: 
http://www.bandolier.org.uk/painres/download/whatis/What_is_critical_appraisal
.pdf. Last accessed 27th November 2017. 
  276 
179. Centre for Reviews and Dissemination, University of York. PROSPERO.  
International prospective register of systematic reviews. Available from: 
https://www.crd.york.ac.uk/prospero/. Last accessed 2nd August 2018. 
180. Machado LA, Kamper SJ, Herbert RD, Maher CG, McAuley JH. 
Imperfect placebos are common in low back pain trials: a systematic review of 
the literature. Eur Spine J. 2008;17(7):889-904. 
181. The King’s Fund. Understanding NHS financial pressures: how are they 
affecting patient care? ; March 2017. Available from: 
https://www.kingsfund.org.uk/sites/default/files/field/field_publication_file/Unders
tanding NHS financial pressures - full report.pdf. Last accessed 29th November 
2017. 
182. Individual Funding Request Team - A partnership between Bristol, North 
Somerset and South Gloucestershire Clinical Commissioning Groups 
Commissioning Group. Commissioning Policy Individual Funding Request.  
Facet Joint Injections and Medial Branch Blocks in Secondary Care Policy. 
Criteria Based Access Policy. Version: 1617.1; 4th November 2016 (date 
adopted). Available from: 
https://www.bristolccg.nhs.uk/media/medialibrary/2016/10/Facet_Joint_Injection
s_and_Medial_Branch_Blocks_in_Secondary_Care_Policy__policy_tRNcMg8.p
df. Last accessed 29th November 2017. 
183. Individual Funding Request Team - A partnership between Bristol, North 
Somerset and South Gloucestershire Clinical Commissioning Groups 
Commissioning Group. Commissioning Policy Individual Funding Request. 
Management of Low Back Pain and Sciatica in over 16s Policy. Criteria Based 
Access Policy; August 2017 (date adopted). Available from: 
https://www.bristolccg.nhs.uk/media/medialibrary/2017/08/20170731_Low_Bac
k_Pain_Policy_FINAL_mCmoZKb.pdf. Last accessed 29th November 2017. 
184. NHS England, Specialised Commissioning Team. Commissioning policy: 
Individual Funding Requests; 17th November 2017. Available from: 
https://www.england.nhs.uk/wp-content/uploads/2017/11/comm-policy-
indivdual-funding-requests.pdf. Last accessed 29th November 2017. 
  277 
185. The Royal College of General Practitioners, November 2013, endorsed 
by the British Pain Society, Chronic Pain Policy Coalition and Faculty of Pain 
Medicine of the Royal College of Anaesthetists. Pain management services: 
planning for the future. Guiding clinicians in their engagement with 
commissioners; 2013. Available from: https://www.rcoa.ac.uk/system/files/FPM-
Pain-Management-Services.pdf. Last accessed 29th November 2017. 
186. IOM (Institute of Medicine), The National Academies Press. Finding 
What Works in Health Care: Standards for Systematic Reviews Washington, 
DC; 2011 updated 13th June 2017. Available from: 
http://nationalacademies.org/hmd/reports/2011/finding-what-works-in-health-
care-standards-for-systematic-reviews.aspx. Last accessed 27th September 
2017. 
187. Amundsen PA, Evans DW, Rajendran D, Bright P, Bjorkli T, Eldridge S, 
et al. Inclusion and exclusion criteria used in non-specific low back pain trials: a 
review of randomised controlled trials published between 2006 and 2012. BMC 
Musculoskelet Disord. 2018;19(1):113. 
188. Oxford Centre for Evidence-Based Medicine. The Oxford 2011 Levels of 
Evidence. Available from: http://www.cebm.net/index.aspx?o=5653. Last 
accessed 2nd August 2018. 
189. Horng S, Miller FG. Ethical framework for the use of sham procedures in 
clinical trials. Crit Care Med. 2003;31(3 Suppl):S126-30. 
190. INVOLVE, Eastleigh. Briefing notes for researchers: involving the public 
in NHS, public health and social care research; 2012. Available from: 
http://www.invo.org.uk/posttyperesource/why-should-members-of-the-public-be-
involved-in-research/. Last accessed 2nd August 2018. 
191. INVOLVE. INVOLVE programme website. Available from: 
http://www.invo.org.uk/. Last accessed 2nd August 2018. 
192. Cohen SP, Doshi TL, Constantinescu OC, Zhao Z, Kurihara C, Larkin 
TM, et al. Effectiveness of Lumbar Facet Joint Blocks and Predictive Value 
  278 
before Radiofrequency Denervation: The Facet Treatment Study (FACTS), a 
Randomized, Controlled Clinical Trial. Anesthesiology. 2018;129(3):517-35. 
193. Medical Research Council. Developing and evaluating complex 
interventions; 2008. Available from: https://mrc.ukri.org/documents/pdf/complex-
interventions-guidance/. Last accessed 2nd August 2018. 
194. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. 
Developing and evaluating complex interventions: the new Medical Research 
Council guidance. Bmj. 2008;337:a1655. 
195. Moore GF, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, et al. 
Process evaluation of complex interventions: Medical Research Council 
guidance. Bmj. 2015;350:h1258. 
 
